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Abstract 
Biofilm formation is one of several significant virulence factors associated with 
life threatening pulmonary infections in immunocompromised individuals caused 
by Aspergillus fumigatus. Previous studies have demonstrated phase dependant 
antifungal activity against A. fumigatus biofilms. Antifungal resistance 
associated with fungal biofilms is a complex multifactorial phenomenon, and it 
remains unclear specifically how this manifests itself in A. fumigatus. This study 
therefore aimed to investigate adaptive resistance mechanisms in A. fumigatus 
biofilms. 
Different phases of A. fumigatus biofilms were grown for 8, 12, 24 and 48h in 
polystyrene plates in RPMI media. Functional efflux pump activity was 
subsequently assessed using an Ala-Nap fluorescent uptake assay. Extracellular 
material was extracted from each phase and the level of extracellular DNA 
(eDNA) was quantifiedusing a microplate fluorescence assay. The minimum 
inhibitory concentrations (MIC) of different classes of antifungals were assessed 
in the presence and absence of different inhibitors using a checkerboard assay, 
or with a fixed concentration, by the broth microdilution method to assess 
synergism, antagonism, or otherwise. The presence of eDNA and phenotypic 
changes in biofilm caused by antifungal agents and inhibitors were assessed by 
confocal laser scanning microscopy (CLSM) and scanning electron microscopy 
(SEM) techniques. The resultant biofilm biomass for different experiments was 
evaluated using a crystal violet assay. SYBR green qRT-PCR was used to assess 
the expression of different genes implicated in biofilm resistance (AfuMDR 1-4, 
ChiA-E, HSP90 and Fks1) over the period of multicellular development, using a 
diffusion chamber in a murine model and a Galleria mellonella infection model. 
The results from this study demonstrated phase dependant expression of efflux 
pumps in A. fumigatus biofilm populations, which actively contributes to azole 
resistance. Moreover, voriconazole treatment induced efflux pump expression in 
both in vitro and in vivo models.These data suggest that A. fumigatus efflux 
pump proteins, which evolved to become integral to their natural physiological 
function, have inadvertently induced resistance to azole drugs, albeit in the 
early phases of biofilm development. 
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Assessment of A. fumigatus biofilm extracellular matrix (ECM), associated with 
maturing biofilms, showed that eDNA is an important architectural component of 
the biofilm, helping to maintain its stability. The antifungal sensitivity of 
different phases of A. fumigatus growth decreased significantly in the presence 
of DNase, indicating that decreased susceptibility to antifungals in the A. 
fumigatus is mediated in part by eDNA.Its release was shown to correlate 
withchitinase activity, a marker of autolysis, suggestive that autolysis was 
associated with eDNA release. It was hypothesised that heat shock protein 90 
(HSP90) was involved in this autolytic pathway. Therefore, when HSP90 was 
pharmacologically inhibited this led to a decrease in matrix eDNA level, 
providing a compelling mechanism through which HSP90 might regulate biofilm 
antifungal resistance. To test whether these mechanisms of adaptive resistance 
had any bearing clinically, a G. mellonella model was developed. It was shown 
that each of the key genes were expressed during infection, both in control and 
antifungal treated larvae. This validates the potential use of this insect model 
for resistance and virulence studies. 
Overall, this study establishes several novel adaptive resistance mechanisms 
regulating biofilm drug resistance in A. fumigatus biofilms. Moreover, it 
highlights the potential to target these mechanisms as a therapeutic strategy for 
managing and improving clinical outcomes in these hard-to-treat infections.  
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1.1 Aspergillus species 
The genus Aspergillus is an Eurotiomycetes, which was first classified by Pier 
Antonio Micheli, an Italian priest and biologist in 1729 (Bennett, 2010). The word 
‘Aspergillus’ came from its structural resemblance in the shape of an 
aspergillum (Figure 1.1), used to sprinkle holy water by Roman Catholic priests. 
Aspergillus species are ubiquitous saprophytes in nature, being present in soil, 
grain and decaying vegetation. The genus consists of more than 200 species and 
variants, although only ten are pathogenic in humans (Bennett, 2010). 
Aspergillus fumigatus is one of the leading pathogenic species that cause disease 
in immunocompromised patients (Howard and Arendrup, 2011, Howard et al., 
2009). In addition, Aspergillus flavus, Aspergillus nidulans, Aspergillus niger and 
Aspergillus terreus are other pathogenic species that have also been identified 
as harmful pathogens (Denning, 1998).  
1.1.1 Aspergillus fumigatus 
Aspergillus fumigatus is an airborne saprotroph, which survives and grows on 
organic debris. It plays an important role in carbon and nitrogen recycling in the 
environment (Haines, 1995). The A. fumigatus conidiophore sporulates 
thousands of grey green conidia at a size of 2–3 μm that are readily airborne 
(Figure 1.1c). As a specie we inhale hundreds of conidia every day from the 
atmosphere (Dagenais and Keller, 2009). Inhalation by healthy individuals does 
not normally cause any adverse effects since the innate immune system 
eliminates the conidia (Latge, 1999). However, a host with a compromised 
immune system, such as acquired immune deficiency syndrome (AIDS), chronic 
obstructive pulmonary disease (COPD), chemotherapy and transplant patients, 
are vulnerable to A. fumigatus infections(Palousova et al., 2012, Greenberger, 
2012, Bulpa et al., 2007, Mahfouz and Anaissie, 2003, Ruhnke, 2004). Not only 
does it affect humans, but it also causes serious problems in birds and animals 
(mallards and other ducks, penguins in zoos and old horses fed with poor-quality 
hay) (Beernaert et al., 2010, Tell, 2005, Shannon, 1992).  
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Figure 1.1 - Aspergillus fumigatus.  (a) First A. fumigatus drawing by George 
W. Fresenius in 1863 showing aspergillum structure (Schmidt and Schmidt, 1999) 
(b) a micrograph displaying conidial heads of A. fumigatus(x920). (c) SEM picture 
of A. fumigatus (Wellcome images, http://images.wellcome.ac.uk). 
 
1.2 Aspergillosis 
A. fumigatus causes a spectrum of disease in humans called aspergillosis. The 
term aspergillosis includes infections and growth of fungus as well as allergic 
reactions it causes in the host (Latge, 1999). Aspergillosis can occur in variety of 
organs. It is often started with lungs (pulmonary aspergillosis) and spreads to 
other sites (invasive aspergillosis [IA]) such as sinuses (Sambatakou et al., 
2006b), skin (Carvalho et al., 2008), nails (Mastella et al., 2000), heart (Montoya 
et al., 2003), kidney (Singh and Husain, 2003), bones (Perfect et al., 2001) and 
eyes (Vermes et al., 2000) via the bloodstream (Filler and Sheppard, 2006) 
(Figure 1.2). The percentage incidence of aspergillosis varies with organs (Table 
1.1) (Patterson et al., 2000). A. fumigatus primarily causes three main 
syndromes which includes allergic bronchopulmonary aspergillosis (ABPA), 
aspergilloma and IA. 
 
 
C C 
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Figure 1.2  - Aspergillosis clinical images. a) ABPA, CT scan image of a patient 
demonstrating bronchiectasis in the right lung. b) Aspergilloma, PM sample 
showing fungal ball formation in lung of leukaemia child. c) Aspergilloma, Lung 
tissue from tuberculosis patient showing cavitation (white arrow) and presence 
of fungal ball (black arrow). d) Aspergillus keratitis, Aspergillus growth in eye of 
a patient with corneal ulcer. e) Aspergillus onychomycosis, toenails showing 
Aspergillus infection. f) Primary cutaneous aspergillosis, circular papules with 
white eschars on the neonate back showing Aspergillus infection. Pictures were 
taken from the Aspergillus website (www.Aspergillus.org.uk). 
a) b) 
c) d) 
e) f) 
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Table 1.1 - Percentage incidence of aspergillosis with different organs 
(Patterson et al, 2000). 
                                                     * n = 595 patients with invasive aspergillosis 
 
Table 1.2 - Percentage incidence of aspergillosis in relation to underlying 
patient conditions (Patterson et al, 2000). 
 
 
 
 
 
 
 
 
 
                                          * n = 595 patients with invasive aspergillosis 
 
Organ % incidence* 
Pulmonary 56 
Multiorgan dissemination 19 
Skin 5 
Paranasal sinuses 5 
Central nervous system 6 
Tracheobronchitis 1 
Other  9 
Underlying condition % incidence* 
Allogeneic stem cell transplantation 25 
Haematological malignancy 28 
Pulmonary disease 9 
Solid organ transplantation 9 
AIDS 8 
Autologous stem cell transplantation 7 
Immunosuppressive therapy 6 
Other underlying conditions 6 
Non-compromised hosts 2 
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1.2.1 Allergic bronchopulmonary aspergillosis 
ABPA is a condition caused by allergic lung reaction to A. fumigatus spores. ABPA 
primarily affects asthma and cystic fibrosis patients (Greenberger and Patterson, 
1988). A. fumigatus growth in the trachea and bronchi invokes both type I 
(formation of IgE) and type III hypersensitivity response (formation of IgG) in the 
host (Kurup et al., 1994, Kurup, 2000). The type I response to A. fumigatus 
causes mast cell degranulation with broncho constriction and increased capillary 
permeability. The type III response together with deposits of inflammatory cells 
within the airway mucous membrane causes necrosis (Zeaske et al., 1988). Some 
of the common clinical symptoms of ABPA are increased sputum production, 
wheezing, coughing up mucus with brown, black, or green elements, shortness 
of breath and fever (Greenberger, 1986).  
The standard diagnosis of ABPA are to fulfil the following criteria a) asthma, b) 
immediate reactivity to A. fumigatus, c) high serum IgE level (> 1000ng/mL), d) 
precipitating antibodies to A. fumigatus present in serum, e) eosinophilia and f) 
central bronchiectasis on chest CT (Greenberger and Patterson, 1988). Treating 
ABPA is quite difficult and there is no complete cure for ABPA. All treatments 
are carried out to avoid any lung damage. There are two treatment aspects for 
ABPA. One is to control inflammation and hypersensitivity reactions by using oral 
corticosteroids and the other is to control fungal growth by antifungal drugs. 
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Figure 1.3 - Infection process of A. fumigatus. A. fumigatus spores readily 
become airborne. Inhalation of airborne conidia by immunocompromised 
patients causes significant inflammation followed by conidium establishment in 
the lungs, germination of conidia and PMN recruitment. With neutropenic 
conditions excessive hyphal growth and dissemination is possible (Dagenais and 
Keller, 2009). 
 
1.2.1.1 Epidemiology 
ABPA has a worldwide distribution, there are likely to be signiﬁcant geographic 
differences in its prevalence. There are different factors influencing the 
occurrence of ABPA which includes environmental factors such as atmospheric 
concentrations of conidia (Esposito et al., 2009, Young et al., 1970, Jayshree et 
al., 2006), genetic factors such as CFTR gene mutation (Miller et al., 1996, 
Marchand et al., 2001, Eaton et al., 2002), interleukins IL 4,13,15 polymorphisms 
(Knutsen et al., 2006, Escande et al., 2011), tumour necrosis factor(TNF)-α 
polymorphisms (Escande et al., 2011), TLR9 polymorphisms (Carvalho et al., 
2008), and patients underlying conditions such as asthma. The prevalence of 
ABPA varies depending on treatment centre and diagnostic criteria used 
(Mastella et al., 2000). The first ABPA case was reported in UK in 1952 by 
Hinson(Hinson et al., 1952). In 1967 ABPA cases were reported in USA and 
Australia, followed by India in 1971(Shah, 1971). The reported incidence of ABPA 
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in asthma patients varies from 13 to 45% in different parts of the world (Table 
1.3). Previous studies have shown that asthma patients exposed to Aspergillus 
had an increased risk of death (Taff et al., 2012). However, none of these 
studies specifically evaluated ABPA in relation to severity of asthma.  
The impaired mucus clearance and airway obstruction in CF patients are other 
risk factors associated with ABPA. The association of CF and ABPA were reported 
in 1965 in UK (Loussert et al., 2010).  From surveys and epidemiology registries, 
about 7.8 % of patients in Europe and 7% in United States with CF are estimated 
to have ABPA. Table 1.4 shows the prevalence of ABPA in Europe (Mastella et 
al., 2000). As like incidences with asthma, the incidence of ABPA in CF patients 
also shows geographical variances. In European countries for example the 
incidence varied from 2.1% in Sweden to 13.6 % in Belgium (Mastella et al., 
2000). In USA, the incidence varied from 0.9% in the South West region to 4% in 
the West region (Geller et al., 1999).  
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Table 1.3 – Prevalence of ABPA in asthma patients. 
Country Number of 
Patients with 
asthma 
Prevalence of 
ABPA (%) 
Reference 
UK 656 85 (13) 
(Ramage et al., 
2009b) 
USA 100 38 (38) 
(Huang and Kao, 
2012) 
Australia 79 26 (33) 
(Martins et al., 
2010) 
South Africa 500 110 (22) 
(Ben-Ami and 
Kontoyiannis, 2012) 
Saudi Arabia 53 12 (23) 
(Walker et al., 
2010) 
India 755 294 (39) (Nett et al., 2010b) 
 
Table 1.4 - Prevalence of ABPA in CF patients in Europe(Mastella et al., 2000). 
Country Number of patients with CF  Prevalence of ABPA (%) 
Austria 169 9 (5.3) 
Belgium 44 6 (13.6) 
Denmark 320 11 (3.4) 
France 2935 217 (7.4) 
Germany 3070 353 (11.5) 
Ireland 621 68 (11.0) 
Netherlands 353 24 (6.8) 
Sweden 424 9 (2.1) 
UK 4511 271 (6.0) 
All 12447 971 (7.8) 
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1.2.2 Invasive aspergillosis 
IA is a serious Aspergillus infection and involves the initial colonisation and 
consequential spread to other parts of the body by haematogenous and 
angioinvasion (Figure 1.4). Some of the common risk factors associated with IA 
are AIDS, solid organ transplantation, intensive chemotherapy regimens and 
increased use of immunosuppressive regimens (Baddley, 2011, Herbrecht et al., 
2012, Segal and Walsh, 2006, Cornet et al., 2002).  Patients with IA have 
symptoms including fever, cough, chest pain, difficulty breathing and poor 
response to standard antibiotics (Aleksenko and Gyasi, 2006, Latge, 1999). The 
earlier the diagnosis the better the treatment but there is no single diagnostic 
method that is either universally applicable or sensitive or specific enough to 
establish IA. Radiological evaluation, microscopy and culture from sputum 
sample, serological test for Aspergillus and molecular diagnostic methods are 
generally used for diagnosis. Antifungal drugs include voriconazole, itraconazole, 
caspofungin or amphotericin B are used for treatment of IA. The overall success 
rate with these antifungals varies significantly between different patient groups. 
Surgical excision and cytokine therapy are other treatment methods in practice 
for IA (Rajbanshi et al., 2012, Lang et al., 1983, Safdar, 2010, Lehrnbecher et 
al., 2012). 
1.2.2.1 Epidemiology 
The incidence of IA varies depending on the patients underlying conditions and 
geographic location (Lang et al., 1983, Walker et al., 2010). A percentage of up 
to 7% is reported in Europe to have IA (Table 1.5) composed of about 38% in 
acute myelogenous leukaemia, 50-60% with organ transplant patients and 70-85% 
in other immunocompromised patients (Rajbanshi et al., 2012, Lang et al., 1983, 
Walker et al., 2010, Ghannoum et al., 1996, McCulloch et al., 2009). The onset 
of IA also varies with underlying patient condition. About 72% of heart transplant 
patients are diagnosed with IA in the first three months of post-surgery(Montoya 
et al., 2003), with approximately 50% of liver and lung transplant patients 
diagnosed within 3-5 months (Singh and Husain, 2003). The rate of mortality 
associated with haematopoietic stem cell transplants ranged from 53.8 to 84.6% 
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and with solid organ transplants 20 to 66.7% after 3 months. A multicentre study 
(24 medical centres) from 2001 showed out of 1209 IA cases diagnosed 
approximately 750 patients died within three months of diagnosis(Perfect et al., 
2001). 
 
Table 1.5 – Prevalence of IA in Europe. 
Country Year Patient 
group 
Number of 
patients 
Prevalence 
of IA (%) 
Reference 
Austria 2000-
2003 
HSCT* 104 23 (Adams, 
2004) 
Belgium 2000-
2003 
Critically 
ill 
1850 6.9 (Walker et 
al., 2010) 
Italy 1999-
2003 
HSCT 1249 6.3 (Lang et al., 
1983) 
Spain 1996-
2000 
HSCT 395 9.4 (Bowman 
and Free, 
2006) 
Finland 1990-
2001 
HSCT 1188 0.8 (Selvaggini 
et al., 2004) 
Poland 1990-
2006 
liver 
transplant 
recipients 
277 3.6 (Leach et 
al., 2012) 
* HSCT, haematopoietic stem cell transplant 
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Figure 1.4 – Model of invasive aspergillosis. The process of IA involves three 
steps alveolar infection, angioinvasion and dissemination. (a)Alveolar infection 
includes adhesion of inhaled conidia (b) with pulmonary epithelial cells, (c) 
endocytosis within the epithelial cells, (d) germination of conidia and hyphal 
growth within the epithelial cells, and (e) hyphal extrusion from the epithelial 
cells. Angioinvasion involves (f) penetration of abluminal surface by emergent 
hyphae, (g) induced cell damage, and (h) spreading of hyphal fragments via 
blood stream. Finally in dissemination process (i) the hyphal fragments adhere to 
the cell surface, (j)cells invasion, (k)cell damage  and (l)invasion of other deep 
organs (Filler and Sheppard, 2006). 
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1.2.3 Aspergilloma 
An aspergilloma, also known as fungal ball, is a rounded mass of hyphal material 
usually combined with mucus and cellular debris, existing within scarred lungs or 
a pre-existing body cavity (Figure 1.5).  The body cavities such as in the lungs 
caused by cystic fibrosis, tuberculosis, lung cancer, lung abscess, 
coccidiodomycosis, sarcoidosis and histoplasmosis are most susceptible to an 
aspergilloma (Chatzimichalis et al., 1998, Kawamura et al., 2000, Massard et al., 
1992, Hadjiliadis et al., 2002, Greenberg et al., 2002, Kunst et al., 2006). 
Typically, patients with aspergilloma are asymptomatic but a small percentage 
of this Aspergillus growth invades into cavity walls and can result in 
haemoptysis. The size of fungal ball formation can range from 3-7cm in diameter 
and is commonly diagnosed by sputum culture, chest X-ray, chest CT, 
bronchoscopy or serum precipitins for Aspergillus(Munoz, 2006). Often, no 
treatment is necessary for aspergilloma but patients with haemoptysis need 
medical attention (Chen et al., 1997). Angiography can be used to detect the 
location of bleeding and surgery may be necessary to remove the fungal ball 
formation and to prevent further bleeding. Antifungal drugs such as azoles are 
also used for aspergilloma treatment but none has been shown to eradicate 
Aspergillus growth. 
 
Figure 1.5 – Model of aspergilloma. Aspergilloma, a rounded mass of hyphal 
material exists within scarred lungs. (Adam images, 3434_72EWJ, 
www.adamimages.com) 
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1.2.3.1 Epidemiology 
Currently, information about the incidence of aspergillomas is limited. Unlike 
other types of aspergillosis the incidence of aspergilloma was reported in 
patients with normal immunity but structurally abnormal lungs, with pre-existing 
cavities. One of the common underlying pulmonary conditions reported to be 
associated with development of aspergilloma was TB (Karas et al., 1976, Massard 
et al., 1992, Regnard et al., 2000, Kawamura et al., 2000).About 25 - 80% of TB 
cases were reported to have aspergilloma(Chen et al., 1997). A study from 
France reported the incidence of aspergilloma from 1974-1991, where 57% of 
patients were reported to be associated with TB (Massard et al., 1992). Later in 
1992-1997 the association of TB was reported to be only 17% (Chatzimichalis et 
al., 1998). Similar pattern of reduction in percentage of TB associated 
aspergilloma of 82% in 1977-1987 and 60% in 1987-1997 reported by another 
study from France indicates the epidemiologic shifts in TB associated 
aspergilloma(Regnard et al., 2000). Pulmonary sarcoidosis, bronchiectasis from 
any cause and other pulmonary cavities are the other conditions shown to be 
associated with incidence of aspergilloma (Chen et al., 1997, Hadjiliadis et al., 
2002, Kawamura et al., 2000, Lee et al., 2004) 
1.3 Treatment of Aspergillosis 
Treatment options for aspergillosis are limited. Due to severity of aspergillosis in 
immunocompromised patient prophylaxis treatment is quite common. The use of 
pharmacological agents to control or treat aspergillosis is the first line of 
treatment option by clinicians. According to a study from USA about 47% of IA 
patients undergo monotherapy and 29% received combination therapy (Karas et 
al., 1976). The monotherapy includes azole (60-70%), polyene (13-15%) and 
echinocandin treatment (10%) (Karas et al., 1976, Kawamura et al., 2000).  For 
patients with an aspergilloma, surgery is the only effective option (Regnard et 
al., 2000). The different treatment options and complications are now discussed 
in the following sections. 
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1.3.1 Prophylaxis 
Aspergillosis morbidity and mortality is associated with the neutropenia resulting 
from intensive cancer chemotherapy, stem cell transplantation, lung and liver 
transplant recipients. Given the high risk associated with aspergillosis, it is not 
surprising that prophylaxis against A. fumigatus is apparently a sensible 
therapeutic approach. One of the common prophylaxis methods for aspergillosis 
is by minimising the patient exposure to airborne spores by providing a filtered 
air environment(Levenson et al., 1991). It is achieved by two means, laminar air-
flow and high efficient particulate air (HEPA) filter (Buckner et al., 1978, Navari 
et al., 1984, Petersen et al., 1988, Berthelot et al., 2006). Control of Aspergillus 
growth by pharmacologic agents is the next most common prophylaxis approach 
by clinicians (Drew et al., 2004, Conneally et al., 1990). Initially, the polyene 
drug amphotericin B was used to prevent aspergillosis. Later, due to drug 
toxicities, amphotericin B was discontinued to use for prophylaxis.  The triazole 
drugs are the next improvement in prophylactic agents. In late 1980s, 
fluconazole was introduced and has changed the epidemiology of aspergillosis 
following stem cell transplantation. In the 1990s, itraconazole was tested for 
prophylaxis(Grant and Clissold, 1990). Later another improved triazole drug 
posaconazole was licensed for prophylaxis treatment with neutropenic patients 
(Petraitiene et al., 2001). According to the recent reports an echinocandin drug 
caspofungin may be an attractive option for prophylaxis treatment due to 
comparatively less adverse effects than others (Massard et al., 1992, Hadjiliadis 
et al., 2002). There are different pharmacological agents tested for controlling 
fungal infections and the prophylaxis regimen is still not clear and standardised. 
 
 
 
Chapter 1: Introduction 
38 
 
1.3.2 Antifungal drugs 
Antifungal therapy is a method of eradicating fungi from host by using 
pharmacological agents exploiting differences between human and fungal 
cells(Dixon and Walsh, 1996). The formulation of antifungal agents are mainly 
administered orally (54.2%) or by intravenous methods (Kawamura et al., 2000) 
(Table 1.6).  Unlike antibacterial drugs, to date relatively few antifungal targets 
were exploited because fungal cells are closely related to humans. There are 
only three antifungal targets, cell wall components, membrane sterols and DNA 
synthesis that have been found with varying degrees of success(Kathiravan et 
al., 2012, Dixon and Walsh, 1996) (Figure 1.6). Fungal membrane sterols are 
different enough from humans so antifungal agents targeting this can kill fungi 
but not mammalian cells(Ghannoum and Rice, 1999). Fungal cells synthesise β-
glucans, an important cell wall component, it is absent in human cells so drugs 
targeting glucan biosynthesis display low side effects(Kathiravan et al., 2012). 
Some of the main points of consideration with antifungal therapy is drug 
specificity, broad spectrum of antifungal activity, fungicidal rather than fungi 
static, drug interactions, and low cost. Currently, there are three principal 
classes of antifungals azoles, polyenes and echinocandins used in antifungal 
therapy(Dixon and Walsh, 1996). 
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Figure 1.6 - Antifungal drug targets. 1) Azoles inhibit Erg11, affects ergosterol 
biosynthesis, which cause fungal membrane stress. 2) Polyenes bind with 
membrane sterol, thereby forming trans membrane pores, which cause cell 
leakage 3) Echinocandins inhibit β-(1, 3) - glucan synthase, thus disrupt cell-wall 
integrity 4) Flucytosine inhibits DNA and RNA synthesis, disturbs the translation 
of certain crucial proteins (adapted from Doctor Fungus [http://www. 
doctorfungus.org/thedrugs/antif_pharm.htm]). 
 
1 
 2   3 
4 
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Table 1.6 - List of antifungal drugs and classes, formulation and year 
introduced. 
 
 
 
 
Class Generic name Formulation Year 
Azole 
Ketoconazole oral, topical 1981 
Fluconazole 
oral, topical, 
intravenous 
1990 
Itraconazole oral, intravenous 1992 
Voriconazole oral, intravenous 2002 
Posaconazole oral, intravenous 2006 
Echinocandin 
Caspofungin intravenous 2002 
Micafungin intravenous 2005 
Anidulafungin intravenous 2006 
Polyene 
Amphotericin B oral, intravenous 1960 
Amphotericin B 
lipid complex 
intravenous 1995 
Amphotericin B 
Liposomal 
intravenous 1997 
Other Flucytosine oral 1964 
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1.3.2.1 Azoles 
Azole drugs are the mainstay of treatment for aspergillosis. They inhibit the 
fungal cytochrome P450 dependent enzyme called lanosterol 14α-demethylase. 
The inhibition of this enzyme depletes the ergosterol synthesis from lanosterol, 
which affects the fungal membrane leading to fungal growth inhibition. Azole 
drugs can be categorised into two main classes, imidazoles and triazoles. Both 
classes share the same mechanism of action but are slightly different in 
structure. Imidazole is a five membered synthetic ring (Figure 1.7 a) that confers 
antifungal activity. It includes ketoconazole, miconazole and tioconazole. The 
poor antifungal response and toxicity associated with imidazoles led to the 
development of new azoles, namely triazoles (Maertens, 2004). Triazoles are 
developed by a minor modification in imidazole ring (Figure 1.7 b), which gives 
improved activity and less adverse effects. Triazoles include fluconazole, 
itaconazole, voriconazole and posaconazole. According to a recent survey 
fluconazole (60.5%) was one of the most used antifungal agents in European 
hospitals and voriconazole (70%) in USA and Canada (Karas et al., 1976, 
Kawamura et al., 2000). 
 
 
 
 
 
Figure 1.7 - Azoles. Structure of two different classes of azoles, (a) imidazole 
and (b) triazole. 
 
 
(a)Imidazole         (b)Triazole 
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1.3.2.2 Polyenes 
The polyene class of antifungals remain an important antifungal option for life 
threatening invasive aspergillosis. Polyenes are naturally-occurring  poly-
unsaturated compounds consist of seven conjugated carbon-carbon double 
bonds, a carboxyl group, an ester and a primary amino group along the side 
chain (Figure 1.8 b). Amphotericin B is one of the organic polyene compounds 
first isolated in the mid-1950s from Streptomyces nodosus (Dixon and Walsh, 
1996). Amphotericin B presents a broad spectrum of antifungal activity. It binds 
with membrane sterols, forming a transmembrane channel causing cell leakage, 
leads to cell death (Figure 1.8) (Ghannoum and Rice, 1999, Milhaud et al., 2002). 
One of the problems with polyenes is their drug target, sterols. Both mammalian 
(cholesterol) and fungal (ergosterol [Figure 1.8a]) cell membranes contain 
sterols, they are similar in structure so polyenes can be cytotoxic to host cells by 
forming pores within the cell membrane (Baginski and Czub, 2009, Ghannoum 
and Rice, 1999). Later studies mixed amphotericin B with lipid emulsions and 
demonstrated reduced toxicity, while having similar efficacy. Then a different 
lipid formulation of Amphotericin B was developed and in 1990s three distinct 
formulations were approved, ABCD, Amphotericin B lipid complex and 
unilamellar vesicle liposomal formulation.  
 
Figure 1.8 - Polyenes. Amphotericin B binds with membrane sterol and alters 
permeability of cell membrane. Chemical structure of (a) ergosterol and (b) 
amphotericin B. 
a) b) 
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1.3.2.3 Echinocandins 
Previously mentioned antifungal classes, azoles and polyenes are associated with 
drug toxicities, problem with drug interactions and nonlinear pharmacokinetics 
(Sheehan et al., 1999, Worth et al., 2008, Lewis, 2011, Albengres et al., 1998). 
The lipid formulations of amphotericin B were demonstrated to be less toxic but 
their acquisition cost is high. Given these drawbacks, scientists were forced to 
look for new drug targets. In 1970s, researchers found a new class of antifungals 
to treat fungal infections called echinocandins. Echinocandins are non-
competitive inhibitors of 1, 3 - β glucan synthase, an enzyme necessary for the 
synthesis of fungal cell wall glucan(Dixon and Walsh, 1996). Inhibition of glucan 
synthesis disrupts the cell wall integrity leads to fungal growth inhibition or cell 
death. The echinocandins display broad spectrum of antifungal activity. They are 
fungicidal against some species including Candida and fungistatic to others such 
as Aspergillus (Canton et al., 2010, Chen et al., 2011a). Caspofungin was the 
first licensed echinocandin drug in the market then micafungin (Figure 1.9) and 
anidulafungin were licensed and available for antifungal treatment.  
 
 
 
 
 
 
 
Figure 1.9 - Echinocandins. Chemical structure of (a) caspofungin and (b) 
micafungin. 
a) Caspofungin c) Micafungin 
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1.3.2.4 Flucytosine 
Flucytosine is a pyrimidine chemical compound (Figure 1.10). It is an 
antimetabolite type of antifungal drug that inhibits translation of mRNA in fungal 
cells by replacing uracil with 5-flurouracil in RNA. It also inhibits DNA synthesis 
by obstructing thymidylate synthetase via 5-fluorodeoxy-uridine monophosphate 
(Vermes et al., 2000). It is active against some strains of Candida, Aspergillus, 
Cryptococcus and Cladosporium spp both in in vitro as well as in vivo conditions. 
Resistance to flucytosine is quite common with its use alone in antifungal 
treatment. Mutations in cytosine permease or cytosine deaminase enzymes are 
shown to be associated with flucytosine resistance (Polak and Scholer, 1975). To 
avoid resistance flucytosine is always administered with polyenes or azoles or 
with both antifungals as combination therapy (Esposito et al., 2009). Flucytosine 
is commercially available as oral capsules since 1972 however its intravenous 
formulation is no longer available.  
 
 
 
Figure 1.10 – Flucytosine. Chemical structure of flucytosine. 
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1.4 Emergence of antifungal resistance 
Resistance to antimicrobial drugs are well documented and remains a topic of 
discussion by both the scientific and non-scientific community (Neu, 1992, Okeke 
et al., 2005). Over the past decade antifungal resistance has emerged in 
pathogenic fungi such as C. albicans and A. fumigatus (Helmerhorst et al., 1999, 
Hsueh et al., 2005, Pfaller et al., 2011, Messer et al., 2006). Antifungal 
resistance has been associated with treatment failure in patients with life 
threatening fungal infections such as candidiasis and aspergillosis. The term 
‘antifungal resistance’ can be described as a relative decrease in susceptibility 
of fungus to an antifungal agent when compared to other isolates. Standardised 
test protocols from the Clinical and Laboratory Standards Institute (CLSI, USA) or 
the European committee on antimicrobial susceptibility testing (EUCAST, 
Europe) is often used for in vitro susceptibility testing to detect 
resistance(Pfaller et al., 2010, Arendrup et al., 2010, Arendrup et al., 2011, 
2008, Arendrup et al., 2012, Canton et al., 2009). Results from these in vitro 
tests are useful in calculating clinical breakpoints and epidemiological cut off 
values (ECV) (Table 1.7). The cut off values are valuable data helpful to identify 
the acquired resistance in fungi (Meletiadis et al., 2012).  
 
Table 1.7 - MIC of azole drugs and ECVs for A. fumigatus (Lewis, 2007b). 
 
 
 
 
a Values in bracket indicate the percentage of MICs ≤ ECV. 
 
Antifungal agent No. of isolates tested 
MIC (μg/ml) 
Range Mode ECV (%)a 
Itraconazole 637 0.015-2 0.25 1 (99.8) 
Posaconazole 637 0.06-1 0.03 0.25 (99.8) 
Voriconazole 637 0.12-4 0.25 1 (99.2) 
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Azole drugs are one of the recommended antifungal agents for both clinical 
settings and in agriculture. In clinical settings azoles are the first line treatment 
choice for aspergillosis, with echinocandins and polyenes as second line. Recent 
surveys report the association of long term treatment and prophylaxis in relation 
to antifungal resistance (Auberger et al., 2012, Escribano et al., 2012).  In the 
last ten years, azole resistance has predominantly been described for A. 
fumigatus (Figure 1.11a)(Howard and Arendrup, 2011). Azoles drugs are the only 
oral formulated agent available for antifungal treatment that is often used over 
long period of time, for example the CF patients exposed to itraconazole for 
along time were associated with higher prevalence of azole resistance (Burgel et 
al., 2012). In the Netherlands, the prevalence of azole resistance was reported 
to vary between 0.9 to 9.4%, and the use of azoles for protecting agriculture 
crops and material preservation were described to be a risk factor (Verweij et 
al., 2012).  
Currently, A. fumigatus resistance to azoles has been reported all over the 
world, including Belgium, Denmark, France, Norway, Spain, Sweden, Netherland 
and UK in Europe, India, China and Japan in Asia and USA and Canada in North 
America(Lockhart et al., 2011, Snelders et al., 2008, Morio et al., 2012, 
Chowdhary et al., 2012, Bueid et al., 2010, Mortensen et al., 2010, Vermeulen 
et al., 2012, Bowyer et al., 2011). Recently a study from University hospital of 
South Manchester published azole susceptibility data of 749 A. fumigatus isolates 
collected from 1997-2009. This study reports a significant rise in the number of 
azole resistant isolates from 7% in 1999 to 20% in 2009 (Figure 1.11a). Among 64 
resistant isolates from 2008-09, 97% are resistant to itraconazole, 3% are 
voriconazole only resistant and 78% are multi azole resistant isolates (Howard et 
al., 2009, Bueid et al., 2010). One of the commonly reported mechanisms of 
azole resistance in A. fumigatus isolates is mutation within the cyp51A gene 
responsible for ergosterol biosynthesis. However, in Manchester the number of 
resistant isolates from 2008-09 with cyp51A mutations is less compared to other 
areas, about 43% of isolates were non- cyp51A mutants (Figure 1.11b) (Bueid et 
al., 2010). This indicates some other novel mechanism of resistance must be 
responsible. Currently, resistance to other class of antifungals are less known. A. 
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fumigatus resistance to caspofungin has been reported by several studies in 
relation to mutation or overexpression of Fks1 gene (Lewis et al., 2011, Walker 
et al., 2010, Gardiner et al., 2005, Arendrup et al., 2008). Fks1 is the β-glucan 
synthase gene that produces glucan, which is deposited in the extracellular 
surface forming the biofilm matrix (Beauvais et al., 2001).The extracellular 
glucan was shown to be associated with fungal biofilm resistance by impeding 
drug diffusion (Nett et al., 2010b). Antifungal resistance is often associated with 
multicellular development and biofilm formation by fungal cells (d'Enfert, 2006). 
Fungal biofilm-associated infections are frequently recalcitrant to conventional 
therapy because of resistance to antifungal agents. The following sections in this 
chapter discuss in detail about fungal biofilm formation and its associated 
mechanisms of antifungal resistance. 
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a) 
 
 b) 
 
 
 
 
 
Figure 1.11 - Prevalence of azole resistance in Aspergillus fumigatus 1997-
2009. 
a) Bar graph showing the percentage of overall azole resistant isolates for each 
year above each column and colour code indicates the proportion of resistant 
isolates to individual azole drug or multiazole drugs. b) Graph showing the 
percentage of azole resistance isolates in 2008 and 2009 with cyp51A mutations 
above each column. (Bueid et al., 2010). 
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1.5 Clinical significance of Aspergillus multicellular development 
A. fumigatus can cause a wide spectrum of clinical disease and its growth as 
aspergilloma is relatively difficult to treat in comparison to other aspergillosis. 
Aspergillomas can develop in immune competent hosts, but usually require a 
pre-existing cavity such as those resulting from prior tuberculosis. The 
aspergilloma, a localised infection consisting of a spherical mass of hyphae has 
clear biofilm characteristics (Figure 1.12). Another form of aspergillosis 
infection, aspergillary bronchitis, is characterized by bronchial casts containing 
mucus and mycelia, which are associated with pathological damage (Young et 
al., 1970). Compact masses are formed which may be expectorated. Moreover, 
bronchopulmonary lavage (BAL) in some patients with aspergillosis reveals the 
presence of numerous hyphae in the form of a complex multicellular mycetoma 
structure when examined histologically (Jayshree et al., 2006). In contrast, IA 
disease is more diffuse with multiple points of angioinvasion within the 
pulmonary tissue. Nevertheless, filamentous intertwined hyphae are important 
to this process, as in other forms of aspergillosis (Mowat et al., 2007b). Notably, 
antifungal treatment is often ineffectual, which may relate to the Aspergillus 
growth phenotype. 
Clearer evidence of Aspergillus biofilms is demonstrated in infections affecting 
other sites. Aspergilli can enter the host through alternative routes causing other 
serious biomaterial related biofilm infections, including catheters, joint 
replacements, cardiac pace makers, heart valves and breast augmentation 
implants (Langer et al., 2003, Rosenblatt and Pollock, 1997, Jeloka et al., 2011, 
Escande et al., 2011).Aspergillus is also frequently associated with complex 
sinus infections, which in canines have been described as superficial mucosal 
fungal plaque (Day, 2009, Laury and Delgaudio, 2010, Sato et al., 2010, Grosjean 
and Weber, 2007). The urinary tract, whilst less frequently associated with A. 
fumigatus, has been reported to support an aspergilloma (Lee, 2010, Muller et 
al., 2011).  
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Figure 1.12 - Filamentous growth of Aspergillus fumigatus. (a) Scanning 
electron micrograph of A. fumigatus biofilm (Mowat et al., 2009), (b) Histologic 
section of aspergilloma shows branching hyphae of Aspergillus mixed with few 
red cells and neutrophils (Challa et al., 2011). (c-d) Chest radiograph shows a 
thin walled cavitary lesion within the right upper lobe measuring 4.8 x 5.2 x 5.4 
cm. and CT of the thorax demonstrates soft tissue mass within the cavitary 
lesion this makes the diagnosis of aspergilloma most likely (Sandra Lee D.O., MSU 
Radiology).(e-f) a gross specimen slice shows a centrally located aspergilloma 
(arrowhead) delimited by a fibrous wall (arrow) (Bierry et al., 2009). 
a 
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1.6 Aspergillus biofilms 
Microbiologists have historically studied planktonic (free floating and 
homogeneous cells) in pure-culture. However, there has been a paradigm shift as 
the link between sessile (surface attached and heterogeneous cells) and 
microbial pathogenesis and human infection is now widely accepted (Costerton 
et al., 1995). There has been much debate within the mycology community of 
what specifically constitutes a biofilm. The ability of fungi to attach to a surface 
and/or to one another and to be enclosed within an extracellular matrix (ECM) is 
sufficient to fit the basic criteria of a microbial biofilm. From the available 
literature it is increasingly clear that different Aspergillus species do have this 
overall capacity, which is hardly surprising given that 80% of all microorganisms 
are proposed to exist within multi-cellular communities. Moreover, 65% of 
human infection is biofilm associated, which is related to the increasing number 
of immunocompromised patients and the escalating use of biomaterials in 
medicine (Ramage et al., 2009a, Donlan, 2002, Blankenship and Mitchell, 2006, 
Polak and Scholer, 1975).  
Biofilms are defined as highly structured communities of microorganisms that are 
either surface-associated or attached to one another, and are enclosed within a 
self-produced protective extracellular matrix (ECM) (Ramage et al., 2009a). The 
advantages to an organism of forming a biofilm include protection from the 
environment, resistance to physical and chemical stress, metabolic cooperation 
and a community based regulation of gene expression. Fungi growing within 
biofilms exhibit unique phenotypic characteristics compared to their planktonic 
counterpart cells, particularly increased resistance to antimicrobial agents 
(Ramage et al., 2009a). In addition to providing safe sanctuary for 
microorganisms biofilms may also act as reservoirs for persistent sources of 
infection in a patient and as such adversely effect the health of an increasing 
number of individuals, including patients with HIV-infection, cancer, transplants, 
patients requiring surgery or intensive care and newborn infants (Calderone, 
2002, Ramage et al., 2006).  
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The adhesion and colonization of complex fungal populations onto biological and 
innate surfaces, such as the oral mucosa or denture acrylic substrates, is 
commonplace for clinically relevant fungi (Ellepola and Samaranayake, 1998, 
Holmes et al., 2002, Radford et al., 1999, Williams et al., 2011). A wide variety 
of environmental factors contribute to the initial surface attachment, including 
the flow of the surrounding medium (urine, blood, saliva, mucus), pH, 
temperature, osmolarity, bacteria, presence of antimicrobial agents and host 
immune factors (Hawser et al., 1998, Baillie and Douglas, 2000, Richard et al., 
2005, Ramage et al., 2002c, Ramage et al., 2008, Chandra et al., 2001b). Fungal 
biofilms have defined phases of development that have been described through 
the use of defined model systems (Al-Fattani and Douglas, 2004, Baillie and 
Douglas, 1998a, Chandra et al., 2001a, Garcia-Sanchez et al., 2004, Nikawa et 
al., 2003, Ramage et al., 2001a, Ramage et al., 2008). These key phases include 
arriving at an appropriate substratum, adhesion, colonisation, extracellular 
matrix (ECM) production, biofilm maturation and dispersal (Blankenship and 
Mitchell, 2006, Chandra et al., 2001a, Ramage et al., 2001b). Understanding this 
entire process has enabled us to begin to unravel some of the mechanisms 
involved in resistance.  
1.6.1 Biofilm development 
The initial non-clinical based studies explored whether an A. fumigatus 
multicellular structure (or mycelial mass) fits the criteria for a biofilm, and 
represents a source of continuing debate (Chandrasekar and Manavathu, 2008, 
Mowat et al., 2008c). A key factor as observed early in these investigations was 
the critical importance of conidial seeding density, a phenomenon also described 
in studies of A. niger biofilms (Villena and Gutierrez-Correa, 2006). Confocal 
laser scanning microscopy (CLSM) and scanning electron microscopy (SEM) 
demonstrated an optimal conidial seeding density of 1  105 conidia/mL of liquid 
medium. Therefore, structural morphology and integrity was dependant upon 
the concentration of conidia (Mowat et al., 2007b). This biofilm system was then 
amenable to high throughput testing required for the screening of clinical 
isolates and defined mutants, or for testing the susceptibility of antifungal 
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agents (Mowat et al., 2008a). This concentration differs from those described 
elsewhere, where it was reported than an optimized conidial density of 1 × 
106conidia/mL was used, a concentration also reported within an epithelial-
biofilm co-culture system (Seidler et al., 2008, Villena and Gutierrez-Correa, 
2006). However, this log difference was due to subtleties of biofilm model 
systems, which both utilise different substrates and media.  
Fungal biofilms, like bacterial biofilms, have defined developmental phases that 
include arrival at an appropriate substrate, adhesion, colonisation, 
polysaccharide production and biofilm maturation, and dispersal (Chandra et al., 
2001a, Donlan, 2002, Blankenship and Mitchell, 2006). Following initial conidial 
seeding there is a lag phase (conidial adhesion), germination (6 to 8 h), 
filamentation and formation of a monolayer (12 h), followed by increased 
structural complexity, ECM production and maturation (24 h). During this time 
the depth of the biofilm increases from 10 to 200 m (Mowat et al., 2007b). 
These phase dependant growth characteristics play a key role in the outcome of 
antifungal treatment. The development of A. fumigatus biofilms are illustrated 
in Figure 1.13.  
The process of A. niger biofilm formation can also be divided into distinct 
phases: (i) adhesion, which is strongly increased by A. niger spore 
hydrophobicity; (ii) an initial growth and development phase from spore 
germination to surface colonization; (iii) a maturation phase, in which biomass 
density is highly increased with development of an internal channel organization 
(Gutierrez-Correa and Villena, 2003). These channels appear to allow fluids to 
pass through, favouring a better mass transfer (Villena et al., 2010, Villena and 
Gutierrez-Correa, 2006, Villena and Gutierrez-Correa, 2007a). There is also 
different spatial growth coordination when fungus adheres to the surface. This 
coordination responds to steric interactions between hypha and tips in contact 
with surfaces. At short distances, binary interactions (tip–hyphae) involve a local 
spatial rearrangement, resulting in a slowing down of the tip extension rate and 
consequently in a control of maximum biomass surface density (Villena et al., 
2010).
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Figure 1.13 - Aspergillus fumigatus biofilm development. The different phases 
of biofilm development are represented schematically, from initial adhesion of 
conidia, germling formation (8 h), a monolayer of intertwined hyphae (12 h) and 
mature 3D filamentous biomass (c. 200 µm) encased within ECM (24 h). These 
are also illustrated in the adjacent confocal laser scanning micrographs stained 
using FUN1 (Molecular Probes) (Ramage et al., 2011). 
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1.6.2 Adhesion 
Filamentous growth is a fundamental feature of fungal biofilms and is an 
important morphological characteristic of A. fumigatus required during the 
development of an aspergilloma (Ramage et al., 2009a). The initial 
establishment of these chronic infections involves the germination of conidia and 
subsequent hyphal invasion of the lung tissues (Filler and Sheppard, 2006). 
Fungal spores adhere to compatible surfaces through several mechanisms, which 
include complex interactions of physical and biological processes. Physical 
properties of support like hydrophobicity, electrostatic charge and surface 
roughness are important at the initial adhesion step of bacteria, as well as 
yeasts and filamentous fungi (Bigerelle et al., 2002, Cunliffe et al., 1999, 
Dufrene, 2000, Webb et al., 1999). 
A small class of amphipathic proteins called hydrophobins principally mediate 
adhesion in filamentous fungi, and have recently been shown to play a role in 
fungal biofilm development (Armenante et al., 2010, Bruns et al., 2010, Perez et 
al., 2011). Hydrophobins stabilize the adhesion of spores to both natural and 
artificial hydrophobic surfaces possibly generating morphogenetic signals (Linder 
et al., 2005, Wosten, 2001, Scholtmeijer et al., 2001). Hydrophobins, a family of 
small-secreted proteins with a characteristic pattern of eight cysteine residues, 
have been reported in A. fumigatus to be responsible for the strong adhesion 
forces of 2858 ± 1010 pN during spore adhesion to surfaces(Dupres et al., 2010, 
Dague et al., 2008). It seems that conidium contact per attachment is required 
to trigger germination (Shaw et al., 2006). 
It has been shown that when A. niger biofilms are under stress caused by low 
water activity (aw) then high amounts of extracellular material are secreted 
(Villena and Gutierrez-Correa, 2007c). In some plant pathogenic fungi like 
Bipolaris sorokiniana the production of extracellular material appears to be 
important for adhering conidia and germlings to the host surface (Apoga et al., 
2001). For the development of A. niger biofilms the spore rough surface is 
important for its first physical attachment to the support surface and this 
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process is also helped by the production of adhesive substances forming a pad 
beneath spores; this has been found when different supports were used, 
indicating that the adhesive substances are part of the adsorption process 
(Villena and Gutierrez-Correa, 2007b, Gamarra et al., 2010, Lord and Read, 
2011).  
Further studies of the genetic basis of biofilm formation have revealed a role for 
medA, which has recently been characterized with respect to conidiation, host 
cell interactions and virulence (Gravelat et al., 2010). Here it was reported that 
in addition to its role in conidiophore morphology, it was shown that its mutant 
phenotype was impaired in biofilm production in addition to adherence to 
plastic, pulmonary epithelial cells, endothelial cells and fibronectin in vitro. 
Moreover, this strain had reduced capacity to damage pulmonary epithelial cells 
and stimulate pro-inflammatory cytokines, which was reflected by reduced 
virulence in both an invertebrate (Galleria mellonella) and a mammalian model 
(mouse) of invasive aspergillosis (Gravelat et al., 2010).  
It was also shown that deletion of cspA (cell surface protein A), which encodes a 
repeat-rich glycophosphatidylinositol (GPI)-anchored cell wall protein, causes 
weakening of the conidial cell wall (Levdansky et al., 2010). Analysis of double 
mutants indicated that CSPA interacts with the cell wall protein-encoding genes 
ECM33 and GEL2, deletion of which results in strongly reduced conidial adhesion, 
increased disorganization of the conidial cell wall, and exposure of the 
underlying layers of chitin and beta-glucan. Given the number of genes integral 
to adhesion and cell wall structure, it is likely that many play a pivotal role in 
the different phases of biofilm formation, and as biofilm becomes an accepted 
term within the Aspergillus research community many future studies will 
elucidate the molecular pathways for its development.  
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1.6.3 Molecular Mechanisms 
Very few reports on the molecular biology and functional genomics of Aspergillus 
biofilms have been published, yet a recent study reported global transcriptional 
and proteomic biofilm specific changes in A. fumigatus(Bruns et al., 2010). 
Planktonic- and biofilm-grown mycelium at 24 and 48 h growth were analysed 
using microarrays and 2-D gel electrophoresis. Both biofilm- and time-dependent 
regulation of many proteins and genes associated with primary metabolism was 
demonstrated, indicating an energy dependant developmental stage of young 
biofilms. Biofilm maturation showed a reduction of metabolic activity and an 
upregulation of hydrophobins, and proteins involved in the biosynthesis of 
secondary metabolites, such as gliotoxin (Bruns et al., 2010). Specifically, it was 
shown that 36 protein spots changed in biofilm mycelium of A. fumigatus in 
comparison to planktonic mycelium, and 78 protein spots changed significantly 
during biofilm maturation. Based on FunCat categorisation these included 
proteins involved in ‘metabolism’, ‘protein with binding function or cofactor 
requirement’ and ‘cellular transport, transport facilitation and transport 
routes’. Transcriptional profiling demonstrated that 740 genes were 
differentially regulated (179 up- and 561 down-regulated) with respect to 24 h 
biofilm versus planktonic cells. The up-regulated genes were mainly involved in 
protein synthesis, metabolism, energy conservation, and encoded for proteins 
with binding function or cofactor requirement. Many down-regulated genes were 
involved in signal transduction, cell type differentiation, interaction with the 
environment, biogenesis of cellular components, regulation of metabolism and 
protein function, as well as cell and protein fate (Bruns et al., 2010). Recent 
work has used RNA-Seq to compare the transcriptomes of biofilm and liquid 
planktonic growth, where sequencing identified 3,728 differentially regulated 
genes in the two conditions (Gibbons et al., 2011). In addition to many genes 
that are likely to reflect the different growth demands, these investigations 
identified many up-regulated genes involved in transport, secondary 
metabolism, and cell wall and surface functions. Mapping of these genes showed 
significant spatial structure across the genome. 1,164 genes were down-
regulated, which were involved in primary metabolic functions, including carbon 
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and amino acid metabolism. Interestingly, these were not spatially structured 
across the genome. This work has provided some initial insight into the genetics 
of biofilm formation. 
1.7 Mechanisms of fungal biofilm resistance 
One of the defining characteristics of biofilms is their increased resistance to 
antimicrobial agents. Fungi have been reported to be up to 1000-fold more 
resistant to antifungal agents than planktonic free floating cells, yet this 
recalcitrance to antimicrobial therapy has yet to be fully elucidated (Di 
Bonaventura et al., 2006, Ramage et al., 2001a, Tre-Hardy et al., 2008). Despite 
some antifungal agents being efficacious against fungal biofilms, particularly the 
echinocandins and liposomal amphotericin B formulations, the intrinsic 
resistance exhibited by these complex structures has promoted detailed 
investigation (Kuhn et al., 2002, Ramage et al., 2002b, Bachmann et al., 2003, 
Bachmann et al., 2002, Mowat et al., 2008a).  
Antifungal resistance is both complex and multi-factorial (Figure 1.14). It can be 
inducible in response to a compound, or an irreversible genetic change resulting 
from prolonged exposure. Specifically, these include alterations or over-
expression of target molecules, active extrusion through efflux pumps, limited 
diffusion, tolerance and cell density, which are all characterised mechanisms 
utilised by fungi to combat the effects of antifungal treatment (Niimi et al., 
2010). Planktonic cells generally rely on irreversible genetic changes to maintain 
a resistant phenotype, whereas biofilms are able to persist due to their physical 
presence and the density of the population, which provides a resistant 
phenotype irrespective of defined genetic alterations. The biofilm formation and 
its underlying resistance mechanisms in Candida species are well documented 
compared to other fungal species. C. albicans is one of the top four fungal 
pathogens causing nosocomial infections in humans. The morphology of A. 
fumigatus biofilms is somewhat analogous to a Candida species (Mowat et al., 
2008a, Mowat et al., 2008c, Chandra et al., 2001a). The following section will 
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now describe some of the pivotal factors that play a role in fungal biofilm 
resistance with an emphasis on the paradigm, i.e. Candida species. 
1.7.1 Physiological state 
The general physiological state of cells in sessile populations has also been 
implicated to influence the susceptibility profiles of biofilms. Metabolic dyes 
assays (e.g. XTT-based assays) confirm that cells within biofilms are undergoing 
mitochondrial respiration during development (Chandra et al., 2001a, Hawser, 
1996, Ramage et al., 2001a, Kuhn et al., 2003, Mowat et al., 2008a). Other 
factors including the effect of growth rate on C. albicans biofilm resistance has 
also been studied, where varying the rates were shown to play no role in 
resistance to amphotericin B (Baillie and Douglas, 1998a). Similarly, biofilms of 
C. albicans grown under glucose and iron limited conditions were shown to both 
be highly resistant to amphotericin B (Baillie and Douglas, 1998b). Furthermore, 
studies of biofilms grown under anaerobic conditions demonstrated that C. 
albicans biofilms were resistant to high levels of amphotericin B and different 
azole antifungals (Dumitru et al., 2004). Nevertheless, factors including pH, 
temperature, oxygen availability and other environmental stresses will alter the 
biofilm architecture and possibly antifungal sensitivity (Kucharikova et al., 2011, 
Pettit et al., 2010). Therefore, whilst the physiological state of the cell may 
have a minor role in resistance (e.g. dormancy), it is more likely that more 
complex factors are involved.  
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Figure 1.14 - Schematic overview of fungal biofilm resistance mechanisms. 
Generic overview of key biofilm resistance mechanisms associated with C. 
albicans, but which are likely to be common to other fungi. This figure 
illustrates the density and complexity of the C. albicans biofilm, with different 
morphotypes present surrounded by ECM. The arrows represent the different 
factors that drive antifungal resistance within the biofilm, including density, 
stress, persisters, ECM, efflux, over-expressed targets and the general physiology 
of the biofilm. These have been placed according to their contribution to 
resistance, with those that have a greater effect closer to the middle and those 
with less impact at the edges (Ramage et al., 2012). 
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1.7.2 Cell density 
The architecture of biofilms is highly ordered to enable the perfusion of 
nutrients and expulsion of waste products. Mature biofilms, whilst densely 
populated, exhibit spatial heterogeneity with microcolonies and water channels 
being present, features are common to both bacterial and fungal biofilms 
(Chandra et al., 2001a, Lawrence et al., 1991, de Beer et al., 1994). Cell density 
is therefore an important resistance factor within complex biofilm populations of 
yeast and filamentous fungal biofilms. It was demonstrated that both planktonic 
and resuspended biofilm cells exhibited azole sensitivity at low cell numbers (103 
cells/ml), which became increasingly resistant as the density of the cells 
increased tenfold (Perumal et al., 2007), a phenomenon also been demonstrated 
in A. fumigatus(Lass-Florl et al., 2003). A phase-dependant increased antifungal 
resistance has been shown in A. fumigatus and C. albicans, respectively (Mowat 
et al., 2008a, Mukherjee et al., 2003), which support the idea that the physical 
density of the biofilm produces recalcitrance to antifungal agents.  
Within dense biofilms there is cooperation between individual cells through 
quorum sensing processes, which provide the ability of microorganisms to 
communicate and coordinate their behaviour via the secretion of signalling 
molecules in a population dependent manner (Miller and Bassler, 2001). In fungi 
this was first described in C. albicans when Hornby and colleagues identified 
farnesol trans, trans 3,7,11-trimethyl-2,6,10-dodecatrien-1-ol (Hornby et al., 
2001). Exposing C. albicans to exogenous farnesol results in genome wide 
responses, including genes involved in drug resistance (CaFCR1 and CaPDR16) 
(Cao et al., 2005, Enjalbert and Whiteway, 2005). It has now been shown that 
quorum sensing in C. albicans is likely driven by the two component regulatory 
system of Chk1p (Kruppa et al., 2004). However, when deleted the chk1 strain 
shows a similar azole resistance profile to that of wild type (Perumal et al, 
2007), indicating that regulatory circuit that controls biofilm resistance may be 
yet to be discovered, or cell density is not a defined biofilm resistance factor. 
However, given that echinocandins are highly effective against biofilms suggests 
cell density has a limited effect (Bachmann et al., 2002). In addition, previous 
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work has shown that disrupted biofilms that are resuspended and tested using 
the CLSI methodology in comparison to planktonic cells retain a resistant 
phenotype (Ramage et al., 2002a), indicating alternative mechanisms of 
resistance. The process of quorum sensing in A. fumigatus biofilms is unclear. 
The quorum sensing molecule farnesol was shown to be associated with cell wall 
integrity pathway in A. fumigatus (Dichtl et al., 2010), but its role in controlling 
cell density or biofilm resistance is not known.  
1.7.3 Alterations of drug targets 
The azoles are generally fungistatic against yeasts, including Candida species, 
and fungicidal against moulds, such as Aspergillus species. The fungistatic 
nature of the azoles towards C. albicans induces a strong directional selection on 
the surviving population to evolve drug resistance (Anderson, 2005, Cowen, 
2008). In fact, high levels of azole resistance in C. albicans clinical isolates often 
accumulate through multiple mechanisms including the alteration of 
ERG11(Anderson, 2005). Azoles actively target the 14 α-demethylase enzyme, 
blocking ergosterol biosynthesis and leads to depletion of the ergosterol content 
of membranes and results in the accumulation of toxic sterol pathway 
intermediates, such as 14-methylergosta-8,24(28)-dien-3b,6a-diol, which 
inhibits growth (Akins, 2005, Cannon et al., 2007). The principle drug target, 
Erg11p, can develop point mutations or be overexpressed (Akins, 2005, Cannon 
et al., 2007, White, 1997). Common mutations in the Erg11p that confer 
moderate azole resistance are S405F, Y132H, R467K and G464S (Marichal et al., 
1999, Perea et al., 2001, Sanglard et al., 1998, Blosser and Cramer, 2012). In A. 
fumigatus, point mutations in ERG11 such as N22D, M220 (I, V, K, T), G54 (R, E, 
K, V), Y491H, T440A, M236 (V, K, T) and S35S or overexpression of ERG11 gene 
were shown to be associated with azole resistance (Blosser and Cramer, 2012, 
Diaz-Guerra et al., 2003, Edlind et al., 2001, Mellado et al., 2001, Chen et al., 
2005) 
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Given the importance of ergosterol as a target of azoles and the high level 
resistance exhibited by these structures, then the sterol composition of C. 
albicans biofilms has been investigated. Sterol analyses showed that ergosterol 
levels were significantly decreased in intermediate (12 h) and mature phases (48 
h), compared to those in early-phase biofilms (6 h) (Mukherjee et al., 2003). In 
contrast, in one of the first C. albicans biofilm studies to use microarray analysis 
over-expression of ERG25and ERG11 was reported (Garcia-Sanchez et al., 2004). 
Enrichment or redistribution of ergosterols in biofilm membranes may explain 
their resistance to both azole- and polyene derived antifungal agents. For 
example, C. albicans biofilms cultured in a flow cell for 36 h were compared to 
planktonic cells, where it was shown that a subpopulation of blastospores from 
the biofilm were 10 times more resistant to amphotericin B than planktonic 
populations (Khot et al., 2006). Transcriptional analysis of planktonic and the 
biofilm subpopulation for ergosterol genes and beta-1, 6-glucan pathways 
indicated a possible association between the high level of resistance and 
differential regulation of CaERG1, CaERG25, CaSKN1, and CaKRE1. Therefore, 
changes in both the cell membrane and the cell wall may be important 
determinants of resistance in the biofilm. Subsequent work has shown that 
transcriptional responses in young and mature biofilms after exposure to high 
doses of fluconazole or amphotericin B demonstrated differential antifungal drug 
responses (Nailis et al., 2010). Exposure of both young and mature biofilms to 
fluconazole induced up-regulation of genes encoding enzymes involved in 
ergosterol biosynthesis (CaERG1, CaERG3, CaERG11 and CaERG25), particularly 
biofilms exposed for longer periods (22 h). Whereas, treatment of both young 
and mature biofilms with amphotericin B resulted in an overexpression of 
predominantly CaSKN1, with a modest upregulation of CaKRE1. Removal of the 
antifungal in this study depleted further transcriptional changes, except for 
CaSKN1, which was impacted by prior fluconazole exposure. It was speculated 
that this related to biofilm regrowth. Increased ergosterol gene expression has 
also been reported in vivo in a C. albicans central venous catheter biofilm 
model, demonstrating the importance of the molecule within the biofilm (Nett 
et al., 2009). Induction of ergosterol genes has also been described in C. 
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dubliniens is, where incubation with fluconazole and formation of biofilm was 
coupled with up-regulation of the CdERG3 and CdERG25 (Borecka-Melkusova et 
al., 2009). Moreover, up-regulation of genes involved with ergosterol 
biosynthesis has been described in C. parapsilosis biofilms (Rossignol et al., 
2009), which are also resistant to azole antifungal therapy (Katragkou et al., 
2008). Overall these data highlight the importance of ergosterol in biofilm 
resistance. Recent studies have shown that simvastatin, which impairs 
cholesterol metabolism in humans, is capable of inhibiting C. albicans biofilms, 
thus providing a potential novel strategy of combating these tenacious infections 
(Liu et al., 2009).  
1.7.4 Efflux pump mediated resistance 
The primary molecular mechanism leading to high level azole resistance in C. 
albicans is increased efflux of drug, mediated mostly by the ATP-binding 
cassette (ABC) and the major facilitator superfamily (MFS) transporters 
(Albertson et al., 1996, Lopez-Ribot et al., 1999, Sanglard et al., 1997). The ABC 
transporters in C. albicans constitute a multi-gene family, which includes several 
CDR genes (CDR1-4) (Prasad et al., 1995, Walsh et al., 1997). The ABC 
transporters include a membrane pore composed of transmembrane segments 
and two ABCs on the cytosolic side of the membrane, which provide the energy 
source for the pump (Higgins, 1992, Balzi and Goffeau, 1995). Importantly, 
multiple antifungal agents can be substrates for these transporters and thus 
their over-expression can lead to cross-resistance among different drugs, 
particularly azoles. Among members of the MFS, which are secondary 
transporters and use proton-motive force across the plasma membrane, the 
MDR1 gene encodes a major facilitator that has been implicated in C. albicans 
azole resistance, and its over-expression leads to exclusive fluconazole 
resistance (White, 1997, Williams et al., 2011). Echinocandin sensitivity is 
unaffected by efflux pumps (Niimi et al., 2006).  
Genes encoding for drug efflux pumps have been reported in biofilms to be 
differentially regulated during development and upon exposure to antimicrobial 
agents include CaCDR1, CaCDR2 and CaMDR1(Lepak et al., 2006, Mateus et al., 
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2004, Mukherjee et al., 2003, Ramage et al., 2002a). In the first study to 
investigate the role of efflux pumps, it was demonstrated that expression of 
genes encoding both types of efflux pump was upregulated during the course of 
biofilm formation and development. Both CaCDR1 and CaCDR2 were upregulated 
in 24 and 48 h biofilms, whereas CaMDR1 was transiently upregulated at 24 h 
(Ramage et al., 2002a). However, their contribution to resistance in the biofilm 
phenotype was placed in doubt when a set of C. albicans isogenic strains 
deficient in efflux pumps carrying single- and double-deletion mutations 
(Δcdr1, Δcdr2, ΔMDR1, Δcdr1/Δcdr2, and ΔMDR/Δcdr1) that rendered the cells 
hypersusceptible to fluconazole when planktonic retained the resistant 
phenotype during biofilm growth. In a subsequent investigation, C. 
albicans biofilms were formed through three distinct developmental phases that 
were associated with high fluconazole resistance. Again, the same set of 
isogenic C. albicans strains were utilised where it was shown that 6h old biofilms 
formed by double and triple mutants were >4 to 16-fold more susceptible to 
fluconazole than the wild-type strain (Mukherjee et al., 2003). At 12 and 48h, all 
the strains became highly resistant to this azole, indicating lack of involvement 
of efflux pumps in resistance at late stages of biofilm formation.  
Cell density studies of the efflux pump isogenic strains showed these remain 
hypersensitive at low cell concentrations yet resistant at high cell 
concentrations and in biofilm, indicating a contributory resistance role of cell 
density (Perumal et al., 2007). Nevertheless, similar to the study by Ramage and 
co-workers (Ramage et al., 2002a), C. albicans biofilms were shown to express 
CaCDR and CaMDR1 genes in all three phases (6, 12, and 48h), whilst planktonic 
cells expressed these genes transiently. In fact, GFP promoter studies have 
shown induction of efflux pumps after 15 min adherence to provide a tolerant 
biofilm phenotype(Mateus et al., 2004). Animal studies have also shown that 
biofilms formed on implanted catheters express efflux pumps (Andes et al., 
2004, Nett et al., 2009). Transcript upregulation of CaCDR2 at 12h (1.5-fold) and 
CaMDR1 at both 12h (2.1-fold) and 24 h (1.9-fold) was demonstrated (Nett et al., 
2009). In C. glabrata, similar results are reported, where expression of 
CgCDR1 and CgCDR2 was investigated during the early (6h), intermediate (15h), 
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and mature (48h) phases of biofilm development. At 6 h and 15h, the biofilms 
exhibited approximately 1.5- and 3.3-fold upregulation of CgCDR1 and 0.5- and 
3.1-fold upregulation of CgCDR2, respectively, in comparison to planktonic 
cells(Won Song et al., 2008).  
Sequence analysis suggest that A. fumigatus has 278 different MFS and 49 ABC 
transporters (Nierman et al., 2005). A. fumigatus MDR pumps have been 
described in several studies, and have been shown to be associated with 
increased resistance to itraconazole (da Silva Ferreira et al., 2004, Nascimento 
et al., 2003). Currently, however, there is little evidence to suggest that these 
play an active role in clinical biofilm resistance (Cannon et al., 2009). This will 
be explored within this thesis. 
1.7.5 Extracellular matrix 
ECM is a defining characteristic of fungal biofilms, providing the cells protection 
from hostile factors such as host immunity and antifungal agents (Ramage et al., 
2009a). In some of the pioneering work by the Douglas group C. albicans ECM 
was shown to increase when biofilms are grown under dynamic flow conditions 
(Al-Fattani and Douglas, 2004, Baillie and Douglas, 2000, Hawser et al., 1998). 
However, subsequent work has shown that while diffusion is hampered by ECM, 
penetration of antifungal drugs is not thought to play a key role in biofilm 
resistance (Al-Fattani and Douglas, 2004). Recent studies have provided new 
insights that suggest the chemical composition of ECM and its regulation may 
play a central role in resistance.  
The composition of the ECM of these biofilms in C. albicans and C. tropicalis is 
complex, comprising of protein, hexosamine, phosphorus, uronic acid, and 
carbohydrates (Al-Fattani and Douglas, 2006). Recently it has been shown that 
extracellular DNA is another important component of the ECM (Martins et al., 
2010). One of the principle carbohydrate components is beta-1,3 glucans, as 
treatment of C. albicans biofilms with beta-1,3 glucanase helps detach biofilms 
from a substrate (Al-Fattani and Douglas, 2006). Its contribution is confirmed in 
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a series of investigations by the Andes group where it was shown to increase in 
C. albicans biofilm cell walls compared to planktonic organisms, and was also 
detected in the surrounding biofilm milieu and as part of the ECM (Nett et al., 
2007). Beta-1,3 glucans has also been shown to increase in investigations of 
three specific phases of biofilm development grown on both denture acrylic and 
catheter substrates (Yeater et al., 2007). Its contribution to resistance was 
realized when it was also shown that biofilm cells walls bound 4-5 fold more 
azole than equivalent planktonic cells, and culture supernatant bound a 
quantifiable amount of this antifungal agent. Moreover, beta-1,3 glucanase 
markedly improved the activity of both fluconazole and amphotericin B. Addition 
of exogenous biofilmECM and commercial beta-1,3 glucan also reduced the 
activity of fluconazole against planktonic C. albicans in vitro(Nett et al., 2007). 
The group have recently shown that the ECM -1,3 glucan is synthesised from 
Fks1p using a defined knockout and over-expressing strain (Nett et al., 2010b). 
This study demonstrated that beta-1,3, glucan is responsible for sequestering 
azoles, acting as a ‘drug sponge’ and conferring resistance on C. albicans 
biofilms (Nett et al., 2010b). Further studies have shown that they are also 
responsible for sequestering echinocandins, pyrimidines, and polyenes (Nett et 
al., 2010a). This has been confirmed independently where ampB was shown to 
physically bind C. albicans biofilms and beta-glucans (Vediyappan et al., 2010). 
Subsequent studies have identified a role for the CaSMI1 in biofilm ECM 
production and development of a drug resistant phenotype, which appears to act 
through transcription factor CaRlmp and glucan synthase Fks1p (Nett et al., 
2011a).  
In addition to CaFKS1, a zinc-response transcription factor CaZAP1 has been 
shown to be a negative regulator of ECM soluble beta-1,3 glucan in both in vitro 
and in vivo C. Albicans biofilm models through expression profiling and full 
genome chromatin immunoprecipitation (Nobile et al., 2009). Conversely, two 
glucoamylases, CaGCA1 and CaGCA2, are thought to have positive roles in matrix 
production.  A group of alcohol dehydrogenases CaADH5, CaCSH1, and CaLFD6 
also have roles in matrix production, with CaADH5 acting positively, and CaCSH1 
and CaLFD6 acting negatively (Nobile et al., 2009). It is thought that these 
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alcohol dehydrogenases generate quorum-sensing aryl and acyl alcohols, which 
co-ordinate biofilm maturation. Collectively, it appears that C. albicans ECM 
production is highly regulated and is a key resistance factor. It is also present on 
a number of other Candida spp., including C. glabrata, C. parapsilosis, C. 
tropicalis and C. dubliniensis (Silva et al., 2009, Silva et al., 2011).  
Significantly less is known regarding the role of A. fumigatus biofilm ECM in 
antifungal resistance. In an aerial static model, the presence of extracellular 
hydrophobic ECM is composed of galactomannan, alpha-1,3 glucans, 
monosaccharides, polyols, melanin, and proteins, including major antigens and 
hydrophobins (Beauvais et al., 2007b). This study demonstrated that 
hydrophobic matrix cohesively bound hyphae together, and that the matrix 
increased with maturity of the developing structure. Further studies report that 
a new galactosaminogalactan and the galactomannan were the major 
polysaccharides of the in vivo A. fumigatus ECM (Loussert et al., 2010). 
Extensive ECM production was also reported as the maturity of the biofilm 
increases (Mowat et al., 2009). For A. niger, after germination upon a support, 
the new hyphae also produce an ECM (Villena and Gutierrez-Correa, 2007b). The 
production of ECM has also been reported elsewhere, where it has been shown 
to be produced on both polystyrene and cystic fibrosis (CF) bronchial epithelial 
cells by A. fumigatus, that were resistant to antifungal agents(Seidler et al., 
2008). 
Martinez and Casadevall (2006) reported that C. neoformans also have the 
ability to form biofilm structures in vitro, and produces ECM (Martinez and 
Casadevall, 2006). In Pneumocystis spp. confocal microscopy has revealed 
organisms enmeshed in ECM. Intense monoclonal antibody staining to the major 
surface glycoproteins and an increase in (1,3)-β-D-glucan content was also 
evident, suggesting that these components contributed to resistance (Cushion et 
al., 2009). Blastoschizomyces capitatus, Malassezia pachydermatis, 
Sacchromyces cerevisiae, Rhizopus oryzae, Lichtheimia corymbifera, Rhizomucor 
pusillus and Apophysomyces elegans are all reported to produce ECM in their 
biofilms(Beauvais et al., 2009, Cannizzo et al., 2007, D'Antonio et al., 2004, 
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Singh et al., 2011). Therefore, ECM clearly plays a critical role in biofilm 
resistance for a wide number of clinically important fungi, and is one of the 
most significant and regulated resistance mechanisms utilized in the biofilm 
phenotype. Significantly less is known regarding A. fumigatus biofilm ECM and its 
role in antifungal resistance. 
1.7.6 Persisters 
Perister cells are an important mechanism of resistance in chronic infections 
(Fauvart et al., 2011), and a mechanism of resistance that has gathered some 
attention recently in fungal biofilms (Bink et al., 2011, LaFleur et al., 2006, 
Lewis, 2008). Persister cells are “dormant variants of regular cells that form 
stochastically in microbial populations and are highly tolerant to antibiotics” 
(Lewis, 2010)(figure 4). In C. albicans biofilms a small subset of yeast cells have 
been described that are highly resistant to amphotericin B following adhesion, 
which is independent to up-regulation of efflux pumps and cell membrane 
composition (Khot et al., 2006, LaFleur et al., 2006). The first study to describe 
persister cells in fungi, described as a subpopulation of highly tolerant cells. In 
this study C. albicans persisters were detected only in biofilms and not in 
different planktonic populations (LaFleur et al., 2006). Reinoculation of cells 
that survived killing of the biofilm by amphotericin B produced a new biofilm 
with a new subpopulation of persisters, suggesting that these were not mutants 
but phenotypic variants of the wild type, and that attachment to a substratum 
initiated dormancy. The presence of persisters in C. albicans, C. krusei and C. 
parapsilosis biofilms treated with amphotericin B was also described (Al-Dhaheri 
and Douglas, 2008). It was further hypothesized that the periodic application of 
antimicrobial agents may select for strains with increased levels of persister 
cells, so 150 isolates of C. albicans and C. glabrata were obtained from cancer 
patients who were at high risk for the development of oral candidiasis and who 
had been treated with topical chlorhexidine once a day. It was shown that the 
persister levels of the isolates varied from 0.2 to 9%, and strains isolated from 
patients with long-term carriage had high levels of persisters, whereas those 
from transient carriage did not (Lafleur et al., 2010). Therefore, in this clinically 
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relevant scenario prolonged and ineffectual antifungal treatment may be 
beneficial to the biofilm population, which may be responsible for antimicrobial 
drug failure and relapsing infections. 
The role of reactive oxygen species (ROS) in sessile C. albicans cells was 
investigated as they are known to be induced by high concentrations of 
miconazole, allowing 1-2% of miconazole-tolerant cells to persist (Vandenbosch 
et al., 2010). Superoxide dismutases (Sods) were found to be differentially 
expressed by micronazole treated sessile C. albicans cells compared to 
untreated cells. Inhibition of superoxide dismutase resulted in a 18-fold 
reduction of the miconazole-tolerant persister cells and increased endogenous 
ROS levels in these cells (Bink et al., 2011). In biofilms from strains lacking 
Δsod4/Δsod5 at least 3-fold less miconazole-tolerant persisters were observed 
and ROS levels were increased compared to the isogenic wild type. Therefore, 
miconazole-tolerant persisters are linked to the ROS-detoxifying activity of Sods. 
Whether this is the definitive molecular basis for C. albicans persister cells or a 
tolerance mechanism still remains to be determined, but these subpopulations 
are clearly another important fungal biofilm resistance mechanism. 
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Figure 1.15 - Persister cells in biofilm. Antibiotic treatment kills normal cells 
(coloured green) in both planktonic and biofilm populations. The persister cells 
in planktonic population (pink) are killed by host immune system, but in the 
biofilm structure the ECM protects the persister cells (pink) from host defences. 
The survived persister cells then repopulate the biofilm and infect the host 
(Lewis, 2007a). 
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1.7.7  Tolerance 
Stress responses have become more fully realized as defined mechanisms of 
antifungal resistance.  Pathogenic fungi encounter a range of physiological 
stresses from different environments, including temperature changes, ionic 
stress, changes in osmolarity, and oxidative stress, such as that experienced in 
the phagosomes of neutrophils (Cannon et al., 2007). These stresses are sensed 
through various receptors, which elicit responses through conserved signaling 
pathways. One of the most important is the mitogen-activated protein kinase 
(MAPK) signal transduction network, and the many others are subject to review 
(Cannon et al., 2007). It was first shown that the mitogen-activated protein 
kinase (MAPK) MKC1p, which is activated by contact stress, is involved in biofilm 
development. Moreover, the null mutant (MKC1Δ) biofilms were azole sensitive, 
in contrast to the sessile wild type and both planktonic strains. This indicates 
that Mck1p is involved in biofilm resistance through a stress pathway 
(Kumamoto, 2005).  
Calcineurin is a Ca2+-calmodulin-activated serine/threonine-specific protein 
phosphatase that plays many critical stress roles in the fungal cell, including 
amongst other things antifungal drug responses (Steinbach et al., 2007).  In 
planktonic cells, calcineurin is critical for C. albicans survival during azole 
treatment (Sanglard et al., 2003). Inhibiting calcineurin pharmacologically or 
impairing calcineurin function genetically, has synergistic activity with 
fluconazole and renders the azoles fungicidal against C. albicans (Onyewu et al., 
2003). Calcineurin has also been implicated in mediating resistance to the azoles 
in both in vitro and in vivo models of biofilm formation (Uppuluri et al., 2008). 
C. albicans cells in biofilms are up to 1,000-fold more resistant to fluconazole 
than planktonic cells, indicating that inhibitors could be used in combinations as 
novel therapeutic interventions to treat or prevent biofilms, whereas C. 
dubliniensis were unable to form biofilms in the presence of calcineurin 
inhibitors (Chen et al., 2011b). Similar studies have evaluated the efficacy of a 
voriconazole-micafungin combination against C. albicans biofilms. Voriconazole 
significantly antagonized the fungicidal effect of micafungin against biofilms. To 
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investigate the mechanism of antagonism, an inhibitor of calcineurin was 
evaluated, which reversed the voriconazole-induced resistance to micafungin 
(Kaneko et al., 2010).  This study also suggested that heat shock protein 90 
(HSP90) molecular chaperone played a role in this antagonism. HSP90 regulates 
complex cellular circuitry in eukaryotes and potentiates the emergence and 
maintenance of resistance to azoles and echinocandins in C. albicans, at least in 
part via calcineurin (Cowen and Lindquist, 2005). It physically interacts with the 
catalytic subunit of calcineurin, keeping it stable and poised for activation 
(Singh et al., 2009). It is likely that HSP90 plays a significant role in fungal 
biofilm resistance, but further work is required to demonstrate this. For 
example, a recent investigation of the C. glabrata biofilm proteome 
demonstrated upregulation of a heat shock protein (Hsp12p) and other stress 
proteins (Trx1p, Pep4p) (Seneviratne et al., 2010).  
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1.8 Aims and hypotheses 
It is evident from the current literature over the past decade that A. fumigatus 
has become increasingly associated with undefined resistance mechanisms. Our 
increased knowledge and understanding of fungal infections has revealed that 
the biofilm phenotype may explain some of this antifungal resistance. It was the 
general hypothesis of this study that A. fumigatus resistance was related to 
adaptation to its environment during morphological transition within the 
maturing biofilm, which endowed it with ability to withstand antifungal 
challenge.  
The aims of this study were therefore to 1) investigate adaptive resistance 
mechanisms in A. fumigatus biofilms by determining how they adapt and 
respond to antifungal challenge during the different phases of growth and 2) 
develop an insect model to investigate these characteristics in vivo. 
 
 
 
 
 
 
 Chapter 2 
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2.1 Introduction 
As discussed in the previous chapter, therapy for fungal disease is limited to a 
small number of drug classes including azoles, echinocandins and polyenes. The 
azole class, which includes fluconazole, itraconazole, voriconazole and 
posaconazole, have been shown to be effective in the treatment of invasive 
aspergillosis (IA) and are the mainstay treatment of this disease (Oren et al., 
2006, Raad et al., 2008, Sambatakou et al., 2006a, Denning et al., 1989). 
Although the triazoles have proven efficacy with good safety profiles, they have 
been shown to be associated with resistance through their continuous use 
(Howard et al., 2009, Meneau and Sanglard, 2005, Mosquera and Denning, 
2002).The mortality of patients with multi-azole resistant invasive aspergillosis is 
was 88% compared with 30-50% who were infected with azole sensitive strains 
(Howard et al., 2009). Mutations within the cyp51A gene involved in the 
ergosterol biosynthesis pathway have been reported to cause azole cross-
resistance (Howard et al., 2009, Mellado et al., 2007, Snelders et al., 2010, 
Snelders et al., 2008). However, a recent study reported that 43% of azole 
resistant isolates did not carry the cyp51A mutation, indicating that other 
mechanisms of resistance were responsible.   
Another commonly described azole resistance mechanism is mediated by multi-
drug resistance pumps, which are involved in the active extrusion of 
antimicrobial molecules, which includes azoles (Cannon et al., 2009). The major 
facilitator superfamily (MFS) represents key transmembrane proteins that have 
been shown to be clinically important in different pathogenic fungi (Morschhauser, 
2010, Cannon et al., 2009). Among members of the ABC transporters the MDR 
genes have been widely implicated in Candida albicans azole resistance (Wakiec 
et al., 2007, White, 1997). These have also been shown to be important in C. 
albicans biofilms, where they have been reported to be transiently expressed 
and are thought to have a role in detoxification (Andes et al., 2004, Ramage et 
al., 2002a, Mukherjee et al., 2003). 
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It has been shown that A. fumigatus also have the capacity to form biofilms 
encased in polymeric matrix, which is the most likely growth modality with a 
fungus ball (Mowat et al., 2008c, Loussert et al., 2010). As these biofilms grow 
they are differentially sensitive to antifungal drugs (Mowat et al., 2008b). 
Sequence analysis suggest that A. fumigatus has 278 different MFS and 49 ABC 
transporters (Nierman et al., 2005). A. fumigatus MDR pumps have been 
described in several studies, and have been shown to be associated with 
increased resistance to itraconazole (da Silva Ferreira et al., 2004, Nascimento 
et al., 2003). Currently, however, there is little evidence to suggest that these 
play an active role in clinical resistance (Cannon et al., 2009). Nevertheless, it 
could be hypothesised that these pumps are activated as the biofilm develops to 
regulate homeostasis, and following exposure to an antifungal compound. This 
activity may explain phase related resistance profiles previously reported 
(Mowat et al., 2008b).  
The aim of this chapter was to investigate the biological activity of efflux pumps 
in A. fumigatus and its differential expression with respect to morphological 
development and azole treatment.  
 
This chapter has been published in a peer reviewed journal: 
Rajendran, R., E. Mowat, E. McCulloch, D. F. Lappin, B. Jones, S. Lang, J. B. 
Majithiya, P. Warn, C. Williams, and G. Ramage. 2011. Azole resistance of 
Aspergillus fumigatus biofilms is partly associated with efflux pump activity. 
Antimicrob Agents Chemother 55:2092-2097. 
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2.2 Material and methods 
2.2.1 Organisms 
A. fumigatus Af293, AfGFP (Loussert et al., 2010) and thirteen clinical isolates 
(YHCF 1-13) obtained from the Royal Hospital for Sick Children (Yorkhill 
Division), Glasgow, United Kingdom were used throughout this component of the 
study. Af293 and YHCF 1-4 were used for all fluorescent uptake assays and in 
quantitative PCR expression analyses. ATCC1163 was used for the in vivo 
expression analyses. A. fumigatus isolates were typically stored as stock spore 
suspensions in sterile Microbank™ beads (Pro-lab diagnostics) at -80oC and 
subsequently were sub cultured on Sabouraud dextrose agar (SAB) (Sigma-
Aldrich) containing 4% glucose as appropriate at 37oC. 
2.2.2 Harvesting and standardisation of conidia 
A. fumigatus was grown on SAB containing 4% glucose as appropriate at 37oC for 
72h. Spores were harvested in phosphate buffered saline (PBS) (Sigma-Aldrich) 
containing 0.025% (v/v) Tween 20 (Sigma-Aldrich) by flooding the plate with 
5mL. After gentle rocking, the spore suspension was collected into universal 
tube and the spores were counted using a Neubauer haemocytometer. The 
standardised suspension was then adjusted to required conidial count in RPMI 
1640 media (Sigma-Aldrich). All procedures were carried out in a class 2 
biological safety cabinet (MDH Intermed). 
2.2.3 In vitro biofilm formation 
A. fumigatus biofilms were grown on commercially available flat bottom 
polystyrene microtitre plates (96 or 24 well plate) or Thermonox™ coverslips 
(13mm) (Corning Incorporated, Corning). Biofilms were formed by aliquoting 
200µL or 1000µL of 1 x 105 conidia/mL into 96 or 24 well plate. The plates were 
then incubated at 37oC for 8, 12 and 24 h. In each plate appropriate positive and 
negative control wells were added for quality control. After incubation period 
the medium was removed and the biofilms were washed with PBS to remove any 
non-adherent cells. 
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2.2.4 Microscopy 
2.2.4.1 Fluorescent imaging of A. fumigatus biofilm 
A. fumigatus GFP expressing strain (AfGFP) biofilms were formed on 
Thermanox™ coverslips in RPMI media for 8, 12 and 24 h using a seeding density 
of 1  105 conidia/mL as detailed above.  After incubation at 37oC, the coverslips 
were washed in sterile PBS and inverted onto a glass slide so the biofilm faced 
upwards. The biofilms were then coated with mounting media and covered with 
another fresh coverslip. Then the biofilms were visualised under a fluorescence 
microscope (Motic BA400) at an excitation and emission wavelength of 395nm 
and 475nm, respectively. One representative from each group was digitally 
captured using Colorview (Soft Imaging System). 
2.2.4.2 Scanning electron microscopy 
A. fumigatus biofilms were formed on Thermanox™ coverslips for 24 h using a 
seeding density of 1  105 conidia/mL as detailed above.  After incubation at 
37oC, the coverslips were washed in sterile PBS. The biofilms were fixed by 
treating the biofilm with 0.1M cacodylic buffer fixative (pH 7.2 [Fisher 
Scientific]) containing 4% (v/v) formaldehyde and 1% gluteraldehyde (v/v) for 2h 
then washed 3 times in 0.1M cacodylic buffer and H2O, dried overnight and then 
dehydrated with a series of ethanol washes (70% (v/v) for 10min, 90% (v/v) for 
10min, 100% (v/v) for 20min), and finally air dried overnight. The specimens 
were then coated with 40% gold – 60% palladium and observed with a Zeiss Evo 
scanning electron microscope in high vacuum mode at 6 -10 kV. 
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2.2.5 Aspergillus fumigatus phase dependant susceptibility testing 
Voriconazole (Pfizer) was prepared in stock solutions of dimethyl-sulphoxide 
(DMSO, Sigma-Aldrich) and diluted to the required concentrations in RPMI. For 
making up the dilutions an aliquot of 100µLof voriconazole was added to the 
appropriate wells in a 96-well microtitre plate (Corning) and serially diluted two 
fold across adjacent wells of the plate, producing a concentration range of 0 – 
256 mg/L. For testing the biofilm MIC, biofilms were allowed to grow for 8, 12 or 
24 h and then washed with PBS as described above, and then serially diluted 
voriconazole in RPMI were transferred into the wells containing biofilm. The 
plate was then incubated for further 24 h at 37oC. The viability of the cells were 
assessed using an XTT assay or by alamarBlue® assay.  The reduction in 
metabolically activity was assessed by comparing with untreated biofilm 
controls. 
2.2.6 XTT reduction assay 
2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2H-Tetrazolium-5-Carboxanilide (XTT) 
assay was performed as described somewhere else with minor modifications 
(Meletiadis et al., 2001a, Meletiadis et al., 2001b, Antachopoulos et al., 2006). 
In brief, XTT (Sigma-Aldrich) was prepared in stock by dissolving in PBS at a 
concentration of 0.5 g/L. The solution was then filter sterilised using vaccum 
filter with a pore size of 22µm and stored at -80oC. Before each XTT assay an 
aliquot of XTT stock was thawed and supplemented with menadione (Sigma-
Aldrich) to a final concentration of 10 µM. For testing the metabolic activity of 
the cells, a 100 µL of XTT-menadione was added into each well and incubate the 
plate in dark at 37oC for 3h. After incubation, optical density was measured 
using plate reader (FLUOstar omega, BMG Labtech) at 492nm. The change in 
absorbance in the XTT assay directly correlates with the metabolic activity of 
the biofilm as previously described (Ramage et al., 2001a, Meletiadis et al., 
2001a). 
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2.2.7 Ala-Nap uptake assay 
The efflux pump activity of A. fumigatus was assessed by using MC-005,556 (Ala-
Nap) as previously described (Lomovskaya et al., 2001).  MC-005,556 (Ala-Nap) is 
enzymatically cleaved inside the cells to produce highly fluorescent β-
naphthylamine (Figure 2.1). Higher levels of fluorescence reflect low efflux 
pump activity and vice versa. A. fumigatus conidia was standardised to 1 x 
105/mL in RPMI and conidial suspensions inoculated into black flat bottomed 
microtiter plate (Costar 3603, Corning) and incubated for 8 h at 37oC. The 
medium was then aspirated and any non-adherent cells removed by thoroughly 
washing the cells with buffer solution three times (K2HPO4 [50mM], MgSo4 
[1mM], and glucose [0.4%]) at pH 7.0. The reaction was initiated by addition of 
Ala-Nap (Sigma-Aldrich) at a final concentration of 64 - 256 mg/L. Fluorescence 
(RFU) was quantified at 30s intervals at an excitation wavelength of 320nm and 
emission of 460nm over 1 h at 37oC using a fluorescent plate reader (FLUOstar 
Omega, BMG Labtech). 
2.2.7.1 Assessment of phase dependant efflux activity 
An optimised alanine β-naphthylamine (Ala-Nap) fluorescent assay was 
performed on six isolates (Af293 and YHCF1-YHCF4) to assess whether different 
phases of A. fumigatus morphological development exhibited efflux pump 
activity, as described above. Selected isolates were washed and standardised to 
1x105 conidia/mL in RPMI as described above and standardised conidial 
suspensions inoculated into black flat bottomed microtitre plate (Costar 3603, 
Corning) and incubated for 8, 12 and 24 h at 37oC. The biofilms were then 
washed with assay buffer. The dry weight of each biofilm was also quantified for 
normalisation. Mature biofilms (24 h) were also disaggregated and washed three 
times to take account for lack of diffusion. The reaction was initiated by 
addition of Ala-Nap at a final concentration of 128 mg/L and fluorescence was 
quantified as described above. The change in relative fluorescence units (RFU) 
was normalised against the dry weight (mg) of each biofilm and presented as 
RFU/mg of biofilm.  
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2.2.7.2 Assessment of efflux activity with azole treatment 
The effect of pre-treatment with voriconazole was also investigated with Ala-
Nap assay. For this experiment a sub MIC level of voriconazole 0.0625 mg/L (for 
the strain Af293) was selected and used for pre-treatment. Biofilms were grown 
for 8 h as described above and treated them with voriconazole at a defined 
concentration. The medium was then aspirated and biofilm was washed with 
assay buffer to remove the voriconazole and other non-adherent cells. The 
reaction was initiated and fluorescence was measured like mentioned above. 
The change in relative fluorescence units (RFU) was normalised against the dry 
weight (mg) of the biofilm and presented as RFU/mg of biofilm.  
 
 
Figure 2.1- Ala-Nap uptake assay. The compound Ala-Nap is generally not 
fluorescent in media once it gets enzymatically cleaved inside the cell it 
produces a fluorescent compound called β-naphthylamine. It is a general 
substrate of efflux pumps so the efflux system actively engages in pumping out 
this compound before the enzymatic cleavage. Therefore, higher levels of 
fluorescence reflect low efflux pump activity and vice versa. 
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2.2.8 Assessment of azole sensitivity in the presence of an efflux pump 
inhibitor 
 To determine whether azole sensitivity was related to efflux pump activity, an 
efflux pump inhibitor (L-Phe-L-Arg-β-naphthylamide [MC-207,110], Sigma-
Aldrich) was used in combination with voriconazole to determine whether 
antifungal efficacy could be enhanced.  
2.2.8.1 Checkerboard titration assay 
For testing azole susceptibility in combination with MC-207,110, Af293 conidia 
were initially standardised to 1 x 105 conidia/mL, inoculated into 96-well 
microtitre plates and incubated for defined periods (8,12 and 24 h) at 37oC, as 
described above. The medium was then aspirated and any non-adherent cells 
removed by thoroughly washing the cells 3 times with PBS.  A checkerboard 
assay was prepared with both voriconazole and MC-207,110. Voriconazole was 
tested at 11 different concentrations (0.005 - 4 mg/L), while MC-207,110 was 
tested at 7 concentrations (8 - 512 mg/L). Voriconazole was dispensed alone in 
the first row and was combined with MC-207,110 in the remaining rows. MC-
207,110 was also dispensed alone in the first column (Figure 2.2). After 
incubation period, an alamarBlue® colorimetric assay was used to assess 
viability, as per the manufacturer’s instructions (Invitrogen). Following these 
initial experiments, a defined concentration of MC-207,110 was selected (64 
mg/L) for all subsequent microdilution testing on the entire panel of strains, 
with voriconazole at 0.005 to 4 mg/L. 
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Figure 2.2 – Checkerboard assay. In checkerboard format eleven different 
concentrations of voriconazole was tested in combination with seven different 
concentrations of MC-207,110. Voriconazole alone was dispensed along the first 
row and MC-207,110 alone along the first column to find their individual activity 
against A. fumigatus biofilm. Remaining well were designed in the way getting 
different concentration combinations of drug and EPI. 
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2.2.9 RNA extraction from biofilms 
The biofilms were grown in 24 well plate or cell culture flasks (Fisher Scientific) 
for 8, 12 and 24 h and washed with PBS to remove any non-adherent cells as 
described above. The biofilms were then scraped off from the plate surface 
using sterile cell scrapers (Corning) and transferred into 2mL screw cap tubes 
(Stratech) with 1mL of Trizol®. The cells were then mechanical disrupted using 
200µL (0.5mm diameter) of silicon glass beads with a mini Bead Beater™ (Biospec 
Products). The biofilm samples were bead beat for two cycles at 48 Hz for 30s 
and samples were placed on ice for 30s in between each cycle. The homogenized 
biofilm materials were maintained at room temperature for 5min and 100µL of 
1-bromo-3-chloropropane (Fisher Scientific) was added to each tubes followed 
by vortex for 30s. Incubated the tubes at room temperature for 15min and then 
centrifuged at × 10000rpm for 15min at 4oC using refrigerated microcentrifuge. 
The RNA containing upper aqueous layer was carefully transferred to a sterile 
RNase free microcentrifuge tube. The RNA was then precipitated by addition of 
equal volume of 100% isopropanol. The mixture was incubated at -20oC for 
overnight to get the maximum RNA precipitates. After overnight incubation the 
precipitate was centrifuged at x10000 rpm for 10min at 4oC using refrigerated 
microcentrifuge. The supernatant was decanted and replaced with 500µL of 70% 
(v/v) ethanol to wash the formed pellet. The tubes were inverted for 3-4 times 
and centrifuged for 5min at x10000rpm at 4oC. The ethanol was then discarded 
and air-dried for approximately 5min. Finally the pellet was re-suspended in an 
appropriate volume of RNase free water. 
2.2.10 DNase digestion 
The extracted RNA was cleaned up by on column DNase treatment using Qiagen 
RNase-free DNase kit following the manufacturer’s instructions. The quantity 
and quality of RNA was then assessed using a NanoDrop™ spectrophotometer ND-
1000 (Labtech International Ltd) and stored at -80oC until required. 
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2.2.11 cDNA synthesis 
The high capacity RNA-to-cDNA master mix (Applied Biosystem) was used to 
reverse transcribe the RNA as per manufacturer’s instructions. Briefly, the RT 
master mix was thawed and centrifuged them before use. Then 4µL of RT master 
mix or No-RT control mix was added to 100ng-1µg of total RNA and the volume 
of the reaction was made up to a final total of 20µL with RNase free water. All 
the reactions were carried out on ice. Then the reverse transcription reaction 
was performed using MyCycler PCR machine (Bio-Rad) with the following 
program. 25oC for 5min, 42oC for 30min, 85oC for 5min and hold at 4oC. The 
reaction volume was set to 20µL and the PCR tubes were loaded into the thermal 
cycler for reverse transcription run.  
2.2.12 Real time PCR analysis 
A. fumigatus Af293, YHCF1-YHCF4 biofilms were prepared in triplicate on 
polystyrene plates for selected time periods (8, 12 and 24 h) as described above. 
In addition, the effect of pre-treatment with voriconazole (1 mg/L) was 
investigated for Af293, YHCF1 and YHCF2 on each of these populations. RNA was 
extracted by TRIzol™ method and cDNA was subsequently synthesised as 
described above. The expression of the multidrug efflux pump genes, AfuMDR 1-
4, was then assessed using quantitative RT-PCR using SYBR® GreenER™ 
(Invitrogen, Paisley, UK) according to the manufacturers’ instructions. The 
primer sets in Table 2.1 were used, as previously described (Knutsen et al., 
2006). Three independent replicate samples from each strain for each parameter 
were analysed in triplicate using MxProP Quantitative PCR machine and MxProP 
3000 software (Stratagene). The PCR conditions for all primers as follows 5min at 
95oC (initial denature), 30s at 95oC (denaturation), 30s at 50-65oC (annealing), 
30s at 72oC (extension) for 40 cycles, followed by a final extension at 72oC for 
10min. All PCR reactions were carried out in a total volume of 25µL. All the gene 
expressions were normalised to β-tublin housekeeping gene according to the 2-
ΔΔCT method (Livak and Schmittgen, 2001).  
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Table 2.1– List of oligonucleotide primers used for real time PCR analysis of 
efflux pump gene expressions. 
Gene name - ID Primer Sequence 
β-tublin – 
AFUA_1G10910 
β-tub F CAATGGCTCCTCCGATCTCC 
β-tub R TCCATGGTACCAGGCTCG 
MDR1 – 
AFUA_5G06070 
MDR1 F TTCCCTTGTTCACAATTCTCTTCG 
MDR1 R TGACATAGACTGTGACAAACTCG 
MDR2  –
AFUA_4G10000 
MDR2 F TTTAGCTCCACCGGGTTTG  
MDR2 R TCGAAAGACCGAACATGCTTGA 
MDR2 - 
AFUA_3G03500 
MDR2 F TCTGATGGCGGTCATCACT  
MDR2 R ATATCCATCCCCCAGGC 
MDR4 – 
AFUA_1G12690 
MDR4 F GTCGCCGTTACTTTGAGAGC 
MDR4 R ATGAAGGCAACCACATAGGC 
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2.2.13 In vivo biofilm model 
The in vivo analysis, diffusion chamber mouse model was performed by Dr P. 
Warn and colleagues in University of Manchester. All post-processing of the 
biofilms was performed by R. Rajendran. Biofilm samples were collected, 
homogenised and quickly placed in Trizol® solution and stored at -80oC until 
required. 
2.2.13.1 Biofilm chamber 
A diffusion chamber kit (Millipore) was modified to create the biofilm chamber. 
Briefly, durapore polyvinylidene fluoride (PVDF) membrane (Millipore,) with pore 
size 0.45μm was fixed to one side of plexiglass rings (Millipore) and silicon sheet 
was fixed on the other side (Figure 2.3).  
2.2.13.2 Chamber Implantation 
Chambers were autoclaved before implanting in mice. Male CD-1 mice were 
anaesthetized with ketamine and xylazine.  The dorsal flank of mice was shaved 
and a small incision was made in the skin.  The diffusion chamber was implanted 
subcutaneously in such a way that the silicon side of the chamber faced the skin 
and the durapore membrane was touching the body.  The wound was closed 
using Ethicon black braided silk non-absorbable suture.  Meloxicam (2mg/kg) was 
administered intra-peritoneally twice a day up to 72h post-surgery. 
2.2.13.3 A. fumigatus growth and azole treatment in diffusion 
chamber 
Once week after the surgery, A. fumigatus ATCC1163 (1 x 105 spores/mouse) was 
injected into the tissue chamber under isoflorane anaesthesia.  Mice were 
treated with vehicle (control), low dose (LD 3 mg/kg) and high dose (HD 10 
mg/kg) voriconazole orally.  Mice, in at least triplicate, were euthanized at 0, 1, 
4 and 24 h post-infection and the chamber was removed. 
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2.2.13.4 In vivo biofilm RNA extraction 
The collected chambers were opened and the biofilm materials were put in 
Trizol® and stored at -80oC. Each sample was thawed on ice and placed into 2mL 
screw cap tube. The RNA was then extracted by Trizol® – bead beating method as 
described above. 
2.2.13.5 In vivo gene expression analysis by real time PCR 
The complementary DNA sequence of in vivo RNA samples was synthesised using 
High capacity RNA-to-cDNA master mix as described above. The expression of 
multi drug transporter gene (AfuMDR4) was then assessed using quantitative RT-
PCR using SYBR® GreenER™ as described above. The housekeeping gene β-tublin 
was used to calculate the relative expression of AfuMDR4 according to the 2-ΔΔCT 
method. Three animals were used as a baseline for comparison to vehicle control 
(n=3 at 1, 4, and 24 h). 
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Figure 2.3– Biofilm chamber. Diffusion chamber kit was modified as shown 
above to get the biofilm chamber. It contains a silicon sheet attached to plexi 
glass ring at one side and PVDF membrane at the other side of the ring, which 
favours the diffusion of nutrients and other molecules from host to the chamber 
and keeps A. fumigatus grown in them. 
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2.2.14 Efflux pump mutational studies 
The MDR gene knockouts were made in University of Manchester with the 
guidance of Dr M. Bromley and Prof P. Bowyer. 
2.2.14.1 Design of oligonucleotide primers for the generation of 
gene KO cassettes 
Typically eight primers are required to generate the KO cassette, two to amplify 
the 5’ flank, two to amplify the 3’ flank, two to amplify the selectable marker 
and finally two nested primers to amplify the final product. The research group 
in Manchester have optimised this procedure so that a generic selectable marker 
fragment can be used and hence only six primers are needed for each KO 
cassette. For designing the primers, firstly MDR genes were identified on the 
central Aspergillus data repository http://www.cadre-genomes.org.uk/. Then 
the gene sequence was extracted along with 1200bp of flanking sequence using 
the export data page (http://www.cadre-genomes.org.uk/Aspergillusfumigatus 
/export view) and pasted it into a word processor. The start site ATG and stop 
codons were identified in order to ensure the extracted sequence was in the 
correct orientation. If necessary the reverse complement of the output was 
obtained from CADRE using the website http://www.bioinformatics 
.org/SMS/revcomp.html, which aids downstream characterisation.  
All the primers were designed using Primer3 software (http://frodo.wi.mit. 
edu/primer3/input.htm). For designing the primers for amplifying flanking 
regions, 1200 bp of upstream flanking sequence was selected and pasted into 
primer 3. The design settings for primer 3 was set as follows: Product size range 
1000-1200, Primer size Min 18: Opt 20: Max 22, Primer Tm Min 58: Opt 60: Max 
62. After running primer 3, ideally picked primers those have 1-2 G’s or C’s in 
the last 3 bases. The primer marked left primer was named xxxxxxxP1 where the 
x represents the CADRE gene identifier. The primer marked right primer was 
attached with the linker sequence TAGTTCTGTTACCGAGCCGG(X) 18-22 to the 5’ 
end gave primer xxxxxxxP2. For downstream primers, the 1200 bp of 
downstream flanking sequence was selected and repeated the primer design 
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process. The primer marked left primer was attached with linker sequence 
GCTCTGAACGATATGCTCCC(X) 18-22 at the 5’ end gave primer xxxxxxxP3. The 
primer marked left primer was named as xxxxxxxP4. In the Microsoft word 
document with the gene sequence, identified the location of primers P1 and P4. 
Then selected all sequence between P1 and P4 (not including primers P1 and P4) 
and identified the number of bases in the selected sequence which gave the 
value ‘b’. The selected sequence was then pasted into primer3 and entered the 
setting as product size range (b - 200)-b. All other settings are as same as 
mentioned above. The resulting primers were named as xxxxxxxP5 and the right 
xxxxxxxP6. 
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Table 2.2– Gene knock out primers. 
Gene name-ID Primer Sequence 
MDR1 – 
AFUA_5G06070 
AFUA_5G0607
0 P1 
TGGCCATACCTGAGGTTCTC 
AFUA_5G0607
0 P2 
TAGTTCTGTTACCGAGCCGGTTGGTTAACTG
GCGGACAAT 
AFUA_5G0607
0 P3 
GCTCTGAACGATATGCTCCCTCCTTCCCCCTT
CTTCTCAT 
AFUA_5G0607
0 P4 
GCTGTGCTGTTGCAAGGTAG 
AFUA_5G0607
0 P5 
ACAAGAGGGACAGAGCAGGA 
AFUA_5G0607
0 P6 
AGTAAAGCCTCTGCCGAACA 
MDR2  –
AFUA_4G10000 
AFUA_4G1000
0 P1 
TCCTGGTGACCCTCTACACC 
AFUA_4G1000
0 P2 
TAGTTCTGTTACCGAGCCGG 
GAGAGAAGATGCGGAATTGG 
AFUA_4G1000
0 P3 
GCTCTGAACGATATGCTCCC 
GAGGCGCTCACATAGACTCC 
AFUA_4G1000
0 P4 
CCCAAACACCATGAACATCA 
AFUA_4G1000
0 P5 
GTGTATGAACGCCCTCTGGT 
AFUA_4G1000
0 P6 
ACTGTCGAAAGCGCCAATAG 
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Highlighted region shows the linker sequence in the primer. 
MDR3 – 
AFUA_3G03500 
P1 GTCGATATCCAGCCCACACT 
P2 TAGTTCTGTTACCGAGCCGG 
TTGGAACAGATGATGCTTGG 
P3 GCTCTGAACGATATGCTCCC 
AATCTCGTCCATGTCCCTTG 
P4 CTCCCTGCATTTCAGTCACC 
P5 GCCGGCATTATAACTGCTTC 
P6 CCTTCTTCGAAGGCAAACAG 
MDR4 – 
AFUA_1G12690 
 
AFUA_1G12690 
P1 
ATTGGTGGCTACCCAGTACG 
AFUA_1G12690 
P2 
TAGTTCTGTTACCGAGCCGG 
TCACCGATAAGCCAGGTAGG 
AFUA_1G12690 
P3 
GCTCTGAACGATATGCTCCC 
GACTGTGGGACTCTCGGTTC 
AFUA_1G12690 
P4 
AGGCTGTCTTCGAAAGTGGA 
AFUA_1G12690 
P5 
CCCACGCCAAGATACAGAAT 
AFUA_1G12690 
P6 
ACAGATACAGGGACGGATGG 
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Figure 2.4 - Schematic representation of PCR fusion. Step-1: the 5’ flank (i), 
3’ flank (ii) and selectable marker (AnpyrG) were amplified in three separate 
reactions. Step-2: The amplified products have overlapping linkers, which permit 
fusion in a second round reaction. To increase the specificity of this second 
round reaction nested primers were used to aid amplification. Step-3: formation 
of gene knockout cassette was confirmed by gel electrophoresis. 
 
 
Step – 1 
Step – 2 
Step – 3 
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2.2.14.2 PCR amplification of flanking genomic fragments  
The amplification of each fragment was completed using AccuPrime Taq High 
Fidelity DNA polymerase PCR (Invitrogen) as described previously (Ben-Ami and 
Kontoyiannis, 2012). The PCR reaction was carried out with 50µL reaction 
volume and following PCR cycling conditions (Table 2.3). 
Table 2.3 – PCR cycling conditions for amplification of flanking regions. 
 
The PCR products were then cleaned using QIAquick PCR purification kit (Qiagen) 
and gel electrophoresed for product confirmation. The flanking regions were 
amplified using primers P1, P2, P3 and P4 (Table 2.2). Following to amplification 
of flanking regions fusion PCR was carried out with primers P5 and P6 (Table 
2.2). The template consists of the two amplified flanking regions and selectable 
marker. The PCR amplification using primers P5 and P6 fused the three 
fragments into single knockout cassette. The fusion PCR reaction was done using 
the following PCR conditions (Table 2.4).  Finally the fusion PCR product was 
cleaned and gel electrophoresed before transformation. 
 
Cycle Denature Ramp Anneal Ramp Extend Ramp 
1 94°C, 
2min 
          
2–31 94°C, 20s To 70°C at 
maximum 
rate; 70°C, 1 
s; ramp to 
the annealing 
temperature 
at 0.1°C/s 
55°C, 
30s 
To the 
extension 
temperatur
e of 68°C 
at 0.2°C/s 
68°C, 
1 min 
At 
maximum 
rate to 
94°C 
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Table 2.4– Fusion PCR cycling conditions 
Cycle  Denature Ramp Anneal Ramp Extend Ramp 
1 94°C, 
2min 
          
2–11 94°C, 20s To 70 °C at 
maximum 
rate; 70 °C, 1 
s; ramp to the 
annealing 
temperature 
at 0.1 °C/s 
55°C, 
30s 
To the 
extension 
temperatur
e of 68°C 
at 0.2 C/s 
68°C, 5 
min 
At 
maximum 
rate to 
94°C 
12–16 94°C, 20s To 70°C at 
maximum 
rate; 70°C, 1 
s; ramp to the 
annealing 
temperature 
at 0.1 °C/s 
55°C, 
30s 
To the 
extension 
temperatur
e at 
0.2°C/s 
68°C, 5 
min 
extension 
time for 
first cycle 
At 
maximum 
rate to 
94°C 
17–26 94°C, 20s To 70°C at 
maximum 
rate; 70 °C, 1 
s; ramp to the 
annealing 
temperature 
at 0.1°C/s 
55°C, 
30s 
To the 
extension 
temperatur
e at 
0.2°C/s 
68 °C, 5 
min 20 s 
extension 
time for 
first cycle 
At 
maximum 
rate to 
94°C 
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2.2.14.3 Transformation and screening 
For gene knock out spores of Af293 were grown in 100 mL SAB broth containing 
100μg/mL of ampicillin for 14-16 h at 37°C, the resulting mycelium was then 
harvested by filtration through Miracloth (Calbiochem) then digested in 15mL 
sterile 50mM CaCl2, 0.6 M KCl with 6% Glucanex (NovoNordiskFerment) at 37°C 
for 3 h at 100rpm to form protoplasts. These were filtered as before then 
centrifuged at 2000g for 10minutes at 4°C. The pellet was suspended in 50 
mMCaCl2, 0.6M KCl and protoplasts were counted using an improved Neubauer 
haemocytometer (Weber Scientific International) then adjusted to give 
1x107/100μL aliquot. 3 – 4μg purified PCR product was added to each aliquot 
followed by incubation on ice for 25minutes prior to adding 25μL 60% 
polyethylene glycol (PEG6000). After 10 min incubation at RT, the mixtures were 
transferred to Vogels minimal media containing 0.6M KCl and 200μg/mL 
hygromycin and incubated at 37°C for 2 days or until the appearance of resistant 
colonies. 
2.2.14.4 Gene knockout confirmation 
After transformation of gene knockout cassette into protoplast and resistant 
colonies screening, the DNA was extracted from screened colonies and PCR was 
performed to confirm the gene knockout. The confirmation PCR was completed 
with primers in Table 2.5 using Thermal cycler (Biorad). The PCR product was 
then gel electrophoresed to confirm the gene knockout. 
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Table 2.5– Primers for confirming the gene knock out 
Gene Primer Sequence 
MDR1 – 
AFUA_5G06070 
MDR1 L GAACTGTCGCGGAAGAAGTC 
MDR1 R CCACCAATGCGGTAGTCTTT 
MDR2  –
AFUA_4G10000 
MDR2 L GGCCTACGTCAGTCTCAAGC 
MDR2 R AAAGCTCGAAAGACCGAACA 
MDR2 - 
AFUA_3G03500 
MDR2 L ATGTGGGCGGTTATAGCTTG 
MDR2 R AAACATAAGGCGTGGACCAG 
MDR4 – 
AFUA_1G12690 
MDR4 L CACTGAACGCAACTCCTGAA 
MDR4 R CTCGGATCCGGTACAACACT 
 
2.2.15 Statistics 
Analysis of variance (ANOVA) and t-tests were used to investigate independent 
sample data (different strains or on samples from different animals). A 
Bonferroni correction for multiple comparisons was applied to the data where 
appropriate. SPSS (Version 11, Chicago, USA) was used for these analysis and 
GraphPad Prism (Version 4, La Jolla, USA) for the production of the figures. 
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2.3 Results 
2.3.1 Aspergillus fumigatus biofilm formation 
Fluorescence microscopy was used to visualise the phenotype of different phases 
of A. fumigatus biofilm formation, a GFP strain was grown on a coverslip and 
viewed under the fluorescent microscope.  Figure 2.5 a-b shows resting condia 
and germling formation (after 8 h incubation). With 12 h incubation, an 
elongated tube like structure from germlings was visualised indicates the initial 
hyphal formation (Figure 2.5c). A complex multicellular structure was imaged 
after 24 h incubation period, Figure 2.5 d-e shows free floating hyphal cells and 
mesh like biofilm formation respectively.  
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Figure 2.5 – Different phases of A. fumigatus biofilm. A. fumigatus GFP 
expressing strain (AfGFP) biofilms were formed on Thermanox™ coverslips in 
RPMI media for 1, 8, 12 and 24 h(1  105 conidia/mL).  After incubation at 37oC, 
the coverslips were washed in sterile PBS and the biofilms were visualised under 
a fluorescence microscope (Motic BA400). One representative from each group 
was digitally captured using Colorview Soft Imaging System. (a) Round structured 
conidia, (b) germlings after 8 h, (c) initial hyphae after12 h and (d-e) shows 
matured free floating hyphae and biofilm formation after 24 h incubation. 
 
(a) (b) (c) 
(d) (e) 
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2.3.2 A. fumigatus biofilm exhibits phase dependant resistance to 
voriconazole 
For all fourteen A. fumigatus strains examined in this study, voriconazole 
consistently exhibited activity against germlings (8 h), with a sMIC90 range of 
between 0.0315 to 1 mg/L (Table 2.6). The sMIC90 of voriconazole increased by 
up to 16 to 256 fold against a monolayer of proliferating mycelia (12 h) 
compared to germlings. In those multicellular A. fumigatus populations where 
hyphae were densely intertwined (24 h), the voriconazole sMIC90 was 256 mg/L, 
which was >512 mg/L compared to germlings.  
2.3.3 A. fumigatus exhibits phase dependant Ala-Nap uptake 
Analysis of efflux pump activity was assessed by quantifying the change in 
relative fluorescent units (RFU) in 8, 12 and 24 h populations (Figure 2.6, Table 
2.7). The data was then normalised by using biofilm dry weight (RFU/mg). The 
data demonstrated that 8 h germlings exhibited the greatest levels Ala-Nap 
uptake (~1150 RFU/mg), i.e. low levels of efflux. Both 12 h and 24 h phases of 
growth demonstrated significantly lower levels of Ala-Nap uptake of ~600 and 
~410 RFU/mg, respectively (ANOVA; p<0.0001) (Figure 2.7).  
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Table 2.6 - Antifungal activity of voriconazole against adherent Aspergillus 
fumigatus grown for 8, 12 and 24 h. 
 
Strain 
Sessile minimum inhibitory concentration (sMIC90) 
8 h 12 h (ΔMICa) 24 h (ΔMICa) 
AF293 0.5 8 (16) >256 (>512) 
YHAF1 0.0625 1 (16) >256 (>512) 
YHAF2 0.0625 1 (16) >256 (>512) 
YHAF3 1.0 32 (32) >256 (>512) 
YHAF4 0.125 16 (128) >256 (>512) 
YHAF5 0.125 16 (128) >256 (>512) 
YHAF6 0.125 16 (128) >256 (>512) 
YHAF7 0.125 8 (64) >256 (>512) 
YHAF8 0.0312 4 (128) >256 (>512) 
YHAF9 0.0625 16 (128) >256 (>512) 
YHAF10 0.0625 32 (256) >256 (>512) 
YHAF11 0.0625 8 (64) >256 (>512) 
YHAF12 0.0625 8 (64) >256 (>512) 
YHAF13 0.0312 4 (128) >256 (>512) 
aFold change in MIC compared to 8 h germling cells MIC.
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Figure 2.6 – Ala-nap uptake by A. fumigatus biofilms.  Fluorescence produced 
by differently grown A. fumigatus biofilm (8, 12 and 24 h). Standardised A. 
fumigatus conidia were incubated with Ala-Nap (128 mg/L), which is 
enzymatically cleaved to produce fluorescent β-naphthylamine. The change in 
fluorescence (RFU) were determined over 120 min at Ex320nm/Em460nm using 
a fluorescent plate reader.  Increase in fluorescence indicates more ala-nap 
uptake and vice versa. 
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Table 2.7- Assessment of efflux activity by Ala-Nap uptake assay. Blank 
corrected raw data showing relative fluorescence produced with the respective 
phase of A. fumigatus growth. 
Strain 
Relative fluorescence unit (RFU) 
8 h 12 h 24 h 
AF293 40123.2 23422.2 17487.0 
YHAF1 39405.6 21716.7 30319.5 
YHAF2 39592.8 23081.1 11484.0 
YHAF3 35973.6 24028.6 16356.0 
YHAF4 36223.2 18874.2 15051.0 
 
 
 
Figure 2.7 - Aspergillus fumigatus displays phase dependant efflux activity. 
Efflux activity of 8, 12 and 24 h biofilms. Standardised A. fumigatus conidia were 
incubated with Ala-Nap (128 mg/L) and resultant fluorescent production was 
measured using plate reader. The change in fluorescence of dry weight 
normalised biofilms (RFU/mg) was determined.  High values indicate low efflux 
and vice versa. Five different strains were used and the experiments performed 
on three separate occasions. The error bars represent the standard deviation of 
the means. Ala-Nap internal cleavage was normalised (RFU/mg), and shown to 
be maximum after 8 h growth, whilst significantly reduced at 12 and 24 h, 
respectively (*p< 0.0001). * - 0.05, ** - 0.01. 
 
Δ
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2.3.4 Efflux activity is induced by voriconazole treatment 
The 8 h germling growth phase was subsequently examined to evaluate the 
effect of pre-treatment with voriconazole (0.0625 mg/L) on efflux activity 
(Figure 2.8a). This phase was selected as quantifiable efflux activity was 
constitutively low amongst the isolates examined, allowing quantification of any 
changes following voriconazole treatment. The data demonstrated that after 
voriconazole treatment the RFU/mg was reduced from ~1100 to ~980 after 1h, 
and significantly reduced to ~750 (p<0.05) and ~550 (p<0.01) after 4 and 8 h, 
respectively (Figure 2.8b).  
2.3.5 Competitive inhibition of efflux pumps improves A. fumigatus 
sensitivity to voriconazole. 
An efflux pump inhibitor (EPI [MC-207,110]) was used to assess the contribution 
of efflux pumps to voriconazole sensitivity. EPI [MC-207,110] is a competitive 
substrate of efflux pumps. A checkerboard assay was initially developed to test 
combinations of voriconazole and EPI (Figure 2.9). It was demonstrated that EPI 
did not exhibit any antifungal activity at any of the concentrations tested (>512 
mg/L). Therefore 64 mg/L was selected for all combinational experiments. In 
the presence of EPI the MIC range was significantly reduced from 2 to 8 fold (t-
test; p<0.05) (Figure 2.10, Table 2.8) 
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A) 
 
B) 
 
Figure 2.8 - Efflux activity is induced by voriconazole. A. fumigatus was grown 
in 96-well microtiter plates in RPMI at 37°C. (A) Fluorescence produced by 8 h A. 
fumigatus biofilm pre-treated with voriconazole (0.06251 mg/L) for 0, 1, 4 and 
24 h (B) The change in fluorescence of dry weight normalised biofilms 
(RFU/mg) was determined.  High values indicate low efflux and vice versa. The 
error bars represent the standard deviation of the means. (*p < 0.0001).* - 0.05, 
** - 0.01. 
 
Δ
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(a) 
 
(b) 
 
Figure 2.9 - Pharmacological inhibition of efflux pumps enhances the efficacy 
of azoles against A. fumigatus biofilm. A. fumigatus was grown in 96-well 
microtiter plates in RPMI at 37°C. After 8 h (a) or 12 h (b) cells were washed 
with PBS to remove non-adherent cells and fresh media was added with varying 
concentrations of the voriconazole (0-128 µg/mL) in combination with the efflux 
pump inhibitor (EPI) MC-207,110 (0-512 µg/mL) in a checkerboard format. ● 
represents growth in the well and o represents growth inhibition. 
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Table 2.8 – MIC of 8 h A. fumigatus biofilm in the presence and absence of 
EPI. 
Strain SMIC90 
- EPI +EPI Fold change (ΔMIC) 
Af293 0.5  0.0625 8 
YHCF1 0.0625 0.0312 2 
YHCF2 0.0625 0.0156 4 
YHCF3 1.0 0.25 4 
YHCF4 0.125 0.0156 8 
YHCF5 0.125 0.0156 8 
YHCF6 0.125 0.0312 4 
YHCF7 0.125 0.0156 8 
YHCF8 0.0312 0.0078 4 
YHCF9 0.0625 0.0156 4 
YHCF10 0.0625 0.0156 4 
YHCF11 0.0625 0.0078 8 
YHCF12 0.0625 0.0156 4 
YHCF13 0.0312 0.0078 4 
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Figure 2.10 - Aspergillus fumigatus biofilm sensitivity to voriconazole is 
increased in the presence of an efflux pump inhibitor.A. fumigatus biofilm 
were grown in flat bottomed 96-well plates for 8 h, washed and voriconazole 
(0.005 – 4 mg/L) added ± MC-207,110 (64 mg/L). Viability was assessed using 
Alamar blue. Fourteen different strains were used and the experiments 
performed on three separate occasions. The data shows that the MICs of A. 
fumigatus are significantly reduced in the presence of an efflux pump inhibitor 
MC-207,110 by approximately 2-8 fold (t-test; *p=0.0196). The error bars 
represent the standard deviation of the means. 
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2.3.6 A. fumigatus exhibits phase dependant efflux pump expression 
The expression profile of four selected efflux genes (AfuMDR1-4) over different 
phases of biofilm formation were assessed in A. fumigatus. cDNA was produced 
for three different strains of A. fumigatus (one reference Af293 and two clinical 
strains – YHCF1-2) and samples from 8, 12 and 24 h tested in duplicate and 
expression normalised to β-tubulin using the 2-ΔΔCt methodology previously 
described (Livak and Schmittgen, 2001). All the graphs detailing the expression 
profiles of AfuMDR1-4 assessed using real time RT-PCR are shown in Figures 2.11. 
Out of four efflux genes tested AfuMDR2 was one of the highly expressed genes 
and AfuMDR2 was the one expressed in lower level compared to others. The 
AfuMDR1 and AfuMDR4 genes showed a pattern of up regulation over different 
phases of biofilm formation. A significant up regulation of AfuMDR4 gene was 
assessed with 12 and 24 h biofilms compared to 8 h (P<0.0001). 
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Figure 2.11- Transcriptional analysis of efflux genes.Quantitative RT-PCR was 
performed on each cDNA population using β-tublin as a housekeeping gene to 
calculate the relative expression of the genes according to the 2-ΔΔCT method. 
The expression profile of efflux genes were expressed in fold change compared 
to housekeeping gene(a) AfuMDR1, (b) AfuMDR2, (c) AfuMDR2 and (d) AfuMDR4 
was assessed using Quantitative RT-PCR. The error bars represent the standard 
deviation of the means. (*** - P<0.0001). 
 
 
Mdr1 Mdr2 
Mdr3 Mdr4 
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2.3.7 AfuMDR4 expression is associated with azole sensitivity 
The in vitro expression of AfuMDR4 transcripts were assessed in 8, 12 and 24 h 
phases of growth and compared to the fold increase in sMIC90 for five strains, 
and analysed as a fold-change in expression by normalising to the 8 h phase data 
(Table 2.9). Expression of AfuMDR4 was shown to be differentially up-regulated 
in both the 12 and 24 h phases of growth in a strain dependant manner, with 
maximal up-regulation observed at the 12 h phase. The levels of up-regulation 
appeared to correlate with the change in SMIC90, e.g. Af293 showed a 3.89 fold 
change in gene expression and a 16 fold change in MIC, whereas YHCF4 showed a 
65.1 change in gene expression and a 128 fold change in MIC. At 24 h gene 
expression was reduced, which did not correlate with reduced MIC levels. 
2.3.8 Efflux pump expression (AfuMDR4) is induced by in vitro 
voriconazole treatment. 
Three populations were subsequently pre-treated with voriconazole and 
expression analysis of AfuMDR4 performed at 1, 4 and 24 h post-treatment. Data 
was analysed at each time-point in comparison to matched untreated 
populations (Figure 2.12). These data demonstrated that AfuMDR4 within the 8 h 
phase was significantly influenced by voriconazole exposure, increasing by 1.75- 
(p <0.05), 2.5- (p<0.001) and 4.2-fold (p<0.001) after 1, 4 and 24 h, respectively. 
AfuMDR4 within the 12 h phase was also significantly influenced by voriconazole 
exposure, initially increasing 2.6- (p < 0.001), 1.9- (p < 0.01) and 4.4-fold 
(p<0.001) after 1, 4 and 24 h, respectively. AfuMDR4 in the 24 h phase was also 
influenced by voriconazole exposure, but less dramatically, with an increase of 
1.65- (p<0.05), 1.62- (p<0.05) and 1.13-fold (p>0.05) after 1, 4 and 24 h, 
respectively.
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Table 2.9 - A. fumigatus exhibits phase-dependent resistance to voriconazole. 
 
 
 
 
 
 
 
 
 
aFold change in the MIC following efflux pump inhibitor challenge. 
bFold change in expression of AfuMDR4 compared to 8-h germling cells. 
cFold change in the MIC compared to the MIC for 8-h germling cells.
Strain 8 h 12 h 24 h 
sMIC90(ΔMIC
a) ΔMDR4b sMIC90(ΔMIC
c) ΔMDR4 sMIC90(ΔMIC
c) ΔMDR4 
Af293 0.5 (8) 1 8 (16) 3.89 >256 (>512) 2.35 
YHCF1 0.0625 (2) 1 1 (16) 4.37 256 (>512) 3.38 
YHCF2 0.0625 (4) 1 1 (16) 2.31 >256 (>512) 2.72 
YHCF3 1.0 (4) 1 32 (32) 31.60 >256 (>512) 4.50 
YHCF4 0.125 (8) 1 16 (128) 65.10 >256 (>512) 14.80 
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Figure 2.12 - Aspergillus fumigatus AfuMDR4 expression is induced by 
exposure to voriconazole for 1, 4 and 24 h. Exposure to voriconazole induced 
AfuMDR4 expression in the 8, 12 and 24 h phases of A. fumigatus growth. 
Quantitative RT-PCR was performed on each cDNA population using β-tublin as a 
housekeeping gene to calculate the relative expression of AfuMDR4 according to 
the 2-ΔΔCT method. Three isolates were tested on three separate occasions for 
each time point. The error bars represent the standard deviation of the means. 
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2.3.9 Aspergillus fumigatus exhibits phase dependant efflux pump 
expression (AfuMDR4) that is increased by voriconazole 
treatment in vivo. 
The in vivo expression of AfuMDR4 transcripts were assessed in vehicle control, 3 
mg/kg (LD) and 10mg/kg (HD) voriconazole treated animals at 0, 1, 4 and 24 h 
post-treatment, and analysed as a fold-change in expression by normalising to 
the baseline control. Expression of AfuMDR4 was shown to be significantly up-
regulated according to ANOVA following treatment with voriconazole after 1, 4 
and 24 h (Figure 2.13). A significant up-regulation was observed at 1 and 4 h 
with 3 and 10 mg/kg dose (p<0.01, p<0.05 and p<0.01, respectively). At 24 h up-
regulation of AfuMDR4 was still observed (p<0.05 and p<0.01, respectively).  
 
Figure 2.13 -Aspergillus fumigatusAfuMDR4 is expressed in vivo and is   
induced by voriconazole. Treatment with voriconazole (3 and 10 mg/kg) 
induced AfuMDR4 expression 1, 4 and 24 h post treatment. Following removal of 
the subcutaneous A. fumigatus ATCC1163 biofilm and RNA processing, 
quantitative RT-PCR was performed on each cDNA population using β-tublin as a 
housekeeping gene to calculate the relative expression of AfuMDR4 according to 
the 2-ΔΔCT method. Three animals were used as a baseline for comparison to 
vehicle (n=3 at 1, 4, and 24 h), 3 mg/kg (n=3 at 1 and 4 h, with n = 5 at 24 h) 
and 10 mg/kg (n=3 at 1 and 4h, with n = 4 at 24 h). The error bars represent the 
standard deviation of the means. *p<0.05, **p<0.01. 
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2.3.10 AfuMDR 1-4 mutational studies 
2.3.10.1 PCR amplification of flanking regions  
Knocking out of AfuMDR1-4 genes involved two steps. In the first step, the 
flanking regions of the genes were amplified using the designed primers. The 
amplification product was then assessed for their size by comparing with a DNA 
ladder to confirm the amplification of correct target. Figure 2.14 show the gel 
electrograph with bands indicating the amplification of different flanking regions 
for AfuMDR1-4 genes. The product size of 1000-1200bp indicates the correct 
amplification. 
 
 
 
 
 
 
 
 
 
Figure 2.14 - Confirmation of amplified flanking regions. The amplified 
flanking regions of AfuMDR1 (lane 2, 3), MDR2 (lane 4, 5), MDR3 (lane 6, 7) and 
MDR4 (lane 8, 9) were gel electrophoresed to confirm the amplification. The 
bands at 1000-1200bp indicates the amplification of correct target. 
 
 
Mdr1       Mdr2   Mdr3        Mdr4 
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2.3.10.2 Gene knockout cassette 
The fusion PCR reaction was carried out with amplified flanking regions and a 
selectable marker to produce a gene knockout cassette. Figure 2.15 show the gel 
electrograph with bands indicating the formation of gene knockout cassette for 
AfuMDR1 -4. 
 
 
 
 
 
 
 
 
 
 
Figure 2.15 – The fusion PCR product. The amplified flanking regions and a 
marker sequence were fused together by a PCR reaction to form a gene 
knockout cassette. The bands in lane2-5 show the gene knockout cassettes 
formation. Lane 1- DNA ladder, lane 2 – MDR1, lane 3 – MDR2, lane 4 – MDR2, and 
lane 5 – MDR4. 
 
Mdr1  Mdr2  Mdr3  Mdr4 
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2.3.11 Evaluation of MDR gene function 
In order to confirm whether the differentially expressed transporters AfuMDR1 – 
4, played a functional role in azole resistance these genes were knocked out in 
A. fumigatus (Af293). Genes were knocked out and verified using PCR. In order 
to exclude random mutational effects from transformation two individual 
knockout transformants were selected for each gene knockout.  After analysis 
and two rounds of single spore plating knockouts were tested for MIC to 
voriconazole in triplicate (Figure 2.16). The knockouts (AfuMDR1, 2 and 4) 
showed an MIC fourfold lower (0.063 mg/L) than that of the wild type strain 
(0.250 mg/L) for voriconazole reproducibly. The AfuMDR3 knockout showed a 
reproducible two-fold lower MIC for voriconazole. 
 
Figure 2.16 – MIC test with knockout strains and parental isolate. MIC of 
voriconazole against wild type and knockout strains was determined by broth 
microdilution method. The first row indicates the concentrations of voriconazole 
in mg/L along each column. The dark circles indicate growth of A. fumigatus 
isolates and white circles indicate growth inhibition. 
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2.4 Discussion 
A. fumigatus triazole resistance has become increasingly associated with the 
ergosterol biosynthetic pathway through mutation of the CYP51A gene locus. 
Increasing evidence suggests, however, that efflux pump mediated mechanisms 
may also be important determinants of resistance, especially given their 
characterised role in C. albicans. This study has demonstrated for the first time 
that efflux pump activity is associated with biofilm development and is also 
induced by triazole exposure, both of which contribute towards azole resistance. 
This chapter demonstrated in a panel of clinical isolates using modified MIC 
methodologies that A. fumigatus grown in different phases of biofilm growth 
showed an increased resistance to voriconazole, a phenomenon previously 
demonstrated for Af293 by our group (Mowat et al., 2008b). Even when biofilm 
cells were disaggregated and standardised to similar cell counts using 
absorbance readings, a reduced sensitivity to VRZ was observed, which was also 
previously reported for C. albicans(Ramage et al., 2002a). Recent studies are in 
agreement with these observations, as it has been recently shown that triazole 
sensitivity is limited by complex filamentous growth (van de Sande et al., 2010). 
Whether this is because the physical quantity of drug is too low to elicit an 
effect or whether subtle transcriptional events occur in response to antifungal 
challenge, leading to reduced sensitivity, still remains to be determined. It is 
possible that the inoculum effect plays a role in limiting the effectiveness of VRZ 
(Lass-Florl et al., 2003). A recent study reported that voriconazole treatment of 
C. albicans biofilms induced a calcineurin dependant response, resulting in 
changes in cell wall integrity that led to antagonism of the cell wall active 
micafungin (Kaneko et al., 2010). Moreover, global transcriptional analyses of 
voriconazole treated A. fumigatus mycelia demonstrated that over 2000 genes 
were differentially expressed, and amongst these were increased levels of 
transporter mRNA (da Silva Ferreira et al., 2006).  
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Based on this and previous microarray studies by Mowat E (Mowat E, PhD thesis, 
2008), this chapter was decided to focus on efflux as a potential mechanism of 
resistance and analysed biochemical activity of efflux pumps in our model 
system. Active extrusion of a fluorescent molecule was shown to be elevated at 
24 h and 12 h in comparison to 8 h germling cells. Voriconazole treatment of the 
8 h germling cells resulted in a time dependant increase in efflux pump activity. 
The 12 h and 24 h cells were not tested as efflux was constitutively elevated, 
making differentiation of efflux activity difficult. This was potentially because of 
the role of extracellular matrix material, which has been shown to impede 
diffusion of molecules. Disruption and standardisation of the 24 h biofilm 
demonstrated an equivalent fluorescence to the undisrupted biofilm, suggesting 
that poor penetration of Ala-Nap was not a factor in the low levels of 
fluorescence detected in these assays. To demonstrate that efflux was involved 
in the reduced sensitivity to voriconazole, a broad spectrum efflux pump 
inhibitor, MC-207,110, a substrate of efflux pumps was used. These studies on 
the panel of isolates showed a significant MIC reduction to voriconazole of 2-8-
fold.  
Several studies have examined the expression of efflux pumps in C. albicans 
biofilms, where constitutive expression of CaMDR1 was reported during early 
adhesion and in a phase dependant manner thereafter (Mukherjee et al., 2003, 
Mateus et al., 2004, Ramage et al., 2002a). However, to date no studies have 
reported this in A. fumigatus biofilms. In this study, the expression profile of 
AfuMDR1-4 was assessed and found significant up regulation of AfuMDR4 over the 
period of different phases of biofilm formation. Based on this result and previous 
work on itraconazole resistant mutants this chapter was decided to focus on 
AfuMDR4, which for these studies served as a quantifiable example (Nascimento 
et al., 2003). qPCR analysis demonstrated strain dependant up-regulation of this 
gene, particularly in the 12 h cells. Interestingly, those strains that exhibited the 
most elevated resistance and active biochemical efflux showed the highest 
levels of gene expression. Furthermore, voriconazole was shown to induce 
significant up-regulation of AfuMDR4 transcripts in treated 8, 12 and 24 h cells in 
a time dependant manner. Ferreira and colleagues (2004) also observed azole-
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constitutive and induced efflux pump expression on 24 h cultures following 
treatment with itraconazole. Here it was shown that AfuMDR1-4 were 
differentially expressed following itraconazole treatment, and that AfuMDR2 and 
AfuMDR4 were preferentially induced on exposure to the azole, which has also 
been reported for C. albicans(da Silva Ferreira et al., 2004).  
The clinical relevance of these transcriptional changes remains to be seen. 
Therefore, to evaluate whether efflux pump expression occurred in vivo we 
collaborated with Dr Peter Warn (University of Manchester) who devised an 
implanted A. fumigatus biofilm model. This was used to investigate the effects 
of voriconazole treatment on AfuMDR4 expression from A. fumigatus biofilms. 
Expression was shown to be constitutive, and up-regulated in response to 
treatment with two different doses of voriconazole. Similarly, the expression of 
CaMDR1 expression in a catheter based C. albicans biofilm model has been 
reported, but at a lower constitutive level (Nett et al., 2009). Moreover, the 
same group reported induction of CaCDR1 and CaCDR2 in their in vivomodel 
following fluconazole treatment, but no change in the expression of 
CaMDR1(Lepak et al., 2006).  
Disruption of transporter genes AfuMDR1-4 in an A. fumigatus strain resulted in 
minor changes in azole sensitivity. AfuMDR1, 2 and 4 knockouts led to a fourfold 
reduction in MIC to voriconazole with 8 h grown germlings. It indicates the 
contributory role of transporter genes in azole resistance. However, this chapter 
demonstrate maximal strain dependant transcript expression at 12 h, yet 
voriconazole resistance increased to ≥256 mg/L for all strains tested. It is 
plausible that resistance is a highly regulated process, with efflux pump 
mechanisms playing an early role in resistance during colonisation, which is then 
reduced as extrapolymeric matrix is produced during biofilm maturation. 
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Collectively, the data presented herein, in addition to the available literature, 
support the hypothesis that efflux pumps are an important, but not exclusive, 
determinant of resistance to azoles (Morschhauser, 2010, Cannon et al., 2009). 
Their primary role may be for homeostasis within complex environments to 
protect themselves from acute toxicity, but within clinical environments, such as 
an aspergilloma, exposure to azoles drugs may enhance the levels of efflux pump 
expression, therefore either contributing towards or inducing clinical resistance. 
Indeed, expression of these pumps has been shown biochemically, indicating 
these transcripts are translated into protein. These observations may explain 
why treatment failure to azoles may occur clinically, and should raise doubt as 
whether sequential azole therapy is an appropriate treatment strategy for 
aspergillosis. Further studies are required to establish how A. fumigatus efflux 
pumps are regulated and whether inhibitors of these could augment azole 
therapies.    
 Chapter 3 
3 Aspergillus fumigatus extracellular 
DNA is a key component of the 
biofilm matrix 
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3.1 Introduction 
The previous chapter demonstrated phase dependant antifungal activity against 
A. fumigatus biofilms and association of efflux pumps. This work suggests that 
early resistance phenotypes were coincident with increased efflux pump 
activity. This correlation was not evident in mature biofilms, so this chapter 
hypothesises that ECM may play a greater role in the later phases of biofilm 
growth. ECM is a fundamental characteristic of biofilms, providing protection 
from hostile factors, including antimicrobial agents (Flemming and Wingender, 
2010, Ramage et al., 2012). Independent investigations have shown that biofilm 
cells attaching to epithelial cells had increased levels of ECM, which were 
coincidental with decreased sensitivity to antifungal drugs (Seidler et al., 
2008).Whilst the precise role of the ECM is not known, it is hypothesized that it 
plays a significant role in antifungal resistance by adsorbing the molecule and 
preventing its diffusion (Beauvais et al., 2007a). This is supported from data 
emerging from the C. albicans biofilm field, where it was demonstrated that 
ECM expression (specifically beta-glucans), encoded through Fks1, sequesters 
antifungal agents and reduces susceptibility (Nett et al., 2010a). The physical 
binding of amphotericin B by C. albicans biofilms and their ECM components was 
also established using absorbance spectra of amphotericin B (Vediyappan et al., 
2010). Given the role of ECM in decreased antifungal susceptibility the physical 
binding of antifungals by A. fumigatus biofilm matrix and their ECM components 
remain unclear. 
In bacterial biofilms the typical ECM consists of exopolysaccharides, proteins, 
surfactants, lipids, water and nucleic acids (extracellular DNA [eDNA]). In A. 
fumigatus biofilms hydrophobic ECM is composed of galactomannan, alpha-1,3 
glucans, monosaccharides, polyols, melanin and proteins (Beauvais et al., 
2007a).  Despite the growing body of knowledge regarding eDNA in bacterial 
biofilms, there is a scant knowledge concerning its existence and role in fungal 
biofilms. Recent studies have shown that eDNA is also an important component 
of Candida biofilms, including C. albicans, C. tropicalis and C. parapsilosis 
(Martins et al., 2010, Paramonova et al., 2009, Al-Fattani and Douglas, 2006).  
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In C. albicans eDNA has been shown to contribute towards maintenance and 
stability of mature biofilms, but not in their establishment (Al-Fattani and 
Douglas, 2006, Martins et al., 2010), and as a regulator of biofilm cells antifungal 
resistance (Martins et al., 2012a). These data suggest the potential therapeutic 
use of agents that affect the ECM. Remarkably, little is known about the 
presence and contribution of eDNA in A. fumigatus biofilms.  
The purpose of this chapter was to assess the antifungal binding by different 
biofilm components and to investigate the presence and biological role of eDNA 
in A. fumigatus biofilm ECM. 
 
This chapter has been published in a peer reviewed journal: 
Rajendran R, Williams C, Lappin DF, Millington O, Martins M, Ramage G.2013. 
Extracellular DNA release acts as an antifungal resistance mechanism in mature 
Aspergillus fumigatus biofilms. Eukaryot Cell. Epub ahead of print 2013 Jan 11. 
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3.2 Materials and methods 
3.2.1 Strains and conidial preparation 
A. fumigatus Af293, clinical isolates (YHCF1 – YHCF5) obtained from the Royal 
Hospital for Sick Children (Yorkhill Division), Glasgow. An A. fumigatus 
transformant expressing green fluorescent protein (Af-GFP) was used for 
microscopy analysis, as described previously (Wasylnka and Moore, 2002). All the 
isolates were stored as previously described in section 2.2.1. All A. fumigatus 
strains were grown on Sabouraud dextrose agar at 37oC for 72 h. Conidia were 
then harvested as described in section 2.2.2. Conidia were then counted on a 
Neubauer haemocytometer and adjusted to a standardised suspension of 5 × 105 
conidia/ml in RPMI. All procedures were carried out in a class 2 biological safety 
cabinet (MDH Intermed). 
3.2.2 Amphotericin B absorbance spectrum 
The absorbance spectrum of amphotericin B (ampB) was used to assess the 
amount of ampB binding with A. fumigatus biofilm as described previously 
(Huang and Kao, 2012).  The concentrations of ampB starting from 64 mg/L 
serially diluted down to 0.125 mg/L in DMSO was prepared in a 96 well plate 
(Costar). The absorbance spectrum at a wavelength range of 300-500nm of 
serially diluted ampB were measured using a plate reader (Fluostar Optima; BMG 
Labtech). Absorbance maxima at 415nm of ampB were used to plot the standard 
curve. 
3.2.3 Extraction of amphotericin B from A. fumigatus biofilm 
To assess the binding of amphotericin B (ampB) to A. fumigatus biofilm matrix, 
preformed biofilms on Thermanox coverslips (13mm) were exposed to ampB 
for different time periods (0-120min) and ampB was extracted from biofilm ECM 
as perviously described (Vediyappan et al., 2010). In brief, 1 ml of DMSO was 
added to the 5ml plastic bijous containing the biofilms on coverslips. Then the 
bijous were vortexed for 1min to dislodge the biofilm and incubated in the dark 
for 5min at room temperature. The mixture was then centrifuged at x10000rpm 
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for 10min and the supernatant containing ampB was collected in fresh 1.5ml 
micro centrifuge tubes. The absorbance spectra of each extract were then 
assessed as described above. For each experiment ampB untreated biofilms were 
added as controls.  
3.2.4 Amphotericin B binding to fungal components 
The binding of ampB with different fungal components including chitin, β-
glucan, ergosterol and zymosan was assessed by an ampB binding assay. 
Commercially available purified β-glucan from Saccharomyces cerevisiae 
(4mg/mL) (Calbiochem), chitin from crab shells (10mg/ml) (Sigma), ergosterol 
(10mg/mL) (Sigma), zymosan (4mg/mL) (Sigma) and gelatin (10 mg/mL) (Sigma) 
were prepared in distilled water. Then 32 mg/L of ampB was added to each 
component and incubated at room temperature in the dark for 5 min. Then the 
mixture was centrifuged at x4000rpm for 1min to remove the unbound ampB. 
The pellet was then washed with PBS and ampB was extracted using 1 volume of 
DMSO. The extracts were then assessed for absorption spectra using a plate 
reader (Fluostar Optima; BMG Labtech). 
3.2.5 Microscopy 
Standardised conidia of Af293 or Af-GFP were inoculated in RPMI onto 
Thermanox coverslips (13mm) within a 24-well tissue culture plate, and 
incubated for 24 h at 37oC. These were gently rinsed with PBS and stained, 
according to manufacturer’s instruction, with 5M calcofluor white (Af293 only) 
(Invitrogen) that binds chitin and β-glucan of fungal cell walls, and 20M 
propidium iodide (PI) (Sigma) that stains the DNA present within the biofilm. 
Biofilm growth and accumulation of eDNA were visualised under a fluorescence 
microscope (Motic BA400, Colorview system) or confocal laser scanning 
microscope (CLSM) (Leica SP5 laser scanning confocal microscope) at an 
excitation and emission wavelength of 350:400 for calcofluor white, 540:525 for 
propidium iodide, and 480:490 for GFP. One representative from each group was 
digitally photographed. Quantification of the z-stacks was performed using 
Volocity 3D Image Analysis Software (Perkin Elmer). For scanning electron 
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microscopy (SEM) representative biofilms grown and treated on Thermanox 
coverslips were processed and viewed under a scanning electron microscope as 
previously described (Section 2.2.4.2).  
3.2.6 DNA extraction 
ECM was extracted as previously described, with slight modifications (Beauvais 
et al., 2009). Briefly, standardised A. fumigatus conidia were inoculated into a 
75cm2 tissue culture flask (Nunc) containing RPMI, YPD and YNB at 37oC for 8, 
12, 24, 48 and 72 h on a rocking platform. After incubation the biofilm was 
removed from the flasks using sterile cell scrapers and washed with PBS. The 
disaggregated biofilm was then treated with 0.2M EDTA to extract the ECM. The 
samples were then centrifuged at 10000g and the EDTA supernatant was 
recovered and filtered using 0.45µm syringe filter (Millipore). The eDNA from 
EDTA supernatant and genomic DNA from C. albicans and A. fumigatus cells 
were extracted using MasterPure™ Yeast DNA purification kit (Epicenter®), 
according to the manufacturer’s instructions. 
3.2.7 Quantification of ECM associated eDNA 
Different phases of biofilm (8, 12 and 24 h) ± azetazolamide (128 mg/L, Sigma), 
a chitinase inhibitor (Schuttelkopf et al., 2010), were formed at 37oC either in 
microtiter plates or in tissue culture flasks as described above. The quantity of 
eDNA within the ECM was measured using a microplate fluorescence assay (MFA) 
using a DNA binding dye (SYBR Green I), as previously described (Leggate et al., 
2006). Briefly, SYBR Green I (Invitrogen) was added to eDNA extract in a black 
well microtiter plate (Costar3603; Corning) in a ratio 1:1. Binding of this dye 
produces fluorescence in direct proportion with DNA concentration. The levels of 
eDNA were quantified using a fluorescence plate reader (Fluostar Optima; BMG 
Labtech) at the excitation and emission wavelength of 485 and 518 nm, 
respectively. The concentration of eDNA in the sample was quantified by using 
the DNA standard curve as previously described elsewhere (Leggate et al., 2006). 
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3.2.8 RAPD PCR 
The PCR amplification of seven different genes was performed using Reddymix™ 
PCR master mix (Thermo scientific). Primers used for RAPD PCR amplification of 
ANXC4, BGT1, CAT1, LIP, MAT1-2, SODB, ZRF2 and cycling conditions were 
previously described elsewhere (Bain et al., 2007). The following cycling 
conditions were used for PCR amplification. 95°C for 5 min; 35 cycles of 95°C for 
30 s, 60°C for 30 s, and 72°C for 1 min and a final elongation step at 72°C for 5 
min. The PCR reaction was performed in a MyCycler PCR machine (Bio-Rad).The 
amplified samples were then separated using horizontal gel electrophoresis and 
the gel was observed under UV light excitation (Bio-Rad Gel Doc 2000, Bio-Rad 
Life Sciences). 
Table 3.1- List of primers used for RAPD PCR. 
Gene Primer sequence 
ANXC4 F GCGAGATAGCAACACTTCAGT 
ANXC4 R GGATACTGTTGCCCTAGATTTG 
BGT1 F GATCGGTTGCCAGTCTTTGA 
BGT1 R AATGGACGCAGAATGAAACT 
CAT1 F AGCTCAACCGTCGTGAT 
CAT1 R TGCCATGCCCAGACATA 
LIP F CGCCTCACTTCTCCTCA 
LIP R TGCGAAATGGCTGACG 
MAT1-2 F ACACCCTTCGACTTTCCA 
MAT1-2 R GATCGCATAGTGTGAGTGG 
SODB F GCTCCAAGAGCTGCTAC 
SODB R AAGCGCTTCTCCACAGC 
ZRF2 F CTCATCCAAGCTTGTTTCC 
ZRF2 R GTACCGCATCACCATCAA 
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3.2.9 Evaluating biofilm formation and stability 
Biofilms were formed in 96-well microtitre plates as previously described (Mowat 
et al., 2007a). DNase I from bovine pancreas (Sigma-Aldrich), referred to as 
DNase for simplicity, was prepared in 0.15 M NaCl supplemented with 5 mM 
MgCl2 (Martins et al., 2012a). To evaluate the effect of DNase treatment on 
preformed biofilms the Af293 biofilms were grown for 24 h and treated with 
DNase (0.25, 1 and 4 mg/mL) at 37oC overnight, with an untreated buffered 
control included on each plate for comparison. For further controls, heat 
inactivated DNase (0.25 mg/L), RNase (0.25 mg/L) and proteinase K (0.25 mg/L) 
(Sigma-Aldrich) were tested under the same conditions. To assess the effect of 
DNase on biofilm formation the standardised 5x105 Af293 conidia were incubated 
with DNase (0.25, 1 and 4 mg/mL) at 37oC overnight. Finally, to assess the effect 
of exogenous DNA on biofilm formation standardised conidia were incubated 
with salmon sperm DNA (Sigma-Aldrich), C. albicans and A. fumigatus genomic 
DNA (4, 8 and 20 mg/L) at 37oC overnight. DNA was extracted as described 
above. After each treatment the biofilms were washed in PBS and biomass 
quantified using a crystal violet assay.  
3.2.10 Crystal violet assay 
Crystal violet assay was used to assess the biofilm biomass as described 
previously (Christensen et al., 1985, O'Toole and Kolter, 1998). For quantifying 
the biofilm biomass, the spent media was discarded and the biofilm washed 
twice with PBS. The biofilms were then air dried and 100µl of 0.5% crystal violet 
(Fisher Scientific) solution added. The plate was then incubated at room 
temperature for 5-10min and the crystal violet solution was removed from each 
well. The wells were then carefully washed under running water, until all 
unbound crystal violet was removed. Then 100µl of 90% (v/v) ethanol was added 
to each well to de-stain the biofilms. The ethanol was then transferred to a 
clean 96-well microtitre plate and the absorbance read at 570nm using an 
absorbance plate reader (Fluostar Optima; BMG Labtech). The ethanol mixture 
was diluted down appropriately before absorbance measurement for the 
experiments having higher biomass for better sensitivity. A negative control well 
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containing no A. fumigatus was included on every microtitre plate for quality 
control. 
3.2.11 Biofilm susceptibility testing 
DNase was used in combination with different classes of antifungals to 
determine whether antifungal efficacy could be enhanced. Amphotericin B, 
caspofungin and voriconazole were prepared according to the Clinical Laboratory 
and Standards Institute recommendations and used throughout these 
experiments (CLSI, 2008). For testing antifungal susceptibility in combination 
with DNase, a checkerboard assay was performed with 24 h preformed biofilms 
as described previously (Section 2.2.8.1).  An assay was prepared with DNase (0 – 
256 mg/mL) and either amphotericin B (0 - 16 mg/L) or caspofungin (0 - 512 
mg/L) or voriconazole (0 - 512 mg/L) within these ranges in combination. The 
cells susceptibility (sMIC50) was determined at 50% reduction in metabolism 
compared to untreated controls using the 2, 3-bis (2-methoxy-4-nitro-5-sulfo-
phenyl) - 2 H tetrazolium - 5-carboxanilide (XTT)- based reduction assay, as 
previously described (Section 2.2.6). Following these initial experiments, a 
defined concentration of DNase was selected (128 mg/L) for all subsequent 
microdilution testing on different phases of biofilms with the panel of strains 
(n=6).  
3.2.12 Statistics 
Analysis of variance (ANOVA) and t-tests were used to investigate independent 
sample data. A Bonferroni correction was made to the p value to allow for 
multiple comparisons and applied to the data where appropriate. SPSS (Version 
11, Chicago, USA) was used for these analysis and GraphPad Prism (Version 4, La 
Jolla, USA) for the production of the figures. The Spearman’s rho correlation 
coefficient () was determined to investigate the relationship between the 
parameters measured. A p value of less than 0.05 was considered significant. 
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3.3 Results 
3.3.1 Characteristic spectra of Amphotericin B 
The absorption spectra of known quantities of ampB were scanned between 
wavelengths of 300 and 500nm. The absorbance spectrum of ampB in DMSO 
(Figure 3.1a) shows four typical peaks at approx. 350, 370, 390 and 415nm, with 
an absorption maximum at 415nm. This absorption pattern was detectable even 
at a concentration of as low as 0.125 mg/L of ampB. The standard curve of ampB 
in DMSO was obtained by plotting the ampB concentrations along thex-axis and 
the absorbance value measured at 415nm in the fourth derivative spectrum 
along y-axis. Figure 3.1b shows an excellent correlation (r2 = 0.98) between 
ampB concentrations and the absorbance values of the fourth derivative. 
3.3.2 Amphotericin B binds with fungal components 
The binding of ampB with different fungal components was found using 
standardised ampB binding assay. Commercially available fungal components 
including chitin, β-glucan, ergosterol and zymosan were incubated with ampB 
(32 mg/L). The ampB was then extracted from fungal components using DMSO 
and ampB absorption spectra were assessed. Figure 3.2 show the absorption 
spectrum of extracted ampB. It shows ampB was bound to β-glucans, ergosterol 
and zymosan, and no measurable binding with chitin molecules.   Approximately 
3-5 mg/L out of 32 mg/L of added ampB was bound with β-glucans, ergosterol 
and zymosan in 5min. 
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a) 
 
b) 
 
Figure 3.1 - Characteristic spectra of amphotericin B. a) absorption spectra of 
different concentrations (64, 32, 16, 8, 4, 2, 1, 0.5, 0.25 and 0.125 mg/L) of 
ampB was measured between wavelengths of 300 and 500nm. b) Standard curve 
of ampB was plotted using ampB concentrations and absorbance values at 
415nm. R2 value of 0.98 indicates linearity between ampB concentrations and 
absorbance values. 
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Figure 3.2 - Amphotericin B binding with different fungal components. Graph 
shows the absorbance spectra of ampB. Absorption spectrum of ampB extracts 
from ergosterol, chitin, β-glucan and zymosan was assessed between 320 and 
470nm. The absorbance maxima at 415nm were used to quantify the amount of 
ampB bound with the components. 
 
3.3.3 Amphotericin B binds with A. fumigatus biofilm matrix 
The A. fumigatus biofilms grown for 24 h were exposed to ampB (8mg/L) for 1, 
30 and 120 min. After incubation period the ampB binding was assessed using 
absorption spectra. Figure 3.3 shows the spectra obtained with ampB extracts 
after each time point. Approx. 1 mg/L of AmpB was bound with biofilm after 
1min, 2 mg/L in 30min and 3.5 mg/L in 120min. To find out whether the biofilm 
matrix plays a role in ampB binding, the binding was assessed in the presence 
and absence of biofilm ECM. The biofilms were treated with EDTA to remove the 
ECM and incubated with ampB (64 mg/L) for 1h. Figure 3.3b shows a significant 
reduction in AmpB binding in the absence of ECM compared to the EDTA 
untreated controls. Approx. 5 mg/L of AmpB was bound with no ECM biofilm and 
about 8 mg/L of ampB was bound with control biofilms. 
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Figure 3.3 – Amphotericin B binds with A. fumigatus biofilm. a) AmpB binding 
with 24 h grown A. fumigatus biofilm was measured after 1, 30 and 120min 
exposure to 8mg/L of Amp-B. Figure shows the absorption spectra of ampB 
extracts from each time point. b) The AmpB binding was assessed in the 
presence and absence of ECM. Biofilms were pretreated with EDTA to remove 
the ECM and the binding of AmpB was assessed using AmpB absorbance spectra. 
(* p<0.05). 
 
Approx 3.5ug/ml 
Approx 2ug/ml 
Approx 1ug/ml 
8ug/ml 
a) 
b) 
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3.3.4 Presence of eDNA in A. fumigatus biofilm 
The presence of eDNA in bacterial biofilms is known to be associated with 
biofilm formation, stability and dispersal (Berne et al., 2010, Izano et al., 2008, 
Whitchurch et al., 2002). Due to the key structural and functional role of eDNA 
within bacterial biofilm ECM (Allesen-Holm et al., 2006), and more recently in C. 
albicansbiofilms (Martins et al., 2010), it was hypothesised that eDNA might play 
a similar role in A. fumigatus biofilms. The visual inspection using CLSM of 
calcofluor white stained A. fumigatus biofilm counter-stained with PI showed 
the presence of eDNA. Besides staining dead cells PI can be used to map eDNA in 
biofilms (Allesen-Holm et al., 2006). At low magnification localised areas of 
diffuse red fluorescence were observed that were distinct from brightly stained 
dead cells. Higher magnification through the z-stacks of the biofilms indicated 
that eDNA co-localised with hyphae, which was located throughout the biofilm 
structure (Figure 3.4). 
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Figure 3.4 - Presence of eDNA in A. fumigatus multicellular architecture. a) 
CLSM images of 24 h grown A. fumigatus biofilms on Thermanox™ coverslip at 
37oC. The different planer images of PI stained eDNA (diffuse red), which 
diffusely cover and intersperse calcofluor white (blue) stained hyphae (circled). 
(b-c) High magnification SEM images (x2000) of 24 h grown A. fumigatus biofilm 
showing the presence of some punctured hyphae covered and interspersed with 
ECM (circled). The images shown are representative of three independent 
experiments. 
 
 
a) 
b) c) 
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3.3.5 Standardisation of SYBR Green fluorescence assay 
The DNA binding dye SYBR Green was used to quantify the amount of eDNA 
present in different phases of A. fumigatus biofilm formation. To standardise 
this assay different concentrations of salmon sperm DNA was prepared and 
stained with SYBR Green I. The subsequent fluorescence produced was 
quantified and plotted against DNA concentrations. Figure 3.5 show the DNA 
standard curve produced using SYBR Green fluorescence assay. The standard 
curve shows a good correlation (R2 = 0.97) between DNA concentrations and the 
fluorescence measurement. The quantity of eDNA in different biofilm samples 
was assessed by substituting fluorescence value as x in the equation y = 57633x. 
 
 
Figure 3.5 – DNA standard curve from SYBR Green fluorescence assay. 
Different concentrations of salmon sperm DNA was prepared in 96 well black 
plate and stained with SYBR Green I. The subsequent fluorescence was measured 
using fluorescence plate reader. Standard graph was then plotted using the 
fluorescence value (y-axis) and DNA concentrations (mg/L) (x-axis). 
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3.3.6 Aspergillus fumigatus releases extracellular DNA in a phase 
dependent manner. 
A. fumigatus (AfGFP) biofilm grown for 8, 12, 24 and 48 h stained with PI was 
investigated for the presence of eDNA using fluorescence microscopy. Figure 3.6 
shows the presence of eDNA in different phases of biofilm formation. Red or 
Yellow appearance indicates the existence of eDNA in the biofilm. At the earliest 
time points at 8 h and 12 h (Figure 3.6 a-b) no or minimal PI fluorescence was 
observed and it increased over 24 and 48 h biofilms (Figure 3.6 c-d) in a time 
dependent manner.  
Controlling for non-specific binding of PI to ECM was not possible, therefore to 
confirm that the staining observed was a result of eDNA this experiment aimed 
to quantify eDNA content throughout the biofilm. To do so Af293 biofilms grown 
for 8, 12, 24, 48 and 72 h were gently washed with EDTA to remove the ECM.  
Experiments were performed in triplicate on 3 separate occasions. The eDNA 
within the ECM was then quantified using the DNA standard curve from SYBR 
Green fluorescence assay. Significant release of eDNA was observed in a time 
dependent manner (p<0.0001, ANOVA, Bonferroni’s Multiple Comparison Post 
Test) (Figure 3.7). At the earliest time point (8 h) eDNA release was below 
detectable limits, whereas 4 h later 24ng/mL was detected. In comparison to 8 h 
biofilms, a significant increase of ECM associated eDNA was observed within 
biofilms of 24 h (279ng/mL, p<0.01), 48 h (473ng/mL, p<0.001) and 72 h 
(864ng/mL, p<0.001). The accumulation of eDNA released by A. fumigatus into 
ECM was also detectable by qPCR assay. The ct values reflect the quantity of 
eDNA present in each samples. A ct value of 24, 27, 31 and no-ct was obtained 
with 48, 24, 12 and 8 h biofilm samples. 
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Figure 3.6 - Phase dependent eDNA release in A. fumigatus biofilm. 
Fluorescent micrographs (x20 magnification) of A. fumigatus (GFPstrain) grown 
for 8 h (a), 12 h (b), 24 h (c) and 48 h (d) on coverslips in a 24 well plate at 37oC. 
Biofilms were stained with DNA binding dye propidium iodide (PI). The colour 
saturated images of live GFP expressing cells (green) and PI stained eDNA 
(diffuse red) or dead cells (punctuate red) are shown. Yellow appearance 
indicates the presence of both live cells and eDNA. The images shown are 
representative of three independent experiments. 
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Figure 3.7 - The eDNA accumulation in biofilm ECM over time. a) Extracted 
ECM were stained with DNA binding dye SYBR green I and resulting fluorescent 
production was measured using fluorescence microplate reader to assess the 
quantity of eDNA present. Significant increase in eDNA level was found starting 
after 24 h time point compared to 8 h baseline (**P<0.001, *** P<0.0001), b) An 
amplification curve showing the ct values obtained for 8, 12, 24 and 48 h ECM 
samples. 
 
8 h – No ct 
12 h – 31 
24 h – 27 
48 h – 24 
a) 
b) 
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3.3.7 Characterisation of eDNA released by A. fumigatus 
To investigate whether eDNA released from maturing biofilms was different from 
genomic DNA RAPD PCR analysis was performed using defined primer sets 
specific for 7 conserved genes (Martins et al., 2012b). Genomic DNA was 
extracted using standard methods and compared to eDNA extracted from ECM. 
Gel electrophoresis showed equivalent bands for all 7 genes amplified for both 
genomic and eDNA (Figure 3.8). This suggests that eDNA is a result of release 
from dying cells within the maturing biofilm. Microscopic examination of the 
hyphae within the biofilm was undertaken using SEM to investigate whether any 
structural defects were apparent. The SEM images showed occasional hyphae 
distributed throughout the dense filamentous structure had a punctured 
appearance at the hyphal tips coincidental with ECM extrusion (Figure 3.4 b). 
However, whether this event plays a direct functional role within the biofilm 
remained to be determined.  
  
Figure 3.8 - Random amplified polymorphic DNA PCR.  RAPD PCR was carried 
out on extracted genomic (G) and extracellular (E) DNA samples to amplify seven 
different genes (G1 -ANXC4, G2-BGT1, G3-CAT1, G4-LIP, G5-MAT1-2, G6-SODB 
and G7-ZRF2) and the PCR products were electrophorised on an agarose gel.  
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3.3.8 Extracellular DNA improves the structural integrity of Aspergillus 
fumigatus biofilms 
Given that as the biofilm matures eDNA release increases proportionally to the 
levels of ECM, then this suggests that it may play a specific role within the 
biofilm. Studies of P. aeruginosa have shown that eDNA plays a role in biofilm 
development (Whitchurch et al., 2002), indicating that this may also be the case 
for A. fumigatus. To test this hypothesis the addition of DNase to different 
phases of biofilm growth was performed, as has been described from studies of 
C. albicans (Martins et al., 2012a). Both CLSM and biomass assays were used to 
visualise and quantify the impact of 24 h DNase treatment. To control for the 
direct effect of DNase on cells the checkerboard assay demonstrated that no 
direct antimicrobial effect was observed at the concentrations tested. Structural 
integrity of the biofilm was markedly affected by the addition of DNase. CLSM 
imaging showed that the dense structure of mature A. fumigatus biofilms was 
extensively disaggregated, reducing the biofilm depth by approximately 57%, 
and leaving adherent germlings and a scattered number of hyphae compared to 
the untreated biofilm (Figure 3.9a). Quantitative analysis of biofilm depth was 
also shown to be significantly reduced by approximately 57% (p<0.01) (Figure 
3.9b). 
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Figure 3.9 - The eDNA play a role in biofilm stability.  (a) CLSM images of A. 
fumigatus biofilms (24 h) treated with vehicle or DNase (256 mg/L) for 24 h at 
37oC. Biofilms were stained with calcofluor white and propidium iodide. The 
artificially coloured images of cells (white) and PI stained eDNA (red) or dead 
cells (punctuate red) are shown. The images shown are representative of three 
independent experiments. (b) Biofilm disruption was assessed by visualising the 
three dimensional architecture of biofilm under CLSM and thickness were 
analysed using volocity software (** p<0.002). 
a) 
b) 
Control       DNAse treated 
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Assessment of biomass by crystal violet assay demonstrated that the structural 
integrity of the preformed biofilm was shown to be markedly affected by the 
addition of DNase in a concentration dependant manner. Compared to the 
control biofilm 0.25 mg/mL of DNase significantly reduced the resultant biomass 
from an OD570 1.76 to 1.03 (p<0.05), 1 mg/mL to 0.69 (p<0.01), with a maximal 
effect observed with 4mg/mL (0.38, p<0.001) (Figure 3.10a). In contrast, 
treatment with heat inactivated DNase (0.25 mg/mL), RNase (0.25 mg/mL) and 
proteinase K (0.25 mg/mL) did not significantly reduce biofilm biomass 
compared to the vehicle control (p>0.05). To test its effect on biofilm 
development, conidia were treated as before and a significant reduction of 
biofilm biomass was also observed in a concentration dependent manner at 
concentrations of 0.25, 1 and 4 mg/mL (p<0.0001, ANOVA with a Bonferroni Test 
Post Hoc for multiple comparisons) (Figure 3.10b). Compared to the biofilm 
development control 0.25mg/mL of DNase reduced the resultant biomass from 
an OD570 1.34 to 0.79 (p<0.01), 1 mg/mL to 0.57 (p<0.001), with a maximal 
effect observed with 4mg/mL (0.31, p<0.001). 
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b) 
 
 
 
 
Figure 3.10 - The eDNA plays a role in biofilm formation and its stability. The 
biofilm biomass assessed by crystal violet assay following DNase treatment is 
shown in the graph. (a) A. fumigatus conidia were incubated overnight with 
different concentration of DNAse (0, 0.125, 1 and 4 mg/ml). The biomass data 
shows significant inhibition of the biofilm formation with eDNA digestion in a 
dose dependant manner compared to vehicle control. (b) The effect of DNase 
treatment on preformed biofilm was also assessed using crystal violet assay. 
Significant disruption of preformed biofilm is shown with DNase treatment 
compared to vehicle control (* p<0.02, ** p<0.002, *** p<0.0002).  
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3.3.9 Addition of exogenous DNA improves biofilm formation 
Given that DNase treatment led to architectural instability the next hypothesis 
was adding exogenous DNA during initial adhesion would positively promote 
biofilm formation, as has been shown to be the case for C. albicans biofilms. 
Addition of exogenous DNA from salmon sperm, C. albicans and A. fumigatus 
significantly increased the biofilm biomass at 4, 8 and 20 mg/L (p<0.0001, 
ANOVA, Bonferroni Test Post Hoc for multiple comparisons) (Figure 3.11). The 
proportional increase in biofilm was 29%, 82% (p<0.05) and 122% (p<0.01) when 
4, 8 and 20 mg/L of exogenous salmon sperm DNA was added. However, when C. 
albicans and A. fumigatus exogenous genomic DNA was added at 4, 8 and 20 
mg/L the biofilm biomass increase was more notable, significantly increasing by 
49% and 77% (p<0.01), 70% and 124% (p<0.001), and 106% and 126% (p<0.001), 
respectively. 
 
 
Figure 3.11- Exogenous DNA enhances the A. fumigatus biofilm formation. 
Addition of external DNA at concentrations of 0, 4, 8, 20 and 100 mg/L in RPMI 
growth medium showed significant increase in biofilm biomass with 24 h 
incubation in a dose dependant manner (* p<0.01, ** p<0.001 , *** p<0.0001). 
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3.3.10 Extracellular DNA release confers antifungal resistance upon of 
Aspergillus fumigatus biofilms 
Numerous studies have shown the integral relationship between biofilm ECM and 
antifungal resistance. Given that eDNA is an important component of the ECM 
and that a recent study has shown in C. albicans biofilm sensitivity to antifungal 
agents is improved through the addition of DNase (Martins et al., 2012a). This 
experiment aimed to find whether the treatment of A. fumigatus biofilms with 
DNase in combination with different classes of antifungal agent would improve 
their activity. First, a checkerboard assay was conducted to test different 
combinations of DNAse (0 - 512 mg/L) with amphotericin B (0 - 64 mg/L), 
caspofungin (0 - 256 mg/L) or voriconazole (0-256 mg/L). Antifungal testing 
using a checkerboard format on 24 h biofilms showed that the sessile minimum 
inhibitory (sMIC50) values of both amphotericin B and caspofungin treated cells 
decreased with an increase in DNase concentration (Figure 3.12 a-b). No 
significant change in MIC of azole in the presence of DNase was obtained. Based 
on this checkerboard data a fixed concentration of 128 mg/L was used for 
further experimental testing on different biofilm phases. It was shown that the 
susceptibility of 8 h biofilms was unaffected by antifungal and DNase treatment. 
However, the efficacy of both amphotericin B and caspofungin was improved as 
the biofilms matured to 12 h (1 - 2 fold), 24 h (8 - 16 fold) and 48 h (8 - 32 fold) 
(Table 3.2).  
Spearman’s rho correlation coefficient was calculated to test if the level of 
eDNA accumulation from A. fumigatus biofilms was correlated to the levels of 
antifungal sensitivity. Statistically significant correlations were observed 
between the level of eDNA accumulation in biofilms and the biomass (=0.91364; 
p=0.00003), amphotericin B MIC (=0.71729; p=0.00864) and caspofungin MIC 
(=0.82664; p=0.00092). All correlations are shown in Table 3.3. 
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Figure 3.12 - Effect of eDNA digestion on A. fumigatus biofilm susceptibility 
against antifungals. Checkerboard assay was designed to test different 
concentration of DNAse (0 to 256 mg/L) and amphotericin B (0-16 mg/L) and 
caspofungin (0- 512 mg/L) against 24 h biofilm. Green colour indicates growth of 
A. fumigatus below sMIC50 and dark color indicates the growth inhibition above 
sMIC50. 
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Table 3.2 – sMIC (mg/L) of amphotericin B and caspofungin in the presence 
and absence of DNase (128mg/L) 
Amphotericin B 
Strain 8 h 12 h 24 h 48 h 
- + - + - + - + 
Af293 0.0625 0.0625 0.0625 0.0625 0.125 0.03125 1 0.125 
YHCF1 0.015 0.015 0.031 0.015 0.125 0.01563 1 0.125 
YHCF2 0.125 0.125 0.125 0.031 0.125 0.01563 2 0.125 
YHCF3 0.031 0.015 0.0625 0.015 0.125 0.00781 1 0.0625 
YHCF4 0.031 0.031 1 1 1 0.25 4 0.25 
YHCF5 0.007 0.007 0.25 0.25 1 0.25 4 0.25 
 
Caspofungin 
Strain 
8 h 12 h 24 h 48 h 
- + - + - + - + 
Af293 0.015 0.015 2 2 128 32 >256 64 
YHCF1 0.062 0.03125 4 4 128 16 >256 64 
YHCF2 0.062 0.062 8 4 64 8 >256 64 
YHCF3 0.015 0.015 4 2 64 8 128 8 
YHCF4 0.062 0.03125 4 2 64 16 >256 32 
YHCF5 0.015 0.015 2 2 64 16 >256 32 
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Table 3.3– Correlation analysis 
 
 
 
 
 
 
R* = Spearman’s  correlation coefficient  
P
#
  = Probability value based on 2-tailed test 
P < 0.05 denotes significance 
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3.4 Discussion 
The results of this study establish a novel serendipitous role for eDNA release in 
conferring antifungal resistance to A. fumigatus biofilms. A. fumigatus 
infections are typically difficult to manage with antifungal treatment and are 
associated with unacceptably high rates of mortality. It has been hypothesised 
that treatment failure may relate to the presence of innate resistance 
mechanisms associated with multicellular biofilms (Rajendran et al., 2011a, 
Ramage et al., 2012, Robbins et al., 2011). In the previous chapter the 
contributory role of efflux pumps in azole resistance was explained. It suggests 
that the efflux system playing an early role in resistance during colonisation, 
which is then reduced as extrapolymeric matrix is produced during biofilm 
maturation. Previous studies showed that in C. albicans biofilms extracellular 
matrix and their components such as β-1,3-glucans binds with antifungals and 
decreases the biofilm sensitivity to  azole and polyene drugs (Gutierrez-Correa 
and Villena, 2003, Vediyappan et al., 2010). Here in this study the physical 
binding of amphotericin B with A. fumigatus biofilm components was 
investigated. The data show that amphotericin B physically binds with biofilm 
extracellular matrix and to fungal materials including β-glucans, chitin and 
ergosterol (Figure 3.2 - 3.3).  
In addition, this study also investigated the presence of eDNA in A. fumigatus 
biofilm matrix. Given that eDNA has been shown to be an important component 
of biofilm ECM in both bacteria and fungi suggests that this may be conserved 
and possibly an active microbial biofilm process, but this has yet to be 
demonstrated. These data show for the first time that eDNA is a key structural 
component of maturing biofilms, released possibly through autolysis, which 
imparts protective effects against antifungal treatment as evidenced through the 
synergistic effects of DNase with either polyenes or echinocandins.  
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The presence and function of biofilm associated eDNA have been well 
documented in a variety of bacterial species (Allesen-Holm et al., 2006, 
Flemming and Wingender, 2010, Whitchurch et al., 2002), yet in fungal biofilms 
this is limited to Candida spp. (Al-Fattani and Douglas, 2006, Martins et al., 
2010). Recent investigations of C. albicans have confirmed that despite the use 
of different growth media eDNA was present in mature biofilms, and based on 
digestion with DNase and the addition of exogenous DNA at different stages of 
biofilm development it was shown that eDNA contributes to the maintenance 
and stability of mature biofilms(Martins et al., 2010). Initially, a microscopy 
evaluation of mature A. fumigatus biofilms showed the diffuse presence of 
eDNA, which under closer inspection appeared to co-localised in between 
hyphae (Figure 3.4). Moreover, this could readily be detected and quantified. 
This study was also able to show an important structural role, as treatment with 
DNase led to disaggregation and destruction, whereas conversely the addition of 
exogenous DNA led to structurally superior biofilms. These series of 
investigations are the first to demonstrate the presence and critical function of 
eDNA as a biofilm ECM structural component, providing architectural stability to 
A. fumigatus biofilms.  
In addition to providing structural support eDNA release may have a 
multifunctional role for A. fumigatus. The primary role ascribed to eDNA has 
been the regulation of biofilm formation and structure (Whitchurch et al., 2002). 
However, while investigations proceed to elucidate other functions (Grande et 
al., 2011), eDNA has been involved, for instance, in biofilm antimicrobial 
resistance (Tetz et al., 2009, Mulcahy et al., 2008). To further investigate 
alternative functional roles of eDNA its impact on antifungal treatment was 
evaluated. It has been shown that the ECM is a pivotal barrier for antifungal 
activity, as it is known to bind specific classes of antifungal agent and limit 
penetration of others in C. albicans (Al-Fattani and Douglas, 2004, Nett et al., 
2010b). Moreover, it has been shown to have a functional role in A. fumigatus 
(Beauvais et al., 2007b, Ramage et al., 2011). The previous chapter 
hypothesised that the ECM was an important determinant of resistance based on 
differential efflux pump profiles, i.e. low relative efflux pump expression was 
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associated with high levels of azole and echinocandin resistance (Rajendran et 
al., 2011a). Given that eDNA is a key structural component of the ECM it was 
hypothesised that destabilizing it through the simultaneous addition of DNase 
would improve the penetration and sensitivity of antifungal agents, as has been 
shown for amphotericin B against pre-formed C. albicans biofilms (Martins et al., 
2012a).Whilst DNase was shown to have no antifungal effect per se, using this in 
a checkerboard assay combined with antifungal agents increased the sensitivity 
of polyenes and echinocandins upon 24 h biofilms. In fact, this was clearly 
evident from analysis of different phases of biofilm using a fixed DNase 
concentration (Table 3.2). These data suggest that DNase treatment may offer 
an attractive chemotherapeutic strategy for the management of A. fumigatus 
infections.  
Recently, the combined use of drugs (Espinel-Ingroff, 2009), or drugs with other 
agents such as enzymes(Kaplan, 2009), has received considerable attention. ECM 
degrading enzymes present broad-spectrum activity that is unlikely to induce 
antimicrobial resistance. The combined use of ECM degrading agents and 
antifungals has been previously tested in vitro. It was shown that C. albicans 
biofilm cells susceptibility to fluconazole and amphotericin B was increased by 
β-1,3-glucanase (Nett et al., 2007), whereas A. fumigatus biofilm cells 
susceptibility to polyenes was not changed by α-1,3-glucanase (Beauvais et al., 
2007b). Clinically, however, the DNase Pulmozyme® is currently used as a 
therapeutic agent for cystic fibrosis treatment as an adjunct to antibiotic 
treatment (Frederiksen et al., 2006). However, limitations to these 
chemotherapeutic approaches include the expense and increased risk of 
dispersing cells to distal sites of colonization (Kaplan, 2009).  
To summarise, the data from this study demonstrate the physical binding of 
antifungal drug with ECM and this is the first report to show the presence of 
eDNA in A. fumigatus, which impacts antifungal resistance. These observations 
may allow us to improve the treatment of different forms of aspergillosis using 
agents, such as nucleases, allowing disaggregation of filamentous masses and 
improving penetration and efficacy of existing antifungal agents.  
 Chapter 4 
4 Investigating the Mechanisms of 
eDNA Release in Aspergillus 
fumigatus Biofilms 
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4.1 Introduction 
Recent studies have shown that extracellular DNA (eDNA) is a key component of 
both fungal and bacterial biofilms (Martins et al., 2010, Whitchurch et al., 2002, 
Flemming and Wingender, 2010), which is proposed to improve overall structural 
integrity. In Pseudomonas aeruginosa for example it was shown to contribute <1 
to 2 % of the ECM composition. Moreover, bacterial biofilm studies have 
suggested that eDNA has a multifactorial purpose, namely as a nutrient source 
(Mulcahy et al., 2010), facilitator of genetic information exchange (Molin and 
Tolker-Nielsen, 2003), contributor to biofilm stability and dispersal (Whitchurch 
et al., 2002, Izano et al., 2008, Allesen-Holm et al., 2006, Berne et al., 2010), 
and as an antimicrobial resistance factor (Mulcahy et al., 2008, Tetz et al., 
2009). Data from the previous chapter (Chapter-3) demonstrate the presence of 
eDNA within dense A. fumigatus biofilm populations, and that it plays a 
functional role in maintaining structural and architectural integrity and 
antifungal resistance. It also demonstrated that eDNA is most likely to be 
genomic DNA released from A. fumigatus during biofilm growth, but how this is 
regulated was unknown. Therefore this chapter aimed to undertake further 
studies to investigate a potential mechanism of release. 
Mechanistically, cell death and lysis (Qin et al., 2007), quorum sensing (Spoering 
and Gilmore, 2006) and excretion from outer membrane vesicles (Kadurugamuwa 
and Beveridge, 1995) have been proposed to be involved in eDNA release in 
bacteria (Allesen-Holm et al., 2006, Kadurugamuwa and Beveridge, 1995). 
Autolysis is often cited as a key mechanism for the release of eDNA in bacterial 
biofilms (Qin et al., 2007). Evidence exists in eukaryotes from studies of A. 
nidulans that autolysis is regulated by chitinase activity (Shin et al., 2009, Emri 
et al., 2008, Molnar et al., 2006). In addition, chitinase activity was shown to be 
associated with cell wall biosynthesis at the growing tips of hyphae and hyphal 
remodelling of filamentous fungi (Adams, 2004, Bowman and Free, 2006, 
Selvaggini et al., 2004). 
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The molecular chaperone HSP90 regulates complex cellular circuitry in 
eukaryotes by stabilizing regulators of cellular signalling. The HSP90s have been 
proposed to be involved in cell wall biogenesis through the regulation of their 
client proteins Mkc1, Hog1 and Cek1 in C. albicans (Leach et al., 2012). The cell 
wall remodelling is mainly governed by the Mkc1 pathway by inducing the 
expression of remodelling enzymes such as chitinases (Heilmann et al., 2013). 
This study hypothesised that chitinases may play a role in autolysis of A. 
fumigatus biofilms that leads to the release of eDNA. Given the association of 
HSP90 proteins with chitinase expression it was hypothesised that inhibition of 
HSP90 by geldanamycin affects the chitinase regulated eDNA release.  
The aim of this study was to investigate the mechanisms of eDNA release in A. 
fumigatus biofilms. 
 
This chapter has been published in peer reviewed journals: 
Rajendran, R., Williams, C., Lappin, D. F., Millington, O., Martins, M. & 
Ramage, G. (2013) Extracellular DNA release acts as an antifungal resistance 
mechanism in mature Aspergillus fumigatus biofilms. Eukaryot Cell. 
Robbins, N., Uppuluri, P., Nett, J., Rajendran, R., Ramage, G., Lopez Ribot, J. 
L., Andes, D. & Cowen, L. E. (2011) HSP90 governs dispersion and drug 
resistance of fungal biofilms. PLoS Pathog, 7, e1002257. 
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4.2 Materials and methods 
4.2.1 Strains and conidial preparation 
A. fumigatus Af293 and clinical isolates (YHCF1 – YHCF5) were obtained from the 
Royal Hospital for Sick Children (Yorkhill Division), Glasgow and used throughout 
these study. Chitinase deletion mutants Afchi1, Afchi1chi2, Afchi1chi2chi3, 
Afchi1chi2chi3chi4, Afchi1chi2chi3chi4chi5and their parental WT strain KU80 
were generously provided by Jean Paul Latge (Institut de Pasteur, Paris, France). 
An A. fumigatus transformant expressing green fluorescent protein (Af-GFP) was 
used during microscopy, as described previously (Wasylnka and Moore, 2002). All 
the isolates were stored as previously described in section 2.2.1. All A. 
fumigatus strains were grown on Sabouraud dextrose agar at 37oC for 72 h. 
Conidia were then harvested as described in section 2.2.2. Conidia were then 
counted on a Neubauer haemocytometer and adjusted to a standardised 
suspension of 5 × 105 conidia/ml in RPMI. All procedures were carried out in a 
class 2 biological safety cabinet (MDH Intermed). 
4.2.2 Microscopy 
Standardised conidia of Af293 were inoculated in RPMI onto Thermanox 
coverslips (13mm) within a 24-well tissue culture plate, and incubated for 24 h 
at 37oC. These were gently rinsed with PBS and stained, as described in section 
3.2.5, with 5M calcofluor white (Af293 only) (InVitrogen) and 20M propidium 
iodide (PI) (Sigma). Biofilm growth and accumulation of eDNA were visualised 
under a fluorescence microscope (Motic BA400, Colorview system) or confocal 
laser scanning microscope (CLSM) (Leica SP5 laser scanning confocal microscope) 
at an excitation and emission wavelength of 350:400 for calcofluor white, 
540:525 for propidium iodide, and 480:490 for GFP. One representative from 
each group was digitally photographed. Quantification of the z-stacks was 
performed using Volocity software (Perkin Elmer). For SEM representative 
biofilms grown and treated on Thermanox coverslips were processed and 
viewed under a SEM as previously described (Section 2.2.4.2).  
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4.2.3 Quantification of eDNA release 
The quantity of eDNA  released by different A. fumigatus isolates were assessed 
using a fluorescence DNA binding dye assay, as previously described (Section 
3.2.7). Briefly, SYBR Green I (Invitrogen) was added to conidial suspension in a 
black well microtiter plate (Costar3603; Corning) in a ratio 1:4. Binding of this 
dye produces fluorescence in direct proportion with eDNA concentration. The 
levels of eDNA were quantified using a fluorescence plate reader (Fluostar 
Optima; BMG Labtech) at the excitation and emission wavelength of 485 and 518 
nm, respectively every 10 min for the period of  24 h. The concentration of eDNA 
in the sample was quantified using the DNA standard curve. 
4.2.4 Evaluating biofilm formation 
Biofilms were formed in 96-well microtitre plates as previously described 
(Section 2.2.3). To assess the effect of class III chitinase gene mutants on biofilm 
formation, standardised conidia (5x105) of Afchi1, Afchi1chi2, 
Afchi1chi2chi3, Afchi1chi2chi3chi4, Afchi1chi2chi3chi4chi5 and their 
parental WT strain KU80 were allowed to form biofilm in 96 well plate in RPMI 
for 24 h at 37oC. In addition, to evaluate the effect of a chitinase inhibitor, 
azetazolamide (Sigma-Aldrich) treatment on biofilm formation, Af293 biofilms 
were grown for 24 h in the presence and absence of azetazolamide (128 mg/L) 
at 37oC overnight. After each experiment the biofilms were washed in PBS and 
biomass quantified using a crystal violet assay as described in section 3.2.10. 
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4.2.5 Quantitative gene expression 
A. fumigatus Af293, YHCF1-YHCF4 biofilms were prepared in triplicate on tissue 
culture treated flasks as described previously (Section 2.2.3). RNA was extracted 
by mechanical disruption in TRIzol® (Invitrogen) as described previously (Section 
2.2.9 and 2.2.10) and purified using an RNeasy MinElute clean up kit (Qiagen), as 
per the manufacturer’s instructions. RNA was quantified and the quality 
determined using a NanoDrop spectrophotometer™ (ND-1000, ThermoScientific). 
At first, cDNA was synthesised with high capacity RNA to cDNA master mix 
(Applied Biosystems) using a MyCycler PCR machine (Bio-Rad) as described in 
section 2.2.11 and stored at -20oC for expression analysis. The expression of a 
panel of Class III chitinase genes (Chit1-5) was then assessed using quantitative 
RT-PCR using SYBR® GreenER™ (Invitrogen), according to the manufacturers’ 
instructions. Primer for class III chitinase genes and TEF1 and PCR cycling 
conditions were standardised previously by Alcazar-Fuoli and colleagues 
(Alcazar-Fuoli et al., 2011). Primers for HSP90 were previously published by 
Marcin G Fraczek and colleagues (Fraczek et al., 2010). Table 4.1 show all the 
genes and primer sequences used in this chapter. The following PCR cycling 
conditions were used for amplification of chitinase genes, initial incubation at 
95oC for 3 min then 40 cycles of 95oC for 5 s, 58oC for 5 s, 72oC for 15 s, 78oC for 
4 s and 78oC for 1s. For the PCR amplification of HSP90 gene the cycling 
conditions of 5min at 95oC (initial denature) then 40 cycles of 95oC for 30s, 55oC 
for 30s (annealing), and 72oC for 30s, followed by a final extension at 72oC  for 
10min was used. The individual gene expression levels were then calculated 
using 2-Δct method for different phases and normalised to the TEF1 house keeping 
gene.  
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Table 4.1 – Primers used to quantitatively investigate chitinase expression 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Primer Sequence 
Afu5g03760 
ChitA - F CAACCACCGTGACGTTGACA 
ChitA - R TTCAGAAAAGCTGCCGTTGC 
Afu5g03530 
ChitB - F TACCCTGACGCTGCCGATAA 
ChitB - R AACCGTCTTGGCCCAGTTGT 
Afu3g07110 
ChitC - F TGCGATTTGGGTGCAGTTCT 
ChitC - R TTTCCTGGCAGACCGATGAA 
Afu7g05140 
ChitD - F CAACCAGCTCCGCTCCTTGT 
ChitD - R GCAGGCCGCAGTAGTTGTTG 
Afu8g00700 
ChitE - F CGGCTGGGACTTTGACATTG 
ChitE - R AAACTGCGCCTTGGTGACAA 
Afu1g06390 
Tef1 - F CCATGTGTGTCGAGTCCTTC 
Tef1 - R GAACGTACAGCAACAGTCTGG 
Afu5g04170 
 
HSP90 – F TGACCAAGGCTGATTTGATC 
HSP90 - R CAACAAGGTAAGCAGAGTAG 
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4.2.6 Quantifying chitinase activity 
Chitinase activity of A. fumigatus at different phases of biofilm formation was 
assessed using a fluorometric chitinase assay kit (Sigma, UK), as per 
manufacturer’s instructions. In brief, supernatants were collected from different 
time points, and an appropriate volume of each sample was incubated with a 
substrate working solution (4-Methylumbelliferyl N-acetyl-β-D-glucosaminide) at 
37oC for 30 min. Fluorescence was then quantified at an excitation and emission 
wavelength of 360nm and 450nm, respectively. Appropriate positive and 
negative controls included in the kit were added in each plate. Finally, chitinase 
activity was calculated in units (U/mL). One unit of chitinase activity is defined 
as release of 1 µmole of 4-methylumbelliferone from the substrate per min at pH 
5.0 at 37°C. In addition, the chitinase inhibitor, azetazolamide was also tested 
for inhibition of activity using this assay.  
4.2.7 Biofilm susceptibility testing 
For testing the effect of chitinase inhibition on antifungal susceptibility the 
biofilms (Af293 and 5 clinical isolates) formed in the presence of azetazolamide 
(128 mg/L) were treated with amphotericin B (0-32 mg/L) and the cells 
susceptibility (sMIC50) was determined at 50% reduction in metabolism compared 
to untreated controls using the 2, 3-bis (2-methoxy-4-nitro-5-sulfo-phenyl) - 2 H 
tetrazolium - 5-carboxanilide (XTT)- based reduction assay, as previously 
described (Section 2.2.6). 
For testing the effect of Hsp90 inhibition by geldanamycin on antifungal 
susceptibility a checkerboard assay was employed. Amphotericin B, caspofungin 
and voriconazole were prepared according to the Clinical Laboratory and 
Standards Institute recommendations and used throughout these experiments 
(CLSI, 2008). Af293 conidial inoculum (1×105 conidia/mL) was dispensed into flat 
bottomed 96-well microtitre plates and incubated for 8 or 24 hours at 37°C. 
Biofilms were gently washed twice with PBS and each antifungal agent and 
geldanamycin were diluted to working concentrations in RPMI, which were 
tested either alone or in combination in a checkerboard format. Antifungal agent 
Chapter 4: Mechanisms of eDNA release in A. fumigatus 
164 
 
dilutions were from 512 mg/L down to 0 with the following concentration steps 
in mg/L: 512, 256, 128, 64, 32, 16, 8, 4, 2, 1, 0.5. Geldanamycin dilutions were 
from 100 µg/ml down to 0 with the following concentration steps in mg/L: 100, 
25, 12.5, 6.25, 3.125, 1.5625. The cells susceptibility (sMIC50) was determined 
using the XTT- based reduction assay, as previously described (Section 2.2.6). 
4.2.8 Statistics 
Proportional data (fold change) were transformed to natural logarithm values 
before statistical tests were undertaken. Analysis of variance (ANOVA) and post 
hoc Bonferoni test was used to investigate independent sample data across a 
number of groups. The ANOVA and Dunnett t-test post hoc was used when a 
number of groups were compared only with the control group.  Alternately when 
only two groups were under comparison a t-test was utilized. SPSS (Version 11, 
Chicago, USA) was used for these analysis and GraphPad Prism (Version 4, La 
Jolla, USA) for the production of the figures. The Spearman’s rho correlation 
coefficient (R) was determined to investigate the relationship between the 
parameters measured. A p value of less than 0.05 was considered significant. 
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4.3 Results 
4.3.1 Extracellular DNA release during A. fumigatus hyphal formation 
The visual inspection using CLSM of calcofluor white stained A. fumigatus biofilm 
counter-stained with PI showed the presence of eDNA. Besides staining dead 
cells PI can be used to map eDNA in biofilms (Allesen-Holm et al., 2006). At 
higher magnification localised areas of diffuse red fluorescence were observed 
at sites of germination of conidia and growing hyphal edges, which were located 
throughout the biofilm structure (Figure 4.1).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1- Conidial germination and hyphal growth release eDNA. CLSM 
image of A. fumigatus biofilm (24 h). Biofilm was stained with calcofluor white 
and propidium iodide. The artificially coloured image of cells (white) and PI 
stained eDNA (red) is shown. Black arrow indicates the eDNA localization on sites 
of conidial germination and hyphal growth. 
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4.3.2 Transcriptional analysis of chitinase genes 
A transcriptional analysis of five different type III chitinases genes was done 
using real-time qPCR. The graphs in Figure 4.2 show the expression profile of the 
selected chitinase genes over different phases of A. fumigatus biofilm 
formation.  These data showed that all transcripts (Class III - ChitA, B, D and E) 
except for ChitC were significantly up-regulated in a phase dependant manner 
(p<0.05 [8<12<24 h]). Expression levels compared to 8 h ranged from a 2.6 to 
3.43-fold increase at 12 h and 3.6 to 7.25-fold increases at 24 h (Figure 4.2). 
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Figure 4.2 - Phase dependant chitinase gene expression. Quantitative real 
time PCR was carried out to assess the expression of five different class III 
chitinase genes (ChitA-E) over different phases. The individual gene expressions 
were calculated and normalised to the Tef1 house keeping gene. All the results 
presented are expressed in fold change in expression compared to 8 h baseline. 
Statistically significant up regulation of gene expression was found for ChitA,B,D 
and E with 12 or 24 h time point compared to 8 h (* p<0.01, ** p<0.001, *** 
p<0.0001). 
 
ChitC ChitD 
ChitE 
ChitA ChitB 
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4.3.3 Disruption of chitinase gene affects the biofilm formation 
To determine the effect of deletion of chitinase genes on biofilm formation the 
24 h biofilm biomass of Afchi1, Afchi1chi2, Afchi1chi2chi3, 
Afchi1chi2chi3chi4, Afchi1chi2chi3chi4chi5 and WT strain KU80 was assessed. 
Using crystal violet biomass assay it was demonstrated that the chitinase 
mutants Afchi1chi2chi3, Afchi1chi2chi3chi4 and Afchi1chi2chi3chi4chi5 had 
significantly reduced biofilm formation compared to their parental WT strain 
KU80 (*p<0.05, ** P<0.01) (Figure 4.3a). To confirm this, biofilm thickness of the 
quintuple mutant was analysed using Volocity software on CLSM images. The 
data displayed a significant reduction in biofilm thickness from 40µm in WT 
strain to around 30µm in quintuple chitinase mutant (Afchi1chi2chi3chi4chi5) 
(Figure 4.3b-c). 
4.3.4 Chitinase gene knockout affects the eDNA release 
To determine whether this biomass defect was a consequence of reduced eDNA 
release fluorescence assay was used to quantify the release of eDNA by chitinase 
mutants in real time in comparison to their parental WT strain. It was shown 
that release was significantly impeded throughout growth (Figure 4.4a). The 
eDNA release by Afchi1chi2chi3chi4chi5 was around 2 ng/mL with 24 h biofilm 
this is significantly lower compared to eDNA release by parental WT strain KU80 
of around 4 ng/mL (*p<0.05) (Figure 4.4b). The growth kinetics of the quintuple 
mutant and KU80 was also assessed to see whether there was any difference in 
their growth rate. The growth curve shows no difference between the mutant 
and KU80 till 16h but after that time point there was a slight difference between 
these starins.  The quintuple mutant Afchi1chi2chi3chi4chi5 showed a delay in 
reaching stationary phase compared to their parental strain KU80 (Figure 4.4c).  
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Figure 4.3- Knocking out chitinase gene affects the biofilm formation. A. 
fumigatus KU80 and chitinase deletion mutants Afchi1, Afchi1chi2, 
Afchi1chi2chi3, Afchi1chi2chi3chi4 and Afchi1chi2chi3chi4chi5 biofilms 
grown for 24 in a 96 well plate at 37oC. (a) Assessment of overall biofilm biomass 
by crystal violet assay showed significant reduction in biomass with 
Afchi1chi2chi3, Afchi1chi2chi3chi4 and Afchi1chi2chi3chi4chi5 compared to 
parental WT (KU80). (b-c)CLSM imaging and analysis of biofilm thickness using 
Volocity software of WT and quintuple chitinase mutant (Chit-
Afchi1chi2chi3chi4chi5)  biofilm shows a significant reduction in biofilm 
thickness with ΔChit. Data was analysed by analysis of variance (ANOVA) and 
Bonferroni correction for multiple comparisons applied (*p<0.05, ** p<0.01). 
(a) 
(c) (b) 
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Figure 4.4 – Chitinases contribute to eDNA release.A. fumigatus KU80 and 
chitinase deletion mutants Afchi1, Afchi1chi2, Afchi1chi2chi3, 
Afchi1chi2chi3chi4 and Afchi1chi2chi3chi4chi5 were grown in RPMI for 24 h in 
a 96 or 24 well plate at 37oC. (a) The eDNA release by WT and 
Afchi1chi2chi3chi4chi5 were assessed in real time by measuring the relative 
fluorescence (RFU) produced by DNA binding dye SYBR® Green I using a OMEGA 
fluorescence plate reader, (b) the biofilms formed by WT and chitinase mutants 
were gently washed with EDTA to collect the ECM, a SYBR® Green fluorescence 
assay was used to assess the eDNA within the ECM. The bar graph shows the 
amount of eDNA present in ECM of WT and chitinase mutants. Experiments were 
performed in triplicate on 3 separate occasions, (c) Growth curve shows the 
quintuple chitinase mutant has a prolonged exponential phase compared to WT 
strain. Data was analysed by analysis of variance (ANOVA) and Bonferroni post 
test for multiple comparisons applied (*p<0.05). 
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4.3.5 Phase dependant chitinase activity in A. fumigatus 
The chitinase activity of A. fumigatus over the period of biofilm formation was 
assessed using a biochemical assay. It was shown that as the biofilm matured the 
levels of chitinase activity significantly increased (p<0.01). No activity was 
observed for the 8 h phase, but at 12 and 24 h, 0.80 and 1.26 Units/mL were 
detected. Addition of azetazolamide was shown to significantly reduce activity 
of the 24 h biofilm to 0.13 Units/mL (p<0.01) (Figure 4.5), indicating that 
chitinase activity is associated with biofilm maturation. 
 
 
 
Figure 4.5 – Chitinase activity in A. fumigatus biofilm. Chitinase activity was 
assessed using a commercially available fluorometric assay for 8, 12 and 24 h 
biofilms, and in the presence of azetazolamide (24 h + Aze). Data was analysed 
by analysis of variance (ANOVA) and Bonferroni post test for multiple 
comparisons (*p<0.05, ** p<0.01). 
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4.3.6 Effect of azetazolamide on eDNA release 
To test whether chitinase activity is associated with eDNA, chitinase activity was 
biochemically influenced using a chitinase inhibitor, azetazolamide 
(Schuttelkopf et al., 2010). The eDNA release was assessed for each phase of 
biofilm growth ± azetazolamide (128 mg/L) using a SybrGreen I fluorescence 
assay. It was shown that for both 8 and 12 h biofilms azetazolamide did not 
significantly affect eDNA release, however, in 24 h biofilms a significant 
reduction of eDNA release was shown (p>0.01) (Figure 4.6). 
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Figure 4.6 – Inhibition of chitinase activity reduces extracellular DNA release 
in mature biofilms. eDNA release by A. fumigatus (Af293)was assessed in the 
presence of chitinase inhibitor (azetazolamide) for 8, 12 and 24 h using the 
SybrGreen I fluorescence assay. Each bar indicates SybrGreen fluorescence over 
different phases of biofilm formation. Error bar shows the standard deviation of 
the experiment. ** p<0.001. 
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4.3.7 Inhibition of chitinase activity affects biofilm formation 
To investigate whether biofilm development was affected by chitinase activity, 
biofilms were grown in the presence of azetazolamide and biofilm biomass was 
assessed by crystal violet assay. It was demonstrated that the resultant biomass 
was significantly impeded (p<0.01) (Figure 4.7a). These data were confirmed by 
fluorescence microscopy, where it was shown that biofilms formed in the 
presence of azetazolamide were substantially compromised in their ECM and 
presence of eDNA (Figure 4.7 b-c).  
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Figure 4.7 – Inhibition of chitinase activity affects A. fumigatus biofilm 
formation. (a)Conidia were incubated with azetazolamide (128 mg/L) for 24 h 
and the resultant biomass was assessed using a crystal violet assay. Data was 
analysed by analysis of variance (ANOVA) and Bonferroni test post hoc for 
multiple comparisons (** p<0.01,). (b-c) Fluorescent micrographs of A. fumigatus 
biofilm controls (b) or grown in the presence of azetazolamide (c) on 
Thermanox™ coverslips. These were stained with calcofluor white and propidium 
iodide and imaged using Colorview software at x200. 
(a) 
(b) (c) 
(b) (c) 
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4.3.8 Effect of azetazolamide on A. fumigatus growth 
Given the role of chitinase in cell wall biogenesis and sporulation in filamentous 
fungi the effect of chitinase inhibitor on A. fumigatus morphology was assessed 
(Minari et al., 2002, Husni et al., 1998, Fukuda et al., 2003). Interestingly, 
fluorescence micrograph at higher magnification of the hyphae showed a co-
localisation of eDNA at the hyphal tip compared to those treated with 
azetazolamide (Figures 4.8a-b). These data suggest that chitinases are an 
important factor in eDNA release from A. fumigatus biofilms, presumably 
through autolysis. Whether this process is regulated specifically or is a 
serendipitous effect of autolysis used to provide protection to the community of 
cells is at this time unknown.  
 
 
 
 
 
Figure 4.8 - Fluorescent micrographs of A. fumigatus biofilm (48 h) controls 
(a) or grown in the presence of azetazolamide (b) on Thermanox™ coverslips. 
These were stained with calcofluor white and propidium iodide and imaged using 
Colorview software at x400. 
 
 
 
 
 
 
(a) (b) 
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4.3.9 Effect of azetazolamide on biofilm MIC 
The MIC of 24 h biofilms formed in the presence of azetazolamide was assessed 
by broth micro dilution method. The MIC of amphotericin B was investigated and 
showed that biofilms formed in the presence of azetazolamide showed an 
increased sensitivity ranging from 0.0625 to 0.125 mg/L compared to 0.125 to 1 
mg/L (1-8 fold) (Table 4.2).   
 
Table 4.2 – MIC of amphotericin B against 24 h biofilm formed in the presence 
and absence of azetazolamide (mg/L). 
 
 
 
 
 
 
 
 
 
 
 
 
Strain Control + Azetazolamide Fold change 
Af293 0.125 0.03125 4 
YHCF1 0.125 0.125 0 
YHCF2 0.125 0.0625 2 
YHCF3 0.125 0.03125 4 
YHCF4 1 0.125 8 
YHCF5 1 0.25 4 
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4.3.10 HSP90 regulates the eDNA release in A. fumigatus 
To test whether HSP90 is associated with eDNA release, HSP90 was biochemically 
depleted using a HSP90 inhibitor, GdA. The eDNA release was assessed for each 
biofilm growth ± GdA using a SybrGreen I fluorescence assay. It was shown that 
GdA treatment significantly reduces the eDNA release from around 300ng/mL in 
untreated controls to around 200 ng/mL (p<0.05) (Figure 4.9). 
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Figure 4.9 – HSP90 inhibition affects eDNA release by A. fumigatus. Biofilms 
were treated with GdA or vehicle and ECM extracted for eDNA analysis. 
Extracted ECM were stained with DNA binding dye SYBR green I and resulting 
fluorescent production was measured using fluorescence microplate reader to 
assess the quantity of eDNA present. Significant decrease in eDNA level was 
observed with HSP90 inhibition (*p=0.04). 
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4.3.11 Inhibition of HSP90 affects the biofilm morphology 
To test the effect of HSP90 inhibition on biofilm morphology biofilms were 
treated with an HSP90 inhibitor GdA. Scanning electron microscopy revealed 
striking architectural changes of A. fumigatus biofilms upon GdA treatment. 
Upon HSP90 inhibition increased hyphal and matrix production was observed 
compared to untreated control biofilms (Figure 4.10 a-b).  
 
 
 
Figure 4.10 - Pharmacological inhibition of HSP90 by geldanamycin affects 
biofilm biomass. A. fumigatus cells were left untreated (a), or treated with 50 
mg/L GdA (b) for 24 hours. Following GdA exposure, biofilms were fixed and 
imaged by scanning electron microscopy. Biofilms treated with GdA show 
increased biofilm extracellular matrix indicated by arrow. Crystal violet data 
also show a significant increase (* p=0.01) in biofilm biomass with GdA 
treatment. 
 
 
 
 
(a) (b) 
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4.3.12 HSP90 is required for drug resistance of A. fumigatus biofilms 
Since HSP90 was shown to be associated with eDNA release it was interesting to 
find the effect of HSP90 inhibition on drug resistance of A. fumigatus biofilms. 
After 24 hours of growth, A. fumigatus biofilms were subjected to a gradient of 
concentrations of the echinocandins caspofungin or micafungin, or the azoles 
voriconazole, in addition to a gradient of concentrations of the HSP90 inhibitor 
geldanamycin in 96 well microtiter plates under static conditions. Metabolic 
activity was assessed using the XTT reduction assay after an additional 24 hours. 
The biofilms were completely resistant to all the antifungal drugs tested and 
GdA individually, though the combination of GdA with many of the antifungals 
was effective in reducing biofilm development. Geldanamycin displayed robust 
synergy with both caspofungin and micafungin (Figure 4.11), with an FIC value of 
0.375 for both drugs (Table 4.3). Geldanamycin also enhanced voriconazole 
activity (Figure 4.12a), with more potent effects observed when drugs were 
added to biofilms after only 8 hours of growth (Figure 4.12b).  
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Figure 4.11- Pharmacological inhibition of HSP90 enhances the efficacy of 
echinocandins against A. fumigatus biofilms. A. fumigatus was grown in 96-
well dishes in RPMI at 37°C. After 24 hours cells were washed with PBS to 
remove non-adherent cells and fresh medium was added with varying 
concentrations of caspofungin (CF), micafungin (MF) and the HSP90 inhibitor 
geldanamycin (GdA) in a checkerboard format. Drug treatment was left on for 24 
hours. Metabolic activity was measured by XTT assay. Bright green represents A. 
fumigatus growth, and black represents growth inhibition. 
Chapter 4: Mechanisms of eDNA release in A. fumigatus 
181 
 
 
 
 
Figure 4.12- Pharmacological inhibition of HSP90 enhances the efficacy of 
azoles against A. fumigatus biofilms. A. fumigatus was grown in 96-well 
microtiter plates in RPMI at 37°C. (a) After 24 hours cells were washed with PBS 
to remove non-adherent cells and fresh media was added with varying 
concentrations of the voriconazole (VL) in combination with the HSP90 inhibitor 
geldanamycin (GdA) in a checkerboard format. (b) After 8 hours cells were 
washed with PBS to remove non-adherent cells and fresh media was added with 
varying concentrations of the azole voriconazole (VL) in combination with GdA in 
a checkerboard format. Drug treatment was left on for 24 hours. Metabolic 
activity was measured by XTT assay. Bright green represents A. fumigatus 
growth, and black represents growth inhibition. 
(a) 
(b) 
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Table 4.3 – Inhibition of HSP90 has synergistic activity with echinocandins 
against A. fumigatus biofilms 
Antifungal concentration range 
(µg/mL) 
GdA concentration range 
(µg/mL) 
FIC 
indexa 
Micafungin, 64–512 25–100 0.375 
Caspofungin, 128–512 12.5–100 0.375 
aFIC index (MIC50 of drug A in combination)/(MIC50 of drug A alone) + (MIC50 of 
drug B in combination)/(MIC50 of drug B alone). A FIC of<0.5 is indicative of 
synergism. 
 
4.3.13 Inhibition of HSP90 enhance the biofilm damage by 
antifungal treatment 
Next, given HSP90's role in regulating fungal morphogenesis impact of drug 
treatment on morphology of A. fumigatus biofilms were assessed. Treating 
biofilms with caspofungin alone resulted in minimal damage, however, the 
addition of both caspofungin and geldanamycin caused numerous burst and 
broken hyphae throughout the biofilm (Figure 4.13). Finally, voriconazole 
treatment resulted in a flat ribbon-like morphology, and the addition of 
geldanamycin induced further cell damage (Figure 4.13). Taken together, these 
results indicate that inhibition of HSP90 induces changes in morphology of A. 
fumigatus biofilms, in addition to enhancing the efficacy of azoles and 
echinocandins against these otherwise recalcitrant cellular structures. 
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Figure 4.13 – Pharmacological inhibition of HSP90 affects biofilm morphology. 
A. fumigatus cells were left untreated, or treated with 32 µg/mL CF or 256 
µg/mL VL in the absence and presence of 50 µg/mL GdA for 24 hours. Following 
drug exposure, biofilms were fixed and imaged by scanning electron microscopy. 
Biofilms treated with antifungal show increased cellular damage in the presence 
of GdA. The white arrows indicate burst and broken hyphae in the biofilms 
treated with CF and GdA. 
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4.4 Discussion 
In the previous chapter the extracellular DNA was demonstrated to be an 
important component of A. fumigatus biofilm ECM. Following these initial 
findings the aim of this investigation was set out to determine how exactly eDNA 
becomes a key structural component of the biofilm ECM in A. fumigatus. 
Although not well understood, mechanisms of eDNA release in eukaryotic cells 
include active secretion, necrosis and apoptosis (Tamkovich et al., 2008), with 
the possibility of more than one pathway being involved (Fink and Cookson, 
2005). Bacterial autolysis is a commonly described mechanism of eDNA release 
within biofilms, which has been shown to improve Enterococcus faecalis and 
Neisseria meningitides biofilm development (Lappann et al., 2010, Thomas et 
al., 2008). In fungi, such as A. nidulans, the molecular basis of autolysis has 
been investigated. It has been shown that the chitinase ChiB plays a pivotal role 
in fungal autolysis in A. nidulans under carbon starvation (Pocsi et al., 2009, 
Szilagyi et al., 2010). ChiB is necessary to orchestrate the expression of autolytic 
hydrolases, with disruption of these genes leading to a reduced production of 
the cell wall-degrading hydrolase enzymes. Moreover, a recent functional 
analysis of the fungal/plant class 3 chitinases in A. fumigatus concluded that 
these endogenous GPI anchored enzymes may play a role by providing an energy 
source through autolysis (Alcazar-Fuoli et al., 2011). Fungal chitinases are 
secreted enzymes that have been shown to play a role in the digestion of 
exogenous chitin or utilization of fungal chitin during autolysis for energy. It was 
hypothesised in this study that as a consequence of autolysis eDNA is released 
thus conferring structural support for the development and maintenance of 
complex biofilm architecture.  
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Figure 4.14 – Proposed mechanisms of eDNA release. Chitinase activity was 
previously shown to be associated with autolysis process via FlbA pathway (Shin 
et al., 2009). The hydrolytic enzyme chitinase is also established to be a part of 
hyphal remodelling process in filamentous fungi. In this study the chitinase 
regulated autolysis process was proposed to be involved in the eDNA release in 
A. fumigatus. 
 
 
eDNA 
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Analysis of microarray data from different phases of A. fumigatus biofilm 
development published by Mowat E in her thesis revealed an up-regulation of 
class 3 chitinases (Chit A-E) (Mowat, 2008). Targeted real-time qPCR analysis of 
the five specific chitinases described by Alcazar-Fuoli and colleagues also 
showed a growth phase dependent upregulation of each chitinase (Alcazar-Fuoli 
et al., 2011). Using the same quintuple chitinase disruption mutant described in 
this paper it was tested whether its biofilm phenotype was defective. It was 
shown to have a significantly reduced biomass and showed a reduction of eDNA 
release (Figure 4.3-4.4). This study, and others, have demonstrated that this 
mutant has a similar growth rate to the wild type (Alcazar-Fuoli et al., 2011). 
These data indicate that an autolytic event within the complex biofilm is the 
most plausible explanation for the release of eDNA within the ECM.  
It was suspected from our data that class III chitinases play a role in this process 
during cell wall remodeling. However, there are 18 members of the chitinase 
family, which are distributed in two subclasses of fungal/plant (class III) and 
fungal/bacterial (class V) families.  This functional redundancy creates difficulty 
in specifically relating chitinase activity to eDNA release. However, when 
chitinase activity was inhibited biochemically then eDNA release was 
significantly affected. Functional and gene-expression studies in A. nidulans 
recently demonstrated that the β-1,3-endoglucanase EngA is also involved in 
autolytic cell wall degradation resulting from carbon starvation (Szilagyi et al., 
2010). Therefore, autolysis appears to be due to the production of cell wall-
degrading enzymes, which are co-ordinately controlled in a complex manner. 
Within the biofilm there is a buildup of toxic secondary metabolites, and 
nutrients may be limited by diffusion through the ECM. This may provide the 
environmental stresses that induce the expression of these cell wall remodeling 
enzymes in order to liberate nutrients from the cellular community.  
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In a stressful environment fungal cells activate heat shock proteins 
(Hsp90).HSP90 is a key molecular chaperone in stress response stabilizing diverse 
regulators of cellular signalling in eukaryotes (Taipale et al., 2010, Pearl and 
Prodromou, 2006). Given the chitinase regulated autolysis pathway is associated 
with eDNA release and Hsp90 is involved in the antifungal resistance by 
regulating various cellular process. It was hypothesised that depletion of HSP90 
could affect the eDNA release as well. Results presented establish a potentially 
novel role for HSP90 in eDNA release and drug resistance of A. fumigatus 
biofilms. Treating the A. fumigatus biofilms with HSP90 inhibitor appears to 
increase matrix production (Figure 4.9) compared to untreated controls. Future 
studies will dissect the molecular mechanisms by which HSP90 regulates biofilm 
matrix production.  
Given the eDNA is a significant component of biofilm ECM and HSP90 
inhibition upregulates matrix production, a study was designed to assess eDNA 
release in the presence of a HSP90 inhibitor. From the previous chapter it was 
shown that A. fumigatus biofilms possess elevated eDNA content in ECM, which 
affects antifungals from reaching its intracellular target. The ~28% reduction in 
matrix eDNA was observed upon HSP90 depletion (Figure 4.10) likely contributes 
to reduced antifungal resistance. HSP90 could regulate eDNA levels by directly 
or indirectly affecting chitinase autolysis pathway. 
Given Hsp90regulatesdiverse signalling cascades, it could also affect 
biofilm drug resistance in a multitude of other ways, such as by regulating 
remodelling of the cell wall and cell membrane (Mukherjee et al., 2003, Nett et 
al., 2007), signalling cascades important for matrix production(Nett et al., 
2010b, Nobile et al., 2009), or the function of contact-dependent signalling 
molecules that initiate responses to surfaces (Kumamoto, 2005). Future studies 
will determine on a more global scale the impact of cellular state on HSP90 
client protein stability, and the complex circuitry by which HSP90 regulates 
biofilm drug resistance. The results of checkerboard assays showed that 
compromising HSP90 function dramatically improves the efficacy of antifungals. 
Pharmacological inhibition of HSP90 enhances the efficacy of both azoles and 
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echinocandins against A. fumigatus biofilms (Figure 4.10-4.11). The synergy 
between HSP90 inhibitors and echinocandins is more pronounced than that with 
azoles, consistent with findings in the planktonic cellular state (Cowen et al., 
2009). The results suggest that HSP90 is a novel regulator of matrix eDNA levels. 
For A. fumigatus the reduction in matrix eDNA levels upon HSP90 depletion 
provides a mechanism by which HSP90 might govern biofilm echinocandin 
resistance. Thus, inhibition of HSP90 enhances the efficacy of antifungals against 
biofilms formed by the fungal pathogen of humans separated by ~1 billion years 
of evolution, suggesting that this combinatorial therapeutic strategy could have 
a broad spectrum of activity against diverse fungal pathogens. 
To summarise, the expression of chitinase activity in A. fumigatus was shown to 
be associated with eDNA release. This study demonstrates the inhibition of 
chitinase activity and HSP90 decreases the eDNA release, which impactsupon 
antifungal resistance. These observations may allow us to improve the treatment 
of different forms of aspergillosis using agents, such as azetazolamide (chitinase 
inhibitor) and geldanamycin (HSP90 inhibitor) allowing disaggregation of 
filamentous masses and improving penetration and efficacy of existing antifungal 
agents.  
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5.1 Introduction 
Aspergillus fumigatus is the most frequent cause of invasive fungal infection in 
immuno compromised patients. Although a variety of factors are thought to 
contribute to the emergence of fungal infections, including a number of 
environmental or ecological changes, genetic changes resulting in pathogen 
evolution are crucial (Morens et al. 2004). The adaptation of fungal cells to the 
host environment is one of the important factors associated with their evolution 
(Scheffer 1991).  
Adaptation by biofilm cells to azole antifungal treatment was investigated using 
a diffusion chamber mouse model, as outlined in chapter 2. However, this is 
problematic as the use of animal models are expensive, labour intensive, time 
consuming and are not without ethical concern. Therefore, this study aimed to 
develop an alternative in vivo model for studying A. fumigatus infection. 
Invertebrate insects, such as Drosophila melanogaster, Manduca sexta, Bombyx 
mori and Galleria mellonella, respond to microbial infection in a similar way to 
vertebrate animals (Cahill et al., 1997, Duchini et al., 2002, Patterson, 1999, 
Singh et al., 2003, Libanore et al., 2002). These therefore represent potential 
alternative models, thereby reducing the need for mammalian testing. 
Larvae of the wax moth G. mellonellais an ideal model pathogen-host system, 
due to its ease of purchase, maintenance, inoculation and ability to generate 
ethical data more quickly. It has been used previously as an effective infection 
model for the study of different bacteria, such as Pseudomonas aeruginosa and 
the Burkholderia cepacia complex (Sambatakou et al., 2006b, Carvalho et al., 
2008), and in fungal infections, including C. albicans and Aspergillus species 
(Mastella et al., 2000, Montoya et al., 2003, Singh and Husain, 2003).  
The innate host immune response from G. mellonella against microbial 
infections has similarities similar to mammalian immune responses, with 
hemocytes present within the hemolymph of larvae functioning in a similar way 
as neutrophils (Perfect et al., 2001). Although G. mellonella do not exhibit any 
adaptive immune responses, they do show powerful resistance against invading 
pathogens (Vermes et al., 2000). Monitoring some of the humoral immune 
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responses from the insect, such as melanisation and production of antimicrobial 
peptides, are good indicators of virulence and pathogenesis.  
Previous studies showed the use of G. mellonella infection model for antifungal 
efficacy testing (Kunst et al., 2006, Addrizzo-Harris et al., 1997, Akbari et al., 
2005). Though, they have never been used as a model to study the adaptive 
resistance mechanisms in A. fumigatus, such as those described in the preceding 
chapters. Whist in vitro modelling has been useful in the context of A. fumigatus 
biofilms investigations; in vivo models provide a more representative insight into 
these events. Therefore, investigating the correlation between in vitro 
expression profiles and in vivo expression profiles in G. mellonella will help 
determine whether this model is useful for the study of adaptive resistance 
mechanisms. 
The aim of this chapter therefore was to develop an invertebrate G. mellonella 
infection model for A. fumigatus and to use this model for transcriptional 
analysis of different resistance genes in response to antifungal challenge, and to 
ascertain whether this model accurately represents clinical biofilm infection. 
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5.2 Materials and methods 
5.2.1 Strains and conidial preparation 
A. fumigatus Af293 and a transformant expressing green fluorescent protein (Af-
GFP) was used for this study, as described previously (Wasylnka and Moore, 
2002). All the isolates were stored as previously described in section 2.2.1. All A. 
fumigatus strains were grown on Sabouraud dextrose agar at 37oC for 72 h. 
Conidia were then harvested as described in section 2.2.2. Conidia were then 
counted on a Neubauer haemocytometer and adjusted to a standardised 
suspension in PBS. All procedures were carried out in a class 2 biological safety 
cabinet (MDH Intermed). 
5.2.2 Galleria mellonella 
The Galleria wax worms were ordered from Livefoodsdirect.co.uk (Figure 5.1 a). 
The larvae (2cm in length and weigh 0.2-0.3mg) were supplied in a plastic box 
and stored in refrigerator until use.  
5.2.3 G. mellonella infection 
To optimise the inoculum concentration for subsequent survival assays, larvae 
were inoculated with standardised Af293 conidia dorsolaterally by injecting 10µl 
aliquots of the serial dilutions (104 – 107 conida/larvae) into the haemocoel, 
through the last pro-leg using a Hamilton syringe (Figure 5.1 b-e). Ten larvae 
were injected per dilution, and at least four different serial dilutions were 
inoculated. Larvae were incubated in petri dishes at 37°C (Figure 5.1 f), and the 
number of dead larvae was scored 1 to 10 days after infection. A larva was 
considered dead when it displayed no movement in response to touch and was 
melanised.  
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Figure 5.1 – Galleria mellonella infection. a) G. mellonella larvae stock in wood 
shavings, b) Hamilton syringe, c-d) pictures showing the proleg region of larva, e) 
inoculation of larva using Hamilton syringe at proleg region, f) inoculated larvae in 
petri dish ready for incubation, g) section of post infected larva. 
 
a) 
c) 
b) 
d) e) 
f) g) 
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5.2.3.1 Quality control 
For each experiment a negative and positive control set were included to ensure 
that neither the injection procedure nor the drugs was responsible for any 
mortality observed. 
Negative control set consists of:  
(i) Group of 10-20 uninfected, unmanipulated larvae 
(ii) Group of 10-20 larvae pierced into the last pro-leg with the Hamilton 
syringe 
(iii) Group of 10-20 larvae injected with 10l of PBS into the last pro-leg 
A positive control set consists of: 
(i) Group of 10-20 infected only, untreated larvae 
(ii) Group of 10-20 larvae injected with only drug, at identical time points to 
test larvae. 
5.2.3.2 Phase dependant killing of G. mellonella 
The virulence of different phases of A. fumigatus multicellular development was 
assessed using a G. mellonella survival assay. A. fumigatus (103 conidia/ml) was 
grown up to 0, 8, 12 and 24 h in RPMI which provided conidia, germlings, initial 
hyphae and matured hyphae. Then 10µl of each inoculum was injected into 
larvae as described above. The infected larvae were incubated at 37oC and the 
survival was recorded over the period of 7 days. 
5.2.4 Tissue sectioning 
Larvae sectioning was performed to observe fungal cell morphology post-
infection. In brief, larvae were infected with AfGFP conidia (106 conidia/larvae) 
as described above. The infected larvae were fixed with formalin and snap-
frozen with liquid nitrogen. Crude thin sections of the frozen tissue was then 
made by using a surgical scalpel blade, and placed on glass slides for microscopic 
imaging (Figure 5.1 g). 
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5.2.5 Effect of antifungal agents on G. mellonella survival 
An optimised G. mellonella killing assay was used to test the efficacy of 
different antifungal agents against A. fumigatus infection. Larvae were infected 
with 106 conidia/larvaeas described above. After 8 h or 24 h of post infection 
larvae were treated with voriconazole at a concentration of 6 mg/kg. Survival 
was recorded over the period of seven days and larvae samples were collected 
for molecular analysis. 
5.2.6 Nucleic acid extraction 
Total nucleic acid and RNA was extracted from experimental larvae for assessing 
the fungal burden and gene expression studies. Larvae were snap-frozen using 
liquid nitrogenat each defined time point.  These were ground up using a mortar 
and pestle, and then collected in a 2ml screw cap tube. Total nucleic acid was 
then extracted using BioRobot® EZ1 (Qiagen), as per manufacture’s instruction. 
For RNA extraction, ground samples were transferred into 2mL screw cap tubes 
(Stratech) with 1mL of Trizol®. The cells were then mechanically disrupted using 
200µL (0.5mm diameter) of silicon glass beads with a mini Bead Beater™ (Biospec 
Products). The RNA was then extracted as described in section 2.2.9. RNA 
concentration was then assessed using a NanoDrop™ spectrophotometer ND-1000 
and stored at -80oC until needed for cDNA synthesis. 
5.2.7 Real time PCR analysis 
At first, cDNA was synthesised from RNA with high capacity RNA to cDNA master 
mix (Applied Biosystems) using a MyCycler PCR machine (Bio-Rad) and stored at -
20oC for expression analysis as described in chapter 2.  
5.2.7.1 Expression of gallerimycin 
The expression of a gallerimycin was assessed as a biomarker of A. fumigatus 
infection in G. mellonella. The primer sequences for gallerimycin are show in 
Table 5.1. The PCR cycling conditions for these primers are as follow: 94°C 
denaturation for 5 min, 35 cycles of 94°C denaturation for 60 s, 55°C for 90 s, 
68°C extension for 90 s and final extension at 68°C for 10 min.  
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The amplified PCR products were then visualised by electrophoresis through a 1% 
(w/v) agarose gel (Invitrogen), prepared with 1  Tris acetate buffer (Fisher 
Scientific). The agarose solution was heated in a microwave oven until it was 
molten, cooled to a safe handling temperature and 1.5µl of ethidium bromide 
(10mg/ml) added and mixed. This was then poured into a casting tray and 
allowed to solidify at room temperature. The PCR products were mixed with 
appropriate loading dye (approximately 5µl) on a Parafilm® sheet and 10µl of 
each sample loaded into the wells. An aliquot (5µl) of 100bp DNA hyperladder 
(Bioline, London, UK) was loaded into a separate well to estimate the PCR 
product size. The tank was connected to the electric source and run at 50V for 
50min. The gel was observed under the UV light excitation and the image 
digitally photographed (Bio-Rad Gel Doc 2000, Bio-Rad Life Sciences). 
5.2.7.2 Colony forming equivalents 
The colony forming equivalents (CFE) of A. fumigatus (CFE/100mg) were 
determined using an 18S rRNA real-time PCR as described previously (McCulloch 
et al., 2012). The primers and probe sequences targeting 18S rRNA are shown in 
Table 5.1. The PCR cycling conditions for this primers were as follows: initial 
denaturation at 95°C for 10 min, followed by 45 cycles of 95°C for 30 s, 55°C for 
30 s, and 72°C for 30 s. All PCR reactions were carried out in a total volume of 
25µL. The standard total nucleic acid extracted from serially titrated A. 
fumigatus conidia was run in conjunction with each set of samples to quantify 
the Aspergillus burden. 
5.2.7.3 Gene expression study 
Expression of selected resistance genes was assessed using quantitative RT-PCR 
using SYBR® GreenER™ (Invitrogen). Three independent samples from each time 
point for control and voriconazole treatment (6 mg/kg) groups were analysed in 
duplicate using MxProP Quantitative PCR machine and MxProP 3000 software 
(Stratagene). The primer details and PCR cycling conditions for MDR1-4 and 
ChitA-E genes were described in previous chapters (drug efflux – Chapter 2, 
chitinase – Chapter 4). The primer sequences for all other genes are shown in 
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Table 5.1.  The PCR conditions for these primers were as follows 5 min at 95oC 
(initial denature), 30s at 95oC (denaturation), 30s at 50-65oC (annealing), 30s at 
72oC (extension) for 40 cycles, followed by a final extension at 72oC for 10 min. 
All PCR reactions were carried out in a total volume of 25µL. All the gene 
expression levels were normalised to TEF1 housekeeping gene according to the 2-
ΔΔCT method (Livak and Schmittgen, 2001). 
Table 5.1 – List of oligonucleotide primers used for real time PCR analysis. 
Genes  Primers 
Gallerimycin  
 
F 5′-GAAGATCGCTTTCATAGTCGC-3′ 
R 5′-TACTCCTGCAGTTAGCAATGC-3′ 
β actin 
F 5′-GGGACGATATGGAGAAGATCTG-3′ 
R 5′-CACGCTCTGTGAGGATCTTC-3′ 
18s rRNA  
 
F 5′-GCCGCGGTAATTCCAGCTCCAATA-3′ 
R 5′-GAGCAAAGGCCTGCTTTGAACA-3′ 
P 5′-CGCACGGGTCCGCCTCACCGCGAGTACTGCGTGCG-3′ 
Fks1  
F 5′-GCTGCGCCCAAGTCGCCAAATC-3′ 
R 5′-GAACAACAAGTGGGGCAATG-3′ 
HSP90  
F 5′-TGACCAAGGCTGATTTGATC-3′ 
R 5′-CAACAAGGTAAGCAGAGTAG-3′ 
Tef1  
F 5′-CCATGTGTGTCGAGTCCTTC-3′ 
R 5′-GAACGTACAGCAACAGTCTGG-3′ 
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5.2.8 Statistical analysis 
Proportional data (fold change) were transformed to natural logarithm values 
before statistical tests were undertaken. Analysis of variance (ANOVA) and post 
hoc Bonferroni test was used to investigate independent sample data across a 
number of groups.  Alternately when only two groups were under comparison a 
Student t-test was utilized. The Log-rank (Mantel-Cox) test was used to analyse 
the G. mellonella survival curves. SPSS (Version 11) was used for these analysis 
and GraphPad Prism (Version 4) for the production of the figures.  
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5.3 Results 
5.3.1 G. mellonella infection 
5.3.1.1 Melanisation 
Melanisation immune response in G. mellonella was used to monitor the 
pathogenicity of A. fumigatus (Figure 5.2a). With high inoculum concentrations 
(106 or 107 conidia/larvae) melanisation was observed near the proleg region on 
the same day of infection (Figure 5.2b). When the infection progressed over time 
a gradual increase in melanisation was observed (Figure 5.2c), and full 
melanisation observed between day 1 to 3 (Figure 5.2d). The full melanisation 
indicates the death of larvae which was confirmed by lack of movement of 
larvae in response to touch. 
 
 
 
 
 
 
 
Figure 5.2 – Melanisation in G. mellonellalarvae. G. mellonella larvae were 
inoculated with 106 conidia/larvae and incubated for 1-3 days at 37oC. 
Melanisation in larvae were visually monitored everyday and imaged using digital 
camera. Images in this figure shows (a) Uninfected larva with nomelanisation, 
(b) larva infected with 106 conidia showing melanisation near proleg region 
(circled) on same day post-infection, (c) increased melanisation (circled) on day 
1 post-infection with 106 conidia, (d) dead larva displaying full melanisation on 
day 2 post-infection. 
 
a) 
b) 
c) d) 
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5.3.1.2 Filamentation 
A. fumigatus conidia inoculated into the hemocoel are retained by the fat body 
and other internal structures. In order to analyse the A. fumigatus growth in G. 
mellonella model tissue sections of infected larvae were observed by light 
microscopy. The site of inoculation (proleg region) of uninfected vehicle control 
larvae (Figure 5.3a) and infected larvae (with 106 conidia of AfGFP strain) were 
observed 8 h post infection. The 8 h micrograph demonstrated no visual signs of 
infection or melanisation with PBS controls, and in infected larvae the initial 
spread of infection with little melanisation was observed (Figure 5.3b). The 
tissue sections of 24 h post-infected larvae were also imaged, which displayed 
filamentous growth of A. fumigatus in association with G. mellonella internal 
structures (Figure 5.3c). 
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Figure 5.3 - Filamentous growth of A. fumigatus in a G. mellonella infection 
model. G. mellonella larvae were inoculated with 106 conidia/larvae and 
incubated for 24 h at 37oC. Proleg region and larvae sections were imaged after 
8 h and 24 h post infection respectively under fluorescence microscope. Images 
in this figure are the representative  4X magnification micrographs from each 
group showing proleg region of (a) uninfected larva, (b) infected larva and (c) a 
tissue section showing filamentous growth (indicated by white circle) of A. 
fumigatus with G. mellonella internal structures (20x Magnification). 
 
 
 
a) 
b) 
c) 
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5.3.1.3 Fungal burdens - colony equivalents 
An 18S rRNA real-time PCR analysis was performed with nucleic acid extracted 
from 101-106 conidia to standardise the assay. A linearity of qPCR assay is shown 
in Figure 5.4a. The R2 value of 0.99 indicates a good linearity between Ct value 
and conidial count. The bar graph in Figure 5.4b illustrates the tissue burden in 
G. mellonella over a period of infectivity.  CFE data was calculated using the 
standard curve equation. Overall, the trend of the graph shows an increase in 
tissue burden over the period of infection progress. The CFE value of 4.2 from 
100mg of 4 h post infected larvae sample significantly increased to 5.3 with 48 h 
post infected sample (p<0.05, ANOVA, Bonferroni post test formultiple 
comparisons). 
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Figure 5.4 – Assessment of fungal burden by 18s rRNA real time PCR analysis. 
Total nucleic acid was extracted from serially diluted A. fumigatus conidia (101 – 
106 conidia/mL) for assay standardisation and from 4, 8, 24 and 48 h post 
infected larvae for assessing the colony forming equivalents (CFE). The 18S rRNA 
real time PCR analysis was performed and (a) standard graph was plotted using 
the Ct values (y-axis) and no of spores (x-axis). (b) The bar graph in the figure 
shows the fungal burden in G. mellonella over the period of infection progress. 
The error bar in the graph indicates the standard deviation in CFE data among 
the replicates. *p< 0.05, ANOVA with a Bonferroni post test for multiple 
comparisons. 
a) 
b) 
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5.3.1.4 Expression of gallerimycin 
The expression of the gallerimycin gene in G. mellonella larvae was investigated 
as an indicator of A. fumigatus infection. RNA extracts from G. mellonella tissue 
samples were reverse transcribed and gallerimycin gene was amplified by PCR 
process. Gel electrograph in Figure 5.5ashows the expression of gallerimycin 
(300bp) in uninfected controls (Figure 5.5a-Box 2) and infected larvae (Figure 
5.5a-Box 3). Real-time PCR analysis showed the expression of the gallerimycin 
gene was significantly increased from 1.4% in uninfected controls to 16% in A. 
fumigatus infected larvae (Figure 5.5b) (* p< 0.05).  
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Figure 5.5 – A. fumigatus infection induces the expression of gallerimycin. 
RNA extracted from control and infected larvae were used as the template for 
cDNA synthesis and subsequent PCR reactions products were visualised. a) gel 
image showing a bright band with infected larvae samples (box 3, lane 5-7), 
bands of uninfected controls (box 2, lane 2-4) and a DNA ladder (box 1, lane 1), 
b) bar graph showing the % expression of gallerimycin in uninfected and infected 
larvae compared to a house keeping gene β-actin. *p< 0.05, ANOVA, Bonferroni 
post test for multiple comparisons. 
 
a) b) 
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5.4 A. fumigatus kills G. mellonella in a dose dependant manner 
The susceptibility of G. mellonella to different inoculum concentrations was 
assessed by injecting 107, 106, 105 and 104 conidia/larva, and mortality recorded 
up to 10 days post-infection. Injection of a higher inoculum of 107 conidia/larva 
resulted in 100% lethality within 1 to 2 days, with 106/larva causing a delay in 
killing (2-3 days), but still with a 90-100% lethality recorded in all individual 
experiments (Figure 5.6). Doses below 106 conidia/larva caused further delay in 
killing (> 5 days) and reduced lethality (p<0.0001, Log-rank (Mantel-Cox) test). 
No deaths were recorded when larvae were injected with vehicle alone. Thus, 
for subsequent experimental assays 1x106 to 1x107 conidia/larva were used as 
the inoculating dose to study antifungal drug treatment. This dose dependence 
was statistically significant and is shown for A. fumigatus Af293 in figure 5.6. 
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Figure 5.6 – Dose dependant G. mellonella survival. G. mellonella larvae were 
infected with serially ten-fold diluted A. fumigatus conidia (104-107 conidia/ 
larva) and the survival was monitored over the period of 10 days. The survival 
curve in the figure shows the percentage survival of larvae with respect to 
different inoculum concentrations (0, 104, 105, 106 and 107). The survival curves 
of different inoculum dosages are significantly different p<0.0001, Log-rank 
(Mantel- cox) test. 
 
Chapter 5: Developing an in vivo model to evaluate adaptive biofilm resistance 
206 
 
5.4.1 A. fumigatus growth phase dependant killing of G. mellonella 
To assess the effect of A. fumigatus multicellular growth on G. mellonella 
survival, larvae were infected with conidia (0 h), germlings (8 h), initial hyphae 
(12 h) and matured hyphae (24 h), which coincides with selected time points in 
previous chapters. The survival curve in Figure-5.7 illustrates the percentage 
and days survival of larvae infected with different phases of A. fumigatus 
growth. This data shows a growth phase dependant killing of larvae. Injection of 
matured hyphae killed the larvae quicker in less than 2 days (p<0.0001). With 
germlings and initial hyphae the survival was 6 and 4 days receptively. It is 
significantly lower than the resting conidia controls (P<0.0001).  
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Figure 5.7 – Survival of G. mellonella with different phases of A. fumigatus 
growth. G. mellonella larvae were infected with resting conidia (0 h), germlings 
(8 h), initial hyphae (12 h) and matured hyphae (24 h) and incubated at 37oC. 
The survival was recorded over the period of 5 days. The survival curve in this 
figure shows the percentage survival of larvae over 5 day period. The survival 
curves with inoculation of different phases of A. fumigatus growth are 
significantly different to each other p<0.0001, Log-rank (Mantel-Cox) test. 
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5.4.2 Azole treatment prolongs the survival of infected G. mellonella 
To assess whether G. mellonella can be used as an infection model to test the 
efficacy of azoles against A. fumigatus infection, larvae were infected with 106 
or 107 conidia/larva and infected larvae were treated with voriconazole (6 
mg/kg). Treated larvae 8 h post-infection significantly increased the time of 
survival of larvae (Figure 5.8a), (p<0.0001, Log-rank [Mantel-Cox] test) 
compared with the untreated controls. Treatment with voriconazole 24 h post-
infection resulted in reduced length of survival compared to treatment at 8 h 
post infection. Injection with voriconazole (6 mg/kg) alone was not toxic and 
had no effect on the survival of larvae. 
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Figure 5.8 – Voriconazole prolongs the survival of A. fumigatus infected 
larvae. G. mellonella larvae were infected with 106 or 107 conidia/larva. After 8 
h or 24 h post infection the larvae were treated with voriconazole at a 
concentration of 6mg/kg. Survival of larvae was recorded over the period of 10 
days. (a) Survival curves of untreated infected controls (106, 107 conidia/larvae), 
voriconazole treated (VRZ [6 mg/kg]) larvae and uninfected controls, (b) survival 
curves of untreated infected controls (106 conidia/larvae), voriconazole 
treatment after 8 h post infection (8 h-VRZ [6 mg/kg]), voriconazole treatment 
after 24 post infection ( 24 h–VRZ [6 mg/kg]). The survival curves of untreated 
controls were compared with voriconazole treated larvae using Log-rank 
(Mantel-Cox) test and they are significantly different from each other 
(p<0.0001).
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5.4.3 The expression profile of antifungal resistance genes 
The in vivo expression of selected antifungal resistance genes was assessed in 
the G. mellonella infection model. The expression over the period of Day 1, 2 
and 3 post-infection was assessed by real time PCR analysis. All the gene 
expression levels were normalised to TEF1 housekeeping gene using the 2-ΔΔCt 
methodology previously described (Livak and Schmittgen, 2001). Table 5.2 shows 
the percentage expression of each gene on day 1-3 ± standard deviation. Out of 
four efflux genes tested AfuMDR2 was highly expressed at a level of 39% on day 
2, 51% on day 3 and 33% on day 4 , whereas AfuMDR3 was expressed in relatively 
lower levels of 0.02% on day 2, 0.03% on day3 and 0.36% on day 4. The AfuMDR1 
and AfuMDR4 genes showed a pattern of up-regulation over different phases of 
biofilm formation (Table 5.2 a).  
The qRT-PCR results for ChitA and C show a gradual increase in gene expression 
over the period of time (D1<D2<D3 and D1< D2-3) (Table 5.2 c).CHITA gene 
expressed at a level of around 2% on day 2, 3.5% of day 3 and 13.8% on day 4. 
CHITC was expressed at 4.6, 8.6 and 9.5% on day 2, 3 and 4 respectively. But the 
expression of other chitinase genes ChitB and D were undetectable on day 2 and 
3. The expression level of ChitE shows no significant difference over time (Table 
5.5 c). The expression of β-glucan synthase gene FKS1 and stress response 
protein HSP90 gene were found to be the same at all three time points and no 
significant difference was found (Table 5.2b). 
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Table 5.2 – Expression profile of A. fumigatus resistance genes in G. 
mellonella infection model. The numerical values indicate the percentage 
expression compared to Tef1 housekeeping gene ± standard deviation. 
a) Efflux pump genes 
 MDR1 MDR2 MDR3 MDR4 
Day2 0.47±0.12 38.61±6.76 0.02±0.01 13.09±1.34 
Day3 0.77±0.53 51.34±11.44 0.03±0.01 28.86±2.59 
Day4 1.65±0.46 33.22±7.74 0.36+0.59 27.18±6.83 
 
b) β – glucan synthase and heat shock protein genes 
 FKS1 HSP90 
Day2 32.42±4.74 3.75±1.21 
Day3 43.13±31.72 1.09±0.10 
Day4 45.35±22.00 3.29±1.05 
 
c) Chitinase genes 
 ChitA ChitB ChitC ChitD ChitE 
Day2 2.31±1.00 0.06±0.03 4.59±4.94 0.00±0.00 0.07±0.02 
Day3 3.47±1.44 0.00±0.00 8.64±3.58 0.00±0.00 0.16±0.06 
Day4 13.79±2.95 0.88±1.44 9.47±4.41 0.02±0.03 0.30±0.11 
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5.4.4 Azole treatment affects the expression of antifungal resistance 
genes 
The in vivo expression of each gene was also assessed with voriconazole 
treatment. The expression over the period of Day 2, 3 and 4 post-treatment was 
assessed by real time PCR analysis. The results were analysed by calculating fold 
change in expression compared to untreated controls for each time point.  
5.4.4.1 Efflux genes 
With voriconazole treatment, expression of AfuMDR4 was shown to be 
significantly up-regulated according to ANOVA after day 2 post treatment (Figure 
5.9d). A significant up-regulation was observed at day 2 and 3 compared to 
untreated controls (p<0.05 and p<0.001, respectively). AfuMDR2 showed a 
significant up regulation on day 3 and no significanct differences on day 1 and 2 
(Figure 5.9b). The expression levels of AfuMDR1 and 3 were lower in all three 
time points compared to other efflux genes and were not significantly different 
from untreated controls (Figure 5.9a, c). 
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Figure 5.9 – Effect of voriconazole on expression of A. fumigatus efflux genes 
in G. mellonella infection model. Following RNA processing from larvae 
samples, quantitative RT-PCR was performed on each cDNA population using 
TEF1 as a housekeeping gene to calculate the relative expression of AfuMDR 
genes (a)MDR1, (b) MDR2, (c) MDR2, (d) MDR4 according to the 2-ΔΔCT method. 
Three untreated larvae from each time point were used as a control for 
comparison to 6 mg/kg voriconazole treatment (n=3 at D1, D2 and D3). The error 
bars represent the standard deviation of the means. *p<0.05, ***p<0.001, two-
way ANOVA, Bonferroni post-test. 
 
a) b) 
c) d) 
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5.4.4.2 Fks1 gene 
The percentage expression of glucan synthase gene FKS1 was also calculated by 
comparing with Tef1 housekeeping gene. Figure 5.10 details the percentage 
expression of FKS1 gene in untreated and voriconazole treated larvae samples at 
day2, day 3 and day 4 of post treatment. It shows that the level of expression is 
not significantly different over time or with voriconazole treatment. 
 
 
Figure 5.10 – Expression of A. fumigatus FKS1 gene in G. mellonella infection 
model. Following RNA processing from larvae samples, quantitative RT-PCR was 
performed on each cDNA population using Tef1 as a housekeeping gene to 
calculate the relative expression of FKS1gene according to the 2-ΔΔCT method. 
Three untreated larvae from each time point were used as a control for 
comparison to 6 mg/kg VRZ treatment (n=3 at D1, D2 and D3). The error bars 
represent the standard deviation of the means. 
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5.4.4.3 Chitinase genes 
The relative changes in expression for each of the selected 5 chitinase genes 
with and without antifungal treatment are shown in Figure 5.11. The RT-PCR 
results for ChitA and C show a gradual increase in gene expression over the 
period of time (D1<D2<D3 and D1< D2-3) and further upregulation with VRZ 
treatment (* p<0.05, ** p<0.01, *** p<0.001). A significant up regulation with VRZ 
treatment was reported with ChitB expression on day 3 and ChitD on day 4 
compared to untreated controls. The expression level of ChitE was also assessed 
and no significant difference over time or with VRZ treatment was noticed. 
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Figure 5.11 – Voriconazole treatment affects the expression of chitinase 
genes. Following RNA processing from larvae samples, quantitative RT-PCR was 
performed on each cDNA population using TEF1 as a housekeeping gene to 
calculate the relative expression of Chitinase genes (a) ChitA, (b) ChitB, (c) 
ChitC, (d) ChitD and (e) ChitE according to the 2-ΔΔCT method. Three untreated 
larvae from each time point were used as a control for comparison to 6 mg/kg 
VRZ treatment (n=3 at D1, D2 and D3). The error bars represent the standard 
deviation of the means. *p<0.05, **p<0.01, ***p<0.001, two-way ANOVA, 
Bonferroni post-test. 
 
a) b) 
c) 
d) 
e) 
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5.4.4.4 HSP90 gene 
The expression of stress related molecular chaperone HSP90 gene was assessed 
with untreated and VRZ treated larvae samples over three days of post 
treatment. The graph shows the percentage expression of HSP90 in relation to 
Tef1 housekeeping gene. The expression was not significantly different over the 
period of time with untreated controls but up-regulation was noticed with 
voriconazole treatment group. On day 3 and day 4 post treatment group the 
expression was significantly up regulated compared to untreated controls 
(p<0.001). 
 
 
Figure 5.12 – Azole treatment up regulates the expression of HSP90 gene. 
Following RNA processing from larvae samples, quantitative RT-PCR was 
performed on each cDNA population using Tef1 as a housekeeping gene to 
calculate the relative expression of HSP90 gene according to the 2-ΔΔCT method. 
Three untreated larvae from each time point were used as a control for 
comparison to 6 mg/kg VRZ treatment (n=3 at D1, D2 and D3). The error bars 
represent the standard deviation of the means. ***p<0.001.Two-way ANOVA, 
Bonferroni post-test. 
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5.5 Discussion 
Infection models are essential tools for studying fungal pathogenesis. Mammalian 
models such as mice or rats are considered the ‘gold standard’ for studying in 
vivo infections caused by pathogenic fungus such as A. fumigatus, but are 
associated with animal welfare and bioethical issues. Due to these and 
regulatory issues, it is now more challenging to perform LD50 experiments with 
mice. In addition, insect models such as D. melanogaster and C. elegans are 
somewhat more difficult to work with, and A. fumigatus in these models does 
not appear to give consistent results. Therefore, this study aimed to investigate 
A. fumigatus infection and adaptive resistance in a G. mellonella model. The 
data reported from these studies was comparable with other in vitro and in vivo 
infection models.  
Data from this study show that G. mellonella is a sensitive and consistent 
infection model for A. fumigatus and possessed several advantages over other 
mammalian infection models. The progression of A. fumigatus infection in the G. 
mellonella model is comparatively easy to monitor. Infecting G. mellonella 
larvae with fungal cells induces innate immune responses such as melanisation 
and production of antifungal peptides (Singh, 2000, Askew, 2008). However, 
these responses were not sufficient to achieve insect protection from infection. 
It can therefore be used as an indicator, or biomarker, of A. fumigatus virulence 
(Askew, 2008). Gradual increase of melanisation over time indicates the progress 
of disease and host pathogen interaction. Increased expression of gallerimycin, 
an antifungal peptide, in infected larvae is another indicator of infection. The 
fungal burden assessed by 18S rRNA real time PCR shows an increase in colony 
forming equivalents (CE) in a time dependent manner, which confirms the 
infection progress in this model. This result is similar to the pattern of increase 
in fungal burden over time published previously with a rat inhalation model 
(Gibbons et al., 2011). 
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The results from this chapter demonstrate that G. mellonella is susceptible to A. 
fumigatus infection in a dose-dependent manner. This correlates with data 
observed with other fungal pathogens, such as C. albicans and C. neoformans 
(Walsh et al., 2008, Cornet et al., 2002). In this study, it was shown that the 
dose of 1 x 106 conidia/larva is suitable for virulence studies of A. 
fumigatus strains Af293. This inoculum is in line with the inoculum used for 
studying other pathogenic yeasts (Stevens et al., 2003, Walsh et al., 2008). The 
treatment of infected larvae with antifungal drugs such as azoles prolongs the 
survival of G. mellonella larvae. Consequently, the results of this chapter 
confirm previous findings indicating that this model can be used as an in vivo 
system to evaluate toxicity and efficacy of new antimicrobial agents (Grow et 
al., 2002, Cornet et al., 2002, Kunst et al., 2006, Marr et al., 2002) 
There are several studies that have investigated morphological and multicellular 
development of fungi in relation with their pathogenicity (Mowat et al., 2008a, 
Chatzimichalis et al., 1998, Greenberg et al., 2002). The results from this study 
show A. fumigatus proliferates gradually at the site of inoculation, forming 
multicellular hyphae and invading the tissue. These findings resemble 
histological findings for human patients (Greenberger, 2002, Ricketti et al., 
1984) and experimentally infected mice (Lai et al., 2002, Saxena et al., 2003). In 
addition, G. mellonella killing assay testing the virulence of different phases of 
A. fumigatus proliferation demonstrate multicellular hyphal cells are more 
lethal compared to germlings and resting conidia.  A study by Mesa-Arango et al 
(2012) demonstrated that haemocytes of G. mellonella are capable of 
phagocytosing A. fumigatus conidia less than 3.0 µm in diameter, but that 
multicellular hyphae are greater than this and are too large to be 
engulfed(Geller et al., 1999). The data from this study showed 8 h post-infection 
larvae are easier to treat compared to 24 h hyphal infection. This result agrees 
with the previously published in vitro data showing A. fumigatus growth phase 
dependant susceptibility to antifungal drugs (Mowat et al., 2008a).  
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To investigate the phase dependant antifungal resistance previous studies 
assessed the differential expression of various A. fumigatus genes over the 
period of multicellular development in both in vitro and in vivo models. 
Transcriptional profiling of various genes associated with biofilm adaptive 
resistance, including AfuMDR1-4 and ChitA-E, were performed using in vitro 
biofilm model in previous chapters. To further investigate the expression of 
other resistance genes in an in vivo model, samples were collected from 
infected larvae at different time points and real time PCR undertaken. Up-
regulation of AfuMDR1 and 4 gene expression was observed in a time dependant 
manner. Comparing this data with the azole treated group demonstrated that 
AfuMDR4 expression was up regulated. This is similar to the in vitro and in vivo 
data presented in chapter 2. Ferreira and colleagues (2004) also observed azole-
constitutive and induced efflux pump expression in A. fumigatus following 
treatment with itraconazole (da Silva Ferreira et al., 2004).Similarly, the 
expression of CaMDR1 expression in a catheter based C. albicans biofilm model 
has been reported, but at a lower constitutive level (Nett et al., 2009). 
Moreover, the same group assessed the expression of efflux genes CaMDR1, 
CaCDR1 and CaCDR2 in their in vivo murine model following fluconazole 
treatment. This study reported induction of CaCDR1 and CaCDR2 expression with 
fluconazole treatment, but no change in the expression of CaMDR1 (Lepak et al., 
2006). Out of four efflux genes assessed in this study AfuMDR2 was the one 
expressed in high level and AfuMDR3 was expressed in low level and no 
significant difference was found between different time points. These levels of 
expression are similar to the in vitro data published in chapter 2. 
The next resistance gene assessed with this model is FKS1 gene, encoding a 
subunit of the β-1, 3-D-glucan synthase enzyme. The mutation or over expression 
of this gene was reported to be involved in multidrug resistance in A. fumigatus 
(Skov et al., 2005, Zeaske et al., 1988). The β-1-3 glucan is one of the 
predominant constituents of biofilm matrix, which was shown to be elevated 
over the period of A. fumigatus maturation (Nett et al., 2007). In this study the 
expression of FKS1 gene was not significantly different over the period of time 
and with azole treatment a general trend of up regulation was found. However, 
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due to higher standard deviation in the expression level within the treatment 
group it was not statistically significant. A study by Nett et al (2009) assessed 
the time course expression of FKS1 gene in C. albicans using an in vivo venous 
catheter biofilm model and reported differential expression with 24 h compared 
to 12 h (Nett et al., 2009). No such notable time course expression studies were 
done with A. fumigatus for comparison.  
The expression of chitinase genes involved in the cell wall biosynthesis and 
autolysis pathway were also studied with this G. mellonella model. All tested 
class III chitinase genes ChitA-E were found to be up-regulated in a time 
dependant manner but the level of expression is quite variable among these 
genes. Azole treatment induces the expression chitinase genes especially ChitA 
and C. These expression patterns were somewhat similar to the in vitro data 
shown in Chapter 4 but they are not exactly same. The expression of ChitB and D 
on day 2 and 3 from this model were not in the detectable level but they were 
expressed in an in vitro model. A study by Alcazar-Fuoli also detected the 
expression of all of these genes in vitro in resting conidia, swollen conidia and 
germlings except for ChitC gene (Patterson et al., 2000). The difference in 
expression of these genes with this model may be because of interference of 
host immune response at early stage of A. fumigatus proliferation.  
Overall this study demonstrates that G. mellonella is a consistent model for 
studying A. fumigatus infections and antifungal efficacy testing. To study the 
virulence gene expression in A. fumigatus this model will give a better idea 
about the host dependant differential expression of genes. However due to lack 
of data from other mammalian models for correlation analysis further studies 
are needed to give conclusive statement about suitability of this model for 
molecular studies. 
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6.1 Introduction 
In recent decades, fungal pathogens have emerged as a predominant cause of 
human disease, especially in immuno-compromised individuals. Candida and 
Aspergillus species together account for ~70% of all invasive fungal infections, 
with C. albicans and A. fumigatus prevailing as the leading causal agents of 
opportunistic mycoses (Pfaller and Diekema, 2010). In patients with pulmonary 
disorders such as asthma or CF, A. fumigatus infection can cause ABPA leading 
to severe complications, but has also been recently described in the context of 
biofilms, or multicellular communities (Ramage et al., 2009b). For these fungal 
species, there are numerous factors that contribute to the pathogenicity and 
recalcitrance of resulting infections to antifungal treatment, including the 
ability to evolve and maintain resistance to conventional antifungal therapy 
(Cowen and Steinbach, 2008). 
Azoles are the most commonly used antifungal therapy and resistance to these 
has been increasingly observed in Candida and more recently Aspergillus. The 
fungistatic nature of the azoles towards fungal cells culminates in strong 
directional selection on the surviving population to evolve drug resistance 
(Anderson, 2005, Cowen, 2008). The mortality of patients with multi-azole 
resistant invasive aspergillosis was 88%, compared with 30-50% in those infected 
with azole sensitive strains (Howard et al., 2009). Time from diagnosis to 
resolution of the infection or death in invasive forms of fungal disease is 
typically a few weeks, whereas in allergic or chronic diseases patients may take 
antifungal medication for many years. In both cases drug resistance is highly 
problematic. In a recent survey of azole resistant A. fumigatus in a UK referral 
clinic a striking rise in drug resistance was observed (Howard et al., 2009, Bueid 
et al., 2010). Until 2008 all observed resistance was attributable to mutations in 
the cyp51A gene, however between 2008 and 2010 resistant isolates containing 
no mutations in this gene or promoter became more prevalent. In 2010, 51% of 
Manchester isolates that were resistant to azoles were non-cyp51A, indicating 
that other mechanisms of resistance were responsible (Bueid et al., 2010). 
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Antifungal resistance is both complex and multifaceted. It can be inducible in 
response to a compound, or an irreversible genetic change resulting from 
prolonged exposure. Specifically, these include alterations or overexpression of 
target molecules, active extrusion through efflux pumps, limited diffusion, 
tolerance, and cell density, which are all characterized mechanisms utilized by 
fungi to combat the effects of antifungal treatment (Niimi et al., 2010). 
Planktonic cells generally rely on irreversible genetic changes to maintain a 
resistant phenotype, but which comes with a cost to overall fitness (Huang and 
Kao, 2012, Ben-Ami and Kontoyiannis, 2012). Whereas, biofilms are able to 
persist due to their physical presence and the density of the microbial 
community, which provides an inducible or ‘responsive’ resistant phenotype, 
irrespective of defined genetic alterations. 
The overarching hypothesis of this study was that the multicellular biofilm 
phenotype provided A. fumigatus with the ability to respond to environment 
pressures without the need for any defined mutations. Therefore, the objectives 
were to investigate and identify adaptive resistance mechanisms associated with 
these multicellular forms. 
6.2 Adaptive resistance mechanisms in Aspergillus fumigatus 
C. albicans has been described to respond to antifungal drug pressures in an 
adaptive way (Walker et al., 2010). Recently, it has been demonstrated in a 
clinical isolate of C. albicans that in addition to a defined FKS1 hotspot 
mutation, chitin remodelling was also contributing to echinocandin resistance 
(Walker et al., 2010). This demonstrated that dual resistance mechanisms can 
and do occur clinically. The implications of these studies suggest that pathogenic 
fungi have the capacity to adapt to their environment, whether in a human host 
or elsewhere, and resist specific environment selection pressures.  
The basis of this study was the previous reports from our group that A. 
fumigatus exhibited a phase-specific resistance phenotype to azoles, polyenes, 
and echinocandins as multicellular development progressed (Mowat et al., 
2008a). This observation suggested that, like in C. albicans, adaptation during 
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biofilm growth endowed A. fumigatus with an increasingly resistant phenotype. 
The unexplained azole resistance phenotypes described as non-cyp51A 
mechanisms from studies in Manchester gave further evidence that adaptive 
resistance mechanisms may be important in A. fumigatus (Howard et al., 2009, 
Bueid et al., 2010). In fact, it has been recently reported from work in a 
collaboration with our group and Manchester that the efflux pump Cdr1b was 
significantly associated with non-cyp51A azole resistance (Marcin et al., 2013), 
despite previous reports that there is little evidence to suggest that these play 
an active role in clinical resistance (Cannon et al., 2009). 
Sequence analysis suggests that A. fumigatus has 278 different MFS and 49 ABC 
transporters (Nierman et al., 2005). A. fumigatus MDR pumps have previously 
been shown to be associated with increased resistance to itraconazole (da Silva 
Ferreira et al., 2004, Nascimento et al., 2003). In this study it was hypothesized 
that efflux-mediated mechanisms may therefore be an important mechanism of 
resistance during biofilm maturation. It was shown that efflux pump activity was 
an important factor during biofilm maturation, which was demonstrated both at 
a biochemical and molecular level in vitro and in vivo, and that exposure to 
azole stimulated efflux pump expression (Rajendran et al., 2011b). Interestingly, 
expression of Mdr4 transcripts suggested that efflux pump expression was 
biphasic, showing maximal expression during the early to intermediate phases of 
growth. Collectively, this data in addition to the available literature support the 
hypothesis that efflux pumps are an important, but not exclusive, determinant 
of fungal biofilm resistance to azoles (Cannon et al., 2009, Morschhauser, 2010). 
Their primary role may be for homeostasis within complex environments to 
protect themselves from acute toxicity (Piddock, 2006), but within clinical 
environments exposure to azoles drugs may enhance the levels of efflux pump 
expression, therefore either contributing towards or inducing clinical resistance 
(Bueid et al., 2010) (Marcin et al., 2013). However, it is likely that they play a 
greater protective (resistance) role in the early phases of biofilm growth until 
the production of ECM, one of the primary mechanisms of biofilm resistance. 
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ECM has been shown to act as a drug ‘sponge’ for azoles in C. albicans biofilms, 
thereby preventing the ability to the molecule to reach the cell and elicit an 
effect (Nett et al., 2010b). This has been shown to be mediated by the FKS1 
beta-1,3-glucan synthase enzyme, which is inducible in the biofilm phenotype 
(Taff et al., 2012), suggesting this is another adaptive resistance mechanism. 
The presence of ECM during A. fumigatus biofilm maturation has been observed 
in vitro (Mowat et al., 2008c) and within in vivo models(Loussert et al., 2010). 
Degradation of ECM using glucanases has been reported to improve antifungal 
sensitivity in C. albicans biofilm (Nett et al., 2007), whereas in A. fumigatus 
biofilm sensitivity was unchanged, suggesting that other components play a 
greater role in biofilm integrity and resistance (Beauvais et al., 2007a).  A key 
contributing component of the ECM in C. albicans was shown to be eDNA (Martins 
et al., 2010). It was therefore hypothesized that this may be a novel adaptive 
antifungal resistance mechanism in A. fumigatus. Given that eDNA has been 
shown to be an important component in microbial biofilm ECM per se (Montanaro 
et al., 2011), this suggested that this may be conserved and possibly an active 
microbial biofilm process. Detailed analysis showed this to be the case, where it 
was shown to be architecturally important and also impacted antifungal 
sensitivity. Interestingly, chitinase activity correlated with the release of eDNA, 
which is a marker of autolysis and cell wall biosynthesis (Selvaggini et al., 2004). 
Autolytic events may therefore play an active role in environmental adaptation, 
which are controlled centrally through cell stress response pathways, such as the 
calcineurin signalling pathway via heat shock proteins such as HSP90.  
Given that HSP90 has a high degree of connectivity in diverse signalling 
cascades, it could also affect biofilm drug resistance in a multitude of other 
ways, such as by regulating remodeling of the cell wall and cell membrane 
(Mukherjee et al., 2003, Nett et al., 2007), signalling cascades important for 
ECM production (Nett et al., 2010b, Nobile et al., 2009), or the function of 
contact-dependent signalling molecules that initiate responses to surfaces 
(Kumamoto, 2005).The data presented herein supports this hypothesis, as HSP90 
was also shown to affect both eDNA release and antifungal sensitivity, though 
the precise pathway in which this is controlled has yet to be determined. Recent 
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studies in C. albicans have shown that cell wall remodeling and the release of 
ECM are important determinants of antifungal resistance that do not impact cell 
fitness per se (Nett et al., 2011b, Walker et al., 2010). Collectively, the series of 
investigations presented herein have identified several novel mechanisms 
associated with an adaptive resistance phenotype in multicellular A. fumigatus 
biofilms. It was clear from these studies that a level of organization between the 
mechanisms was evident, with efflux mediated resistance acting in the early 
phases of growth until the production of ECM. These, along with stress responses 
pathways during maturation, simultaneously provided protection from antifungal 
agents. The interaction of these pathways is presented in Figure 6.1.  
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Figure 6.1 - Molecular mechanisms of fungal biofilm resistance. Antifungal 
drug resistance in fungal biofilms is both complex and multifactorial. The 
diagram illustrates the mechanisms of different class of antifungal agent action 
(azoles [AZL], polyenes [POL], and echinocandins [ECN]) and resistance: (a) the 
layer of ECM containing eDNA present in the biofilm shields the cells from 
antifungal agents by binding and reducing penetration; (b) the membrane 
transporter system ABC and MFS efflux pumps extrude antifungal molecules and 
reduces its intracellular concentration; (c) mutation in ERG11, cyp51, and FKS1 
genes alters the drug target leading to cross-resistance; (d) antifungal treatment 
induces stress responses, such as the calcineurin signalling pathway, which is 
activated, and coping responses occur through upregulation of various signal 
transducers.  
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6.3 Bench to bedside: translational perspective 
Our new insights into how A. fumigatus responds and adapts to its niche and 
antifungal exposure provides a unique opportunity to devise new 
chemotherapeutic strategies of control, whether as pharmacological targets or 
as augmenting conventional antifungal agents 
6.3.1 Pharmacological inhibitors 
Throughout the studies described within this thesis, the use of inhibitors has 
been shown to improve antifungal activity, even against the most tenacious of 
biofilm structures (Figure 6.2). This work establishes that inhibition of HSP90 
with geldanamycin (17-AAG), that has advanced in clinical trials for the 
treatment of cancer (Usmani et al., 2009, Kim et al., 2009) transforms 
antifungals from ineffective to highly efficacious in an in vitro A. fumigatus 
biofilm model.HSP90 inhibitors also exhibit potent activity against malaria 
and Trypanosome infections, thus extending their spectrum of activity to the 
protozoan parasites Plasmodium falciparum and Trypanosoma evansi (Pallavi et 
al., 2010, Shahinas et al., 2010). The development of HSP90 as a therapeutic 
target for infectious disease may benefit from the plethora of structurally 
diverse HSP90 inhibitors that have been developed, many of which are in 
advanced phase clinical trials, with substantial promise due to the depletion of a 
myriad of oncoproteins upon inhibition of HSP90 (Trepel et al., 2010). Given the 
importance of HSP90 in chaperoning key regulators of cellular signalling in all 
eukaryotes the challenge of advancing HSP90 as a target for infectious disease 
lies in avoiding host toxicity issues. Indeed, although well tolerated in the 
mammalian host individually or in combination therapies(Trepel et al., 2010), 
HSP90 inhibitors have toxicity in the context of an acute disseminated fungal 
infection (Cowen et al., 2009). This toxicity may be due to HSP90's role in 
regulating host immune and stress responses during infection. Toxicity was not 
observed in the studies of biofilm infections in the mammalian model, perhaps 
owing to both the localized infection and drug delivery, suggesting that this 
therapeutic strategy could rapidly translate from the laboratory bench to the 
patients' bedside. In the broader context, the challenge for further development 
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of HSP90 as a therapeutic target for infectious disease lies in developing 
pathogen-selective inhibitors or drugs that target pathogen-specific components 
of the HSP90 circuitry governing drug resistance and virulence. 
In addition to HSP90 inhibitor, this study also showed the potential of chitinase 
and efflux pump inhibitors in enhancing the antifungal drug efficacy. Several 
studies are currently being conducted testing co-administration of natural and 
manmade chemical components to act as inhibitors for chitinases and efflux 
mediated extrusion of antibiotics. A recent study screened a library of marketed 
drug molecules for chitinase inhibition and published that methylxanthine drugs 
are chitinase inhibitors (Rao et al., 2005). Clinically, methylxanthine drugs are 
used as bronchodilators to stimulate the cardiovascular and respiratory systems 
in COPD patients. Further studies are needed to test the potential of this 
component in combination with antifungal drugs to treat fungal infections. The 
use of efflux inhibitors are also in serious investigation for their potential to use 
in combination therapies with existing antimicrobial drugs. As shown in this 
study some of the inhibitors are used to determine the efflux prevalence in 
clinical isolates but none of them are yet in clinical use. The problem using this 
inhibitor in humans is the efflux transporters are also part of human cells 
distributed along particular portions of the renal proximal tubule, intestine, 
liver, blood–brain barrier, and other portions of the brain. Therefore a fungal 
specific inhibitor needs to be developed for combination therapy.  
6.3.2 Biofilm disruption agents 
Recently, the combined use of drugs (Espinel-Ingroff, 2009), or drugs with other 
agents such as enzymes(Kaplan, 2009), has received considerable attention. ECM 
degrading enzymes present broad-spectrum activity that is unlikely to induce 
antimicrobial resistance. The combined use of ECM degrading agents and 
antifungals has been previously tested in vitro. Here in this study it was shown 
that A. fumigatus biofilm susceptibility to polyenes and echinocandins was 
increased by addition of a hydrolytic enzyme DNase. The synergy between these 
components showed the therapeutic potential of DNase against fungal biofilm 
infections. DNase is a hydrolytic enzyme that cleaves phosphodiester linkage in 
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DNA, used in this study exhibited significant anti-biofilm activity (Figure 6.2). 
Clinically, the DNase Pulmozyme® is currently used as a therapeutic agent for 
cystic fibrosis treatment as an adjunct to antibiotic treatment (Frederiksen et 
al., 2006). The dornase alfa (Pulmozyme®) is a recombinant human DNase-I used 
to selectively hydrolyse DNA present in mucus or sputum in CF lungs. Its activity 
against bacterial and fungal DNA in biofilms remains unclear. Since this protein 
therapeutic agent is in use for CF treatment in humans, a nontoxic broad 
spectrum DNase can be developed as a potential component to clear both mucus 
and disrupt biofilms to enhance the efficacy of antifungals. Other mucolytic 
agents such as ambroxol and N-acetylcysteine (NAC) used in respiratory diseases 
has also been shown to offer anti-biofilm activity against bacterial and fungal 
biofilms (Pulcrano et al., 2012, Aslam and Darouiche, 2011). Alginate lyase, 
another similar compound has been reported to be effective against A. 
fumigatus biofilms (Bugli et al., 2012, Papi et al., 2012).A cross species 
interactions between CF pathogens Pseudomonas and Aspergillus has been 
recently published by our group. The data from this study showed the 
importance of quorum sensing molecules at inhibiting biofilm formation of fungi. 
The molecules such as homoserine lactone (HSL), decanol, dodecanol and 
farnesol have been shown to affect the biofilm formation (Hogan et al., 2004, 
Mowat et al., 2010). Given the antibiofilm nature of these compounds, future 
studies will answer whether they can be used to potentiate antifungal 
treatment.  However, limitations to these chemotherapeutic approaches include 
the expense and increased risk of dispersing cells to distal sites of colonisation 
(Kaplan, 2009). 
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Figure 6.2 – Novel antifungals. The pharmacological agents such as inhibitors of 
efflux pumps, HSP90 and chitinase activity interfere with different resistance 
mechanisms and enhance antifungal drug efficacy. In addition a hydrolytic 
enzyme DNase degrades the matrix eDNA, which affects the biofilm formation, 
biofilm stability and in consequence helps antifungals to reach their target. 
 
6.4 Disease modeling and future perspective 
The majority of the studies presented in the preceding chapters used a plastic 
substrate in order to investigate antifungal resistance mechanisms. However, 
whether this relates to how the organism responds within a host is difficult to 
ascertain. Experiments in a chamber model were performed to evaluate efflux 
pump expression, but these were cumbersome and expensive experiments, and 
the validity of a diffusion chamber to invasive A. fumigatus infection can be 
argued. Therefore, alternative approaches to studying this pathogen are 
required, particularly if evaluating novel antimicrobial strategies as eluded to in 
the preceding section. Whilst mammalian rodent models are considered the 
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‘gold standard’ for studying fungal infections, ethical concerns, labour, time and 
cost all impact their utility. Therefore, cheaper models such as the invertebrate 
G. mellonella model have received greater scrutiny. In this study G. mellonella 
was used, which was shown to be easy to maintain and was unrestrictive in 
experimental design. Previous studies have used the G. mellonella infection 
model for antifungal efficacy testing (Mesa-Arango et al., 2012, Cowen et al., 
2009, Rowan et al., 2009).A caveat to its use however is that this invertebrate 
only has an innate immune system, which its use for detailed virulence studies. 
However, for the purpose of this investigation it was used primarily as a vehicle 
to study the effects of antifungal treatment on A. fumigatus infection and to 
study adaptive resistance responses in vivo. The model was shown to be 
effective for comparing antifungal treatments, and provided harvestable A. 
fumigatus cells in order to undertake transcriptional profiling. These latter data 
showed that key adaptive resistance gene transcripts could be detected during 
infection and in response to antifungal treatment.  
Limitations to this model with respect to a ‘biofilm’ phenotype are obvious, i.e. 
do they actually form a biofilm in vivo? Compared to the in vitro models, there 
was little similarity with mature biofilms, whereas the early and intermediate 
forms were more similar due to the long hyphae observed. These differences 
may account for the lack of obvious gene expression patterns, but nevertheless, 
key transcripts were observed. In fact, inoculation with mature cells led to 
enhanced pathogenicity and lack of response to antifungal treatment. A further 
limitation of the study was that the pharmacological agents discussed above 
were not investigated as combinational agents along with conventional 
antifungal agents due to lack of time.  
Given the antifungal resistance in fungal biofilm is complex and multifactorial, 
more than one resistance factors may be involved in the respective biofilm 
phase susceptibility. The efflux activity and HSP90 were shown to be associated 
with early phase azole resistance but the mechanism of resistance with 
intermediate and matured A. fumigatus growth is not clear. Therefore further 
study is needed to investigate the combination of these resistance factors in 
matured fungal biofilm. The inhibition of more than one resistance factors by 
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using combination of inhibitors may help to answer this question. In addition, as 
previously mentioned there are number of other efflux pumps and signaling 
pathways present in fungal cells and their contributions in antifungal resistance 
is yet to be investigated. Due to limitations of techniques, cost and time 
associated with this study it was only possible to investigate a small number of 
them. The use of other techniques such as microarray and small interfering RNA 
(siRNA) and screening of mutant libraries using G. mellonella model may be 
useful to investigate more resistance genes in the future.  It also helps to 
advance our knowledge to make a cocktail of inhibitors along with existing 
antifungal drugs to treat fungal infections. Future studies in this area will help 
to test the hypothesis that supplementary agents could improve the treatment 
of A. fumigatus.   
The majority of patients with invasive fungal infections experience treatment 
failure because of clinical resistance, which is a concept critical to the outcome 
of a fungal infection.  The early diagnosis of invasive fungal infections itself is 
complicated in a clinical setting in this situation identification of resistance 
isolates and their corresponding resistance mechanism is more complex and 
there are no definitive diagnostic criteria for this. Alarmingly, the clinical 
relevance of antifungal resistance and tolerance has been demonstrated 
infrequently. Recent studies by our group suggest the use of molecular methods 
for early diagnosis of invasive fungal infections (McCulloch et al., 2012, 
McCulloch et al., 2009). The current study showed the expression profile of 
various resistance genes over the period of A. fumigatus multicellular 
development and use of inhibitors to identify different resistance factors. These 
data suggest that transcriptional qPCR targets may be an appropriate diagnostic 
approach. The expression profile of other resistance genes needs to be 
investigated before molecular assays can be developed to provide rapid diagnosis 
of drug resistance.  The available methodology to perform in vitro susceptibility 
testing has limitations (Ghannoum et al., 1996). In general, the correlation 
between MICs and the clinical outcome is controversial and still under 
investigation. The exposure of azole drug at a sub MIC level was shown to be up 
regulating the expression of efflux pumps therefore either contributing towards 
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or inducing clinical resistance. Therefore, it is important to be aware of the 
importance of adequate dosing. The data from this study suggest the use of 
inhibitors in antifungal sensitivity testing along with qPCR assay will be helpful 
to know more about resistant isolates before treatment. 
 
6.5 Summary 
To summarise, the key findings of the research work presented in this thesis are 
as follows 
 Efflux pump activity in A. fumigatus 
o Associated with susceptibility of the strain. 
o Up-regulated over the period of biofilm formation. 
o Azole treatment further up-regulates the efflux activity. 
 
 Extracellular DNA in A. fumigatus 
o A. fumigatus release eDNA over the period of multicellular 
development. 
o It contributes to biofilm formation and stability.  
o Associated with phase dependant antifungal resistance. 
o The chitinase regulated autolysis process is one of the mechanisms 
of eDNA release in A. fumigatus.  
o The molecular chaperone HSP90 regulates eDNA release and biofilm 
resistance. 
 G. mellonella infection model was developed in this study to evaluate the 
adaptive antifungal resistance in A. fumigatus. 
Overall these findings help us to develop our understanding of the different 
adaptive resistance mechanisms associated with A. fumigatus biofilms. This will 
contribute to the development of improved novel treatment regimens for 
invasive fungal infections.  
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